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ABSTRACT
Ovarian cancer affects over 5000 women each year in the UK and is the most
common cause of death from gynaecological malignancy, reflecting the late
presentation of the disease. The mechanisms involved in the growth regulation of
ovarian cancer are still poorly understood, however epidemiological studies suggest
that endocrine factors play an important role in the development and progression of
the disease. The majority of ovarian carcinomas possess oestrogen receptors (ER),
and several clinical trials suggest that a subset of patients may be responsive to
anti-oestrogen therapy. As yet, there have been a limited number of studies
investigating the role of oestrogen in the growth regulation of ovarian cancer,
partially due to the paucity of defined ER-positive ovarian cancer models.
The aim of this study was to examine the role of oestrogen in a series ofER-positive
ovarian cancer cell line models, including the first characterised lines with
moderate-high levels of ER. The effects of oestrogen on growth were initially
determined in nine ovarian cell lines possessing a range ofER from 0 to 132 fmol/mg
protein. Sensitivity to oestrogen correlated with the level of ER expression in that
concentrations of 17 P-oestradiol (E2) between 10"12 and 10"6M stimulated the growth
of the PEOl, PE04 and PE06 cell lines which possess moderate-high levels of
receptors between 96 and 132 fmol/mg protein, whereas there was no change in the
growth of the PEA1 and PEA2 cell lines which have an ER content of less than 30
fmol/mg protein. The growth of the ER-negative lines PEOl4, PEOl6 and PE023
was also unchanged by E2 treatment. Concentrations of E2 which were stimulatory to
iv
the PE01 cell line were inhibitory to a cisplatin-resistant derivative, PE01cddp despite
this also possessing moderate-high levels of ER. Effects of E2 on growth were also
examined in two ovarian xenograft models grown in nude mice; PE04 and HOX60
which are ER-positive and ER-negative respectively. Exposure of the xenografts to a
subcutaneously planted oestrogen pellet produced a significant inhibition in PE04
growth but no difference in HOX60 growth as compared to controls.
ER levels in the ER-positive PEOl, PE04 and PE01cddp cell lines were
down-regulated by treatment with 10"'°M E2, whereas there was no change in the
receptor status of the PEA1, PEA2 or ER-negative lines. Levels of progesterone
receptors (PR), shown to be a marker of oestrogen sensitivity in breast cancer, were
up-regulated by the same concentration ofE2 in the ER-positive PE04 and PE06 cell
lines but not in PE01cddp, PEA1, PEA2 or the ER-negative ovarian lines. In the
PE04 xenograft, ER levels were also reduced and PR levels up-regulated by E2, but
no differences in receptor levels were observed in the ER-negative HOX60. There
was only a low level of expression of the oestrogen-inducible protein pS2, in both the
ER-positive and ER-negative ovarian cell lines and this was not altered following E2
treatment. Expression of HSP27, another oestrogen-regulated protein, appeared to
correlate with ER status and oestrogen sensitivity, being highest in the PEOl, PE04
and PE06 cell lines, and lower in the PEA1, PEA2 and ER-negative lines. This was
also observed in vivo; HSP27 expression in the PE04 xenograft was significantly
higher than that seen in HOX60. After exposure to 10"10M E2 HSP27 expression was
significantly down-regulated in the ER-positive PE04 and PEOlCDDP lines, but
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unaltered in ER-negative PE014 cells. No change in expression was observed
following E2 treatment of the PE04 xenograft.
To determine whether oestrogen exerted its growth effects on the ER-positive cell
lines through the modulation of growth factors, the production of TGF-a and EGF
was measured in conditioned medium from cells with or without exposure to 10"10M
E2. Levels of TGF-a secreted by PE04 and PE01CDDI> cells were significantly higher
following E2 treatment as compared to controls, whilst levels were unchanged in
PE014 cells. No detectable levels of EGF were found in any of the conditioned
media. E2 treatment also up-regulated the expression of IGF-I receptors in the
ER-positive PE04 cell line.
If these results reflect the clinical situation, then there is a valid case for the use of
anti-oestrogen therapy in a subset of patients with ovarian tumours expressing
moderate-high levels ofER. PR and HSP27 expression levels may help indicate which
tumours are hormonally sensitive, and thus more likely to respond to treatment.
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It has long been known that hormones, and in particular oestrogens may play a part in
the progression of certain cancers. A relationship between ovarian function and
malignant breast disease was noted almost one hundred years ago by Sir George
Beatson who successfully healed a locally recurrent cancer of the breast following
ovariectomy (Beatson, 1896). There is also evidence to implicate hormones in the
development of ovarian cancer, and the aims of this thesis are to investigate the role
of oestrogen in the biology of this carcinoma.
Evidence for endocrine involvement in ovarian cancer is discussed in the following
introduction which is divided into two main parts. The first section provides a general
background, and the second is concerned with growth regulation.
1.2 Ovarian Cancer
1.2.1 Incidence
Ovarian cancer is one of the most common gynaecological malignancies, with
approximately 5000 women being diagnosed per year in the UK (MRC
Gynaecological Working Party, 1990). It has the highest mortality rate of all
gynaecological cancers (85% will die from their disease) and is the fifth most
common cause of cancer related death in women. Part of the reason for this poor
prognosis is the rapid and asymptomatic progression of the tumour such that it
usually presents as late stage disease. Ovarian cancer can occur at any age but
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incidence of the disease appears to increase around the age of 45, peaking at 70-80
years so that the majority of cases are detected in post-menopausal women (Brinton
and Hoover, 1992, Yancik, 1993). Less than 15 cases per 100, 000 per year occur in
those under 45.
1.2.2 Presentation and staging of disease
Abdominal pain and swelling are the most obvious signs of disease at initial
presentation. This occurs due to expansion of the tumour, adherence to surrounding
tissue and formation of ascites. A diagnosis may be assisted by ultrasonography which
has been developed as a pre-operative guide (Andolf et al., 1986). Ascites as well as
tumours can be detected by this method. Pleural effusions can be demonstrated by
chest radiography, and lymphatic spread by lymphography. Tumour markers such as
CA-125, a high molecular weight mucin glycoprotein, may also aid diagnosis. This
antigen may be present on the surface of both benign and malignant ovarian tumours
(NilofF et al., 1984) but is offen absent or only weakly expressed by normal ovarian
surface epithelia (reviewed in Auersperg et ah, 1996). Levels of circulating CA-125
are elevated in 80% of ovarian cancers (Bast et al., 1983). Currently, it is used as a
marker for monitoring response to therapy and relapsed disease. In this context it has
been shown to have prognostic use, predicting macroscopic disease recurrence by
three months on average (NilofFet al., 1986).
Work by Zurawski et al., (1988) and others have indicated that CA-125 may have
utility in screening for ovarian cancer, showing that 50% of the population had
elevated CA-125 levels eighteen months before clinical appearance of the disease.
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However, two recent interventional studies suggest that elevated CA-125 levels alone
are not sensitive enough as a predictive marker for ovarian cancer. Einhorn et al.,
(1992) showed that in a population screen of 5,550 women, 2% over 50 years had
elevated levels. These women and a similar number of controls were followed up for
further study incorporating 3-monthly CA-125 assessment and 6-monthly
examination and ultrasonography. Six cases of ovarian cancer were detected in this
study but three cases were missed by screening. In another large study, 11 ovarian
cancers were detected by a CA-125 screen but a further 18 were not identified
(Jacobs et al., 1993).
Staging of disease as determined at surgery (laparotomy) is of prognostic value in
determining treatment strategy (Carey et al., 1993). Definitions of the different stages
are given in Table 1.1. The inability to detect cancers early due to lack of adequate
screening procedures and absence of clinical symptoms means that advanced stage
disease has a poor prognosis. Patients with stage I disease have the best outcome
with a 5 year survival rate of 80-90%. Stage II disease has a poorer outcome with a 5
year survival rate of 40-60%. The poorest prognoses are observed with stage III
(10-15%) and stage IV disease, this having a 5 year survival rate of less than 5%
(Friedlander and Dembo, 1991).
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Table 1.1
FIGO (International Federation ofGynaecology and Obstetrics) staging for
carcinoma of the ovary, 1985
Stage I Growth limited to the ovaries
Stage la Growth limited to one ovary
(i) No tumour on the external surface; capsule intact
(ii) Tumour present on the external surface; and/or capsule ruptured.
Stage lb Growth limited to both ovaries; no ascites.
(i) No tumour on the external surface; capsule intact
(ii) Tumour present on the external surface; and/or capsule ruptured.
Stage Ic Tumour at either stage la or lb, but with tumour on surface of one or both ovaries;
or with capsule ruptured; or with ascites present containing malignant cells or with
positive peritoneal washings.
Stage II Growth involving one or both ovaries with pelvic extension.
Stage Ha Extension and/or metastases to the uterus and/or fallopian tubes.
Stage lib Extension to other pelvic tissues.
Stage lie Tumour at either stage Ila or lib, but with tumour on surface of one or both
ovaries; or with capsules ruptured; or with ascites present or peritoneal washings.
Stage III Growth involving one or both ovaries with intraperitoneal metastases outside the
pelvis and/or positive retroperitoneal nodes or inguinal nodes. Superficial liver
metastases equals stage III. Tumour limited to the true pelvis, with histologically
confirmed extension to the small bowel or omentum.
Stage Ilia Tumour grossly limited to the true pelvis with negative nodes but with
histologically confirmed microscopic seeding of abdominal peritoneal surfaces.
Stage Mb Tumour involving one or both ovaries with histologically confirmed implants of
abdominal peritoneal surface, none exceeding 2cm in diameter. Nodes are
negative.
Stage IIIc Abdominal implants greater than 2cm in diameter and/or positive retroperitoneal
or inguinal nodes.
Stage IV Growth involving one or both ovaries, with distant metastases or pleural effusion is
present, with positive cytology or metastasis to the liver parenchyma.
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1.2.3 Pathology
Ovarian neoplasms have a varied histology but can be classified into several groups
depending upon their origin (Figure 1.2), and may be either benign, borderline (those
with low malignant potential) or malignant. The most frequently observed ovarian
carcinomas originate from the surface epithelium of the ovary and account for over
90% of all malignant ovarian neoplasms. These are subcategorised into serous,
mucinous, endometrioid, clear cell, undifferentiated adenocarcinomas and the rare
Brenner tumour.
The different epithelial types portray similar histological characteristics to the tubal,
endometrial and endocervical derivatives of the Mullerian ducts which develop from
the primative mesothelium in the embryo. The ovarian epithelial surface is the adult
equivalent of this mesothelium and neoplasms arising from this retain their embryonic
potential to differentiate. Thus, serous tumours resemble the epithelium of the
fallopian tube, endometrioid and clear cell tumours the endometrium, and mucinous
tumours the endocervical epithelium. The origin of Brenner tumours is different in
that they shows histology similar to that of uro-epithelium and are thought to exhibit




Summary ofMalignant Ovarian Tumour Classification according to WHO
(Serovand Scully, 1973)




D. Clear cell (mesonephroid) tumours
E. Brenner tumours
F. Mixed epithelial tumours
G. Undifferentiated carcinoma
H. Unclassified tumours
II Sex cord stromal tumours
III Lipoid cell tumours
IV Germ cell tumours
V Gonadoblastoma
VI Soft tissue tumours not specific to the ovary
VII Unclassified tumours
VIII Secondary (metastatic) tumours
EX Tumour-like conditions
The most common type of malignant epithelial ovarian tumours are serous
cystadenocarcinomas, representing about 40-60% of cases. Tumours of the mucinous
subtype constitute about 3 to 21%, whilst endometrioid and clear cell subtypes
account for 5 to 20% and 5 to 10% respectively (reviewed in Slotman and Rao,
1988). Presentation of other malignant epithelial tumour types is rare. The degree of
tumour differentiation has also been categorised and should be included in a full
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histopathological diagnosis (Baak et al., 1987). Grade 1 classifies a
well-differentiated tumour exhibiting little cellular atypia and few mitoses.
Moderately-differentiated tumours demonstrating increasing cellular atypia and more
frequent mitoses but retention of histological differentiation are classed as Grade 2,
and Grade 3 tumours are the most aggressive, being poorly-differentiated with
frequent mitoses, and containing layers of poorly or undifferentiated cells with few
distinguishing features making histological classification difficult.
1.2.4 Epidemiology
The cause of ovarian cancer is poorly understood despite extensive research into
environmental, endocrinological and genetic factors. Further insight into the
epidemiology and etiology of this carcinoma may aid prevention and earlier diagnosis.
(i) Endocrine factors
There is considerable evidence to suggest that hormones may be implicated in the
progression of this disease. Ovarian cancer incidence has been linked with breast
cancer which is generally thought to be hormonally influenced. Thus, a woman with a
primary breast carcinoma is twice as likely to develop ovarian cancer, and a patient
with ovarian cancer is four times as likely to develop breast cancer (reviewed in
Hamilton, 1992). Further, the two cancers have etiological factors in common. For
example, early menarche, late menopause, and nulliparity appear to be associated with
an increased risk of ovarian cancer, whereas a decreased risk is linked with pregnancy
(Cramer et al., 1983a, Franceschi et al., 1991, Polychronopoulou et al., 1993). The
increase in the incidence of ovarian cancer above the age of 45 is thought to be
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associated with higher levels of gonadotropins which may contribute to
carcinogenesis (Cramer and Welch, 1983b). Numerous studies have also indicated a
reduced risk with the use of oral contraceptives which suppress ovulation (Stanford,
1991, Rosenblatt et al., 1992). Long term use (five years or more) is associated with
a 50% reduction in ovarian cancer risk, and this protective effect appears to persist
ten or more years after use is discontinued (Vessey and Painter, 1995).
Conversely, an increased risk is associated with women taking oestrogens for
non-contraceptive use. Rodrigez et al., (1995) have recently published the results of a
large study indicating increased ovarian cancer risk of 40% with 6-10 years of
oestrogen replacement therapy, and 70% with greater than 10 years of treatment.
There is also evidence to implicate the use of fertility drugs with a higher incidence of
ovarian cancer. A small study by Ron et al., (1987) showed no increased risk of
ovarian cancer in women who had used fertility drugs, although an increased risk of
endometrial carcinoma was noted. However, a more recent report has demonstrated a
2.5 fold increase in ovarian cancer risk associated with the use of fertility drugs such
as exogenous gonadotropins and pituitary gonadotropin stimulants (Rossing et al.,
1994).
Evidence for the involvement of hormones in the progression of established ovarian
cancer will be covered in section 1.3 under growth regulation.
(ii) Dietary and environmental factors
Ovarian cancer incidence is higher in industrialised countries with the exception of
Japan. However in a pattern that is seen with many cancers, migrant Japanese women
and their offspring in the United States exhibit an increased frequency of ovarian
neoplasms compared to Japanese women living in Japan (Herrinton et al., 1994).
Dietary factors and environmental carcinogens are thought to be contributory
elements. A report by Cramer et al., (1984) proposed an associated risk with animal
fat consumption. Subsequently, a large case-control study into ovarian cancer risk
and diet has suggested that for every lOg of saturated fat ingested per day, the risk of
ovarian cancer increases by 20%, whereas the same weight of vegetable fibre confers
a 37% reduced risk (Risch et al., 1994). Oestrogens and other steroid hormones are
often present in saturated fat (Risch et al., 1994) and high fibre diets have been
shown to reduce serum oestrogen concentrations in premenopausal women (Rose et
al., 1991, Goldin et al., 1994). However, more studies are needed to confirm these
reports.
There is no evidence to suggest that smoking may be a contributory factor in
increasing ovarian cancer risk (Whittemore et al., 1988). Likewise, several studies
have reported no increased ovarian cancer incidence in alcohol drinkers, with two
studies suggesting a protective effect of alcohol in young women (Gwinn et al., 1986,
reviewed in Boyle and Leake, 1996). Coffee drinking has been ascribed with a slight
increase in risk (Byres et al., 1983, Cramer et al., 1984, Whittemore et al., 1988).
Two possible chemical carcinogens suggested to have some association with ovarian
cancer incidence are asbestos and talc (Henderson et al., 1979, Longo and Young,
1979). Talc until recently contained asbestos which is known to be involved in the
development of malignant mesothelioma and lung cancer. Evidence by Cramer et al.,
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(1982) supports a link between talc use and ovarian cancer, however other workers
do not confirm this observation (Whittemore et al., 1988, Harlow et al., 1992,
Wehner, 1994).
A case/control study by Cramer et al., (1989) showed that higher consumption of
lactose/galactose in yoghurt and cottage cheese was associated with lower levels of
galactose-1-phosphate uridyl transferase (GPUT) in ovarian cancer cases as
compared with controls, and there is some evidence to suggest that GPUT may be a
genetic risk factor for early menopause (Cramer, 1990). However, a recent large
Canadian case study has shown that average daily intake of lactose or galactose, or
lactose intolerance is not associated with risk of ovarian cancer (Risch et al., 1994).
(iii) Genetic factors
For the majority of ovarian cancer patients there is no family history of the disease.
However it is estimated that 5% of cases are hereditary, the majority of these being of
the papillary serous subtype (Hamilton, 1992). Three categories of familial ovarian
cancer have been identified (Lynch et al., 1978, Piver et al., 1984). The first is
site-specific disease which is the most common of the three and involves an increased
risk of only ovarian cancer. The second instance is where there is increased risk of
associative ovarian cancer in familial breast cancer cases, the breast-ovarian cancer
syndrome. The final circumstance is the cancer family syndrome (Lynch Syndrome II)
which integrates hereditary non-polyposis colorectal cancer (HNPCC) (Lynch
Syndrome I) with risk of gynaecological (ovary, endometrium), gastrointestinal,
urological and breast cancers (Lynch et al., 1985).
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Familial cancer tends to arise at a relatively early age, around 35 to 40 years,
compared with sporadic cases occuring at a median age of 61 years (Ozols et al.,
1992). It is inherited in an autosomal dominant pattern with high penetrance such that
up to 50% of first degree relatives may inherit the gene (Piver et al., 1991).
Interestingly, in site-specific disease, males may convey predisposition of the gene to
their female offspring, but they and any male progeny do not appear to have any
increased risk of any form of cancer (Piver et al., 1991, Lynch et al., 1990). It was
suggested that the gene involved may be associated with the growth regulation of
only the ovarian epithelial cell type (Hamilton, 1992).
The majority of patients with breast/ovarian cancer syndrome show linkage to a
predisposing gene (BRCA1) (Easton et al., 1993) which was mapped to the long arm
of chromosome 17, in the region 17q 12-21 (Hall et al., 1990, Narod et al., 1991).
The gene was cloned and characterised byMiki and coworkers, (1994), and shown to
encode a zinc finger protein of unknown function. Characterisation of mutations
suggest that BRCA1 may be a tumour suppressor gene (Futreal et al., 1994, Castilla
et al., 1994, Takahashi et al., 1995). The majority of hereditary site-specific ovarian
cancers have also been linked to BRCA1 (Steichen-Gersdorf et al., 1994).
Recent observations imply that BRCA1 is involved in the proliferation and
differentiation of mammary tissue under the influence of ovarian hormones. Marquis
et al., (1995), and Gudas et al., (1995) have shown an increase in BRCA1 mRNA
expression in breast cancer cells following treatment with oestrogen.
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Mutations in a second gene BRCA2, which has been mapped to chromosome 13ql2
proximal to the retinoblastoma gene (Wooster et al., 1994), are also associated with
an excess of ovarian cancers in members of affected families (Narod et al., 1995) and
have been reported to confer a higher risk ofmale breast cancer. Current observations
suggest that other genes are likely to be involved in the remaining cases of inherited
ovarian cancer.
Several predisposing genes for Lynch Syndrome I and II have been cloned recently
(hMSH2, hMLHl, hPMS2 and hPMSl), and shown to encode a family of proteins
whose normal function is involved in post-replication mismatch repair (Fishel et al.,
1993, Kolodner et al., 1995, Nicolaides et al., 1994). Cells with defects in these
genes have been shown to possess a 'mutator phenotype', which is often seen as
mutations in repetitive sequences (microsatellite instability). This has been observed in
heritable forms of ovarian carcinomas, but is not typically found in sporadic cases
(Wooster et al., 1994).
Mutations of the p53 tumour suppressor gene, allele loss and aberrent expression of
the p53 protein have been reported in about 30-50% of ovarian cancer cases and
appear to be associated with serous histology and advanced stage (Marks et al. 1991,
Eccles et al., 1992, Milner et ah, 1993, Runnebaum et al., 1994). Mutations are well
dispersed throughout the p53 gene and seem to be mainly transitions (Kohler et al.,
1993).
Aberrant expression of several oncogenes including c-erbB-2 (HER-2/neu) which
codes for an epidermal growth factor receptor-like protein, ras, myc, fins, jun and
myb has been described in ovarian cancer (reviewed in Berek and Martinez-Maza,
1995). Several studies have shown c-erbB-2 to be overexpressed in about 20-30% of
ovarian cancers investigated and associated with poor survival (Slamon et al., 1989,
Berchuck et al., 1990a, Rubin et al., 1994). Amplification/activation of K-ras, and
occasionally H-ras and N-ras, has been seen in approximately 15% of mainly
advanced ovarian carcinomas (Bolz et al., 1989, Liehr et al., 1993, Yokota et al.,
1986), and a higher proportion of tumours demonstrate overexpression of c-myc,
usually accompanied with amplification of the gene (Kohler et al., 1989, Tashiro et
al., 1992, Liehr et al., 1993).
1.2.5 Treatment
(i) Surgery
The main aims of surgery for primary ovarian cancer are diagnosis, staging and
reduction of tumour burden. With early stage disease (ie. stage Ia/b), surgery can
remove the whole tumour and represent adequate treatment (Young et al., 1990).
Any subsequent recurrence probably develops from occult micrometastases or
implantation of free tumour cells from the peritoneal fluid (Piver et al., 1978). The
surgical procedure in early disease usually consists of tumour removal followed by
bilateral salpingo-oophorectomy and total abdominal hysterectomy (Hudson, 1973).
In the treatment of advanced disease, incomplete erradication of tumour, termed
cytoreductive surgery, is performed in 30-50% of cases. This helps to ease discomfort
and reduce tumour effects on metabolism. It also improves the chances of response to
adjuvant chemotherapy. Size of remaining tumour is the most important prognostic
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factor in advanced disease (Griffiths and Fuller, 1978, Wharton and Herson, 1981,
Cannistra, 1993).
A second-look laparotomy may be performed to assess patients who are clinically
disease free after a course of chemotherapy (reviewed in Podratz and Kinney, 1993).
It may also aid further cytoreductive surgery and restaging of disease. A recent study
by Van der Burg et al., (1995) showed that a second debulking procedure in patients
with advanced stage III and IV (who after initial debulking had residual disease >
lcm followed by 3 courses of chemotherapy), significantly improved the survival of
patients.
(ii) Chemotherapy
Whilst surgery may be adequate for early stage la disease, consideration has to be
given to additional systemic treatment in more advanced tumours. Single alkylating
drugs such as melphalan, chlorambucil and cyclophosphamide have been widely used
for patients with advanced disease since the 1960's and represented the first
successful approach to the treatment of this carcinoma with response rates of 40-60%
(Tobias and Griffiths, 1975, reviewed in Sutton, 1994). They act by generating
carbonium ions which bind to DNA causing crosslinking and single strand breaks.
Non-alkylating drugs such as doxorubicin and hexamethylmelamine have also been
implemented as single agents with similar response rates (De Palo et al., 1977, Weiss,
1981).
Current standard chemotherapy usually consists of cisplatin-containing regimens,
most usually with an alkylating agent such as doxorubicin, which have been shown to
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produce greater response rates than cisplatin alone (Levin et al., 1993). Cisplatin
analogues elicit cell death by forming interstrand and intrastrand crosslinks within
DNA at amino or hydroxyl groups, the major lesions being intrastrand crosslinks
between N-7 atoms of adjacent purines (Sherman and Lippard, 1987). The presence
of these adducts leads to a change in DNA conformation (Anin and Leng, 1990),
which may cause a block in DNA replication, possibly generating DNA double strand
breaks which are a signal for apoptosis (Nelson and Kastan, 1994). Carboplatin, an
analogue of cisplatin, has been shown to be an effective and less toxic substitute in
drug treatment regimens in advanced ovarian cancer. It is less nephrotoxic,
neurotoxic and emetogenic than cisplatin (Wiltshaw et al., 1984, Mangioni et al.,
1989), and in combination chemotherapy demonstrates similar response rates to
cisplatin-containing regimens (Alberts et al., 1992, Swenerton et al., 1992) although
some evidence points to it being less effective in terms of survival (Vermorken et al.,
1993).
In the mid 1980's, clinical trials began with a new series of compounds, the taxanes.
The drug taxol (Paclitaxel), was first isolated in the 1960's from a crude extract of
the bark of the Western Pacific yew tree, Taxus brevifolia, as part of the US National
Cancer Institute's screening programme, and was found to have activity against
several murine tumours (Wani et al., 1971). Taxol and docetaxel (Taxotere), a
semisynthetic analogue obtained from the European yew, are currently the two
compounds in clinical use. Taxanes act as mitotic inhibitors by promoting the
polymerisation and inhibiting the depolymerisation of tubulin which is a component of
the microtubules responsible for spindle formation in mitosis (reviewed in Gore,
1996). The microtubules become stable thus blocking cells in late G2 and/or M phases
of the cell cycle (SchifF et al., 1979). Taxol and docetaxol appear to be promising
second line treatments for ovarian cancer refractory to other drugs with response
rates of around 30% in patients who have failed to respond to prior cisplatin therapy
(Einzig et al., 1992, Kavanagh et al., 1993, Thigpen et al., 1994). There is little data
on the action of taxol as a single agent in previously untreated patients with ovarian
cancer. A report from an ongoing study suggests that the response rate in 28 patients
(32%) is slightly lower than expected (Gore et al., 1995). However, as part of
combination chemotherapy with cisplatin in first line treatment, taxol is reported to
increase survival to 37.5 months versus 24.4 months in patients receiving
cyclophosphamide plus cisplatin (McGuire et al., 1995).
(iii) Drug resistance
Since the introduction of cisplatin in the 1970's, and carboplatin in the 1980's the
survival of patients with advanced ovarian cancer has increased significantly
(Advanced Ovarian Trialists Group, 1991). Comparisons in mortality data from 1975
and 1985 in the West of Scotland show an increase in 3-year survival from 36% to
50% for women under 55 (Gillis et al., 1991). However, in the majority of studies the
median survival of patients treated with cisplatin-based regimens is approximately 21
to 30 months. Chemotherapy frequently produces complete clinical remissions but
relapse is a common event and when clinical drug resistance occurs it is usually fatal
(reviewed in Hamilton et al., 1995, Kaye, 1996). One possibility is altered host
pharmacology, but it is more likely to be due to a combination of both intrinsic and
acquired mechanisms; an outgrowth of intrinsically resistant cells or repeated
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exposure to drugs altering the target cells and rendering them refractory to further
administrations of drug. In the study of cisplatin resistance, investigations using in
vitro cell lines have identified several mechanisms which may be involved: defective
drug transport, increased levels of intracellular metallothioneins, glutathione or
glutathione-S-transferase activity which may inactivate drugs, and enhanced repair of
DNA damage (Andrews and Howell, 1990, Gately and Howell, 1993). Mutations in
the p53 gene may be associated with drug resistance. A recent report suggests that
defects in p53 are associated with resistance to carboplatin (Al-Azraqi et al., 1994)
and several studies suggest that p53 is necessary for certain drugs, including cisplatin
to induce an apoptotic response (Lowe et al., 1993, Clarke et al., 1993, reviewed in
Brown, 1996). Furthermore, changes in oncogene expression may be implicated in
drug resistance. Blocking of c-erbB-2 overexpression with monoclonal antibodies
results in enhanced cytotoxicity of cisplatin in ovarian cancer cells (Hancock et al.,
1991) and a similar effect is noted with antibodies directed against the epidermal
growth factor (EGF) receptor (Christen et al., 1990). These may work by blocking
DNA repair (Pietras et al., 1994). Other studies implicate the overexpression of the
efflux pump P-glycoprotein, which is involved in the classic multidrug resistant
phenotype (MDR), in being partly responsible for the reduced cytotoxicity of drugs
such as doxorubicin in human ovarian cancer cell lines (Bradley et al., 1989, Maeda et
al., 1993). Use ofMDR modulators has been shown to restore the taxol sensitivity of
multidrug resistant cells (Jachez et al., 1993).
These studies in vitro have now led to the use of some potential resistant modulators
for ovarian cancer in clinical trials, which include buthionine sulfoximine (BSO) which
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causes depletion of glutathione (O'Dwyer et al., 1992), aphidicolin, a repair inhibitor
(Sessa et al., 1991) and PSC 833, an MDR modulator in conjunction with taxol
(Fisher et al., 1994).
(iv) Radiotherapy
Recently, interest has been renewed in the use of radiotherapy for the treatment of
ovarian cancer due to the poor survival rate of patients even after a negative second
look laparotomy. However, several studies have shown that the only real benefit from
whole abdominal irradiation appears to be in patients with microscopic disease
(Bruzzone et al., 1990, Lederman et al., 1991).
(v) Hormonal therapy
Tamoxifen, the synthetic anti-oestrogen employed widely in the treatment of breast
cancer has also been used in the treatment of ovarian cancer. The first report of its
use was in 1981 where responses were noted in two patients (Myers et al., 1981).
Following this, a number of small studies reported response rates of around 10%.
However, stabilization of disease was noted in several studies (Landoni et al., 1983,
Shirey et al., 1985, Weiner et al., 1987). More recently, studies have shown a 10%
complete response rate, and a 7% partial response rate in 105 patients with stage
III/IV disease which was considered chemoresistant (Hatch et al., 1991) and an 18%
response rate to tamoxifen in 29 patients with refractory stage III/IV disease which
included two complete responses (Ahlgren et al., 1993). Abrogation of platinum
resistance has been observed in vitro when tamoxifen is added concomitantly
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however the underlying mechanism is still unresolved (McClay et al., 1992, Nakata et
al., 1995).
Progestins have been used in a variety of studies for the treatment of ovarian cancer
with the rationale that they may counteract the growth promoting effects of
oestrogens. Objective response rates of only about 10-15% have been observed in
most studies (reviewed in Slotman and Rao, 1988) but using medroxyprogesterone
acetate (MPA) Rendina et al., (1982) reported a response rate of 55%, although the
majority of tumours treated had a favourable prognosis being of the endometrioid
subtype and well-differentiated. Additionally, progestins have been used in
combination with other agents such as alkylating drugs. Postoperative treatment with
MPA and melphalan yielded response rates of 85% (Bergqvist et al., 1981) and
Guthrie, (1979) recorded complete responses in 46% of patients. These response
rates could not be repeated in three prospective controlled studies where
chemotherapy plus MPA was compared with chemotherapy alone (reviewed in
Slotman and Rao, 1988). In two trials with sequentially administered hormonal
therapy consisting of oestrogen treatment (to induce progesterone receptors, PR)
followed by a progestin, 14-17% response rates were produced (Freedman et al.,
1986, Fromm etal., 1991).
Luteinizing hormone releasing hormone (LHRH) receptors are reported to be present
in about 80% of ovarian cancers (Emons and Schally, 1994) and another therapeutic
approach has employed gonadotropin-releasing hormone analogues to treat patients
with refractory ovarian cancer. Response rates and disease stabilization in about
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10-50% of patients treated with LHRH agonists have been reported (Emons et al.,
1992, Ron et al., 1995).
An important consideration that should be borne in mind is that whilst low response
rates have been observed in these studies, (about one in six patients respond), these
trials were performed after failure of other treatment strategies, thereby selecting a
subgroup of patients with poor prognosis. In addition, most of the studies did not
make use of tumour estrogen or progesterone receptor status. When selecting
endocrine therapy in breast cancer, the predisposition of tumours to hormonal control
is a most important parameter and receptor measurements are routinely performed in
the management of this disease. If markers of hormonal response are assessed in
ovarian cancer patients, it may help define a set of oestrogen-sensitive tumours.
1.2.6 Prognostic factors in ovarian cancer
Defining prognostic markers in tumours helps characterize certain subgroups of
patients who then can be optimally treated according to this assessment. In breast
cancer the identification of several predictive markers has helped to define a subset of
hormonally responsive tumours which will respond to endocrine therapy. Further
markers are being characterised.
One of the most useful prognostic indicators in ovarian cancer is tumour stage, the
more advanced the disease the worse the outcome. Several other factors which have
utility include tumour histology, patient age and residual tumour size after surgery
(de-Souza and Friedlander, 1992). In general mucinous, endometrioid and clear cell
tumours appear to have the best outcome (reviewed by Slotman and Rao, 1988). In
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addition, well-differentiated tumours tend to be associated with lower stage disease.
As mentioned previously, a better response to chemotherapy is observed in patients
with minimal residual disease after cytoreductive surgery. This is the most important
prognostic factor for patients with advanced disease (Wharton et al, 1981).
Analysis of tumour DNA content has also been shown to be a strong independent
prognostic factor. Rates of aneuploidy are high in ovarian cancer and generally are
associated with poor prognosis (Brescia et al., 1990, Friedlander et al., 1984)
although other studies do not agree (Sahni et al., 1989, Schneider et al., 1990).
C-erbB-2 is overexpressed in about a third of ovarian cancers but some doubt
remains as to its prognostic significance (Haldane et al, 1990, Rubin et al, 1993). As
mentioned previously, p53 mutations are associated with serous histology and
tumours of advanced stage which have a poor prognosis (Niwa et al., 1994, Eccles et
al, 1992), however there is some debate as to p53 status being an independent
marker (Sheridan et al, 1994, Frank et al, 1994). A recent study suggests that
patients with normal sequence p53 are more likely to respond to chemotherapy than
those with mutations in the gene (Al-Azraqi et al, 1995).
Investigation of markers of hormonal sensitivity in ovarian cancer may not only help
determine the role of oestrogen in this disease but identify tumours which may
respond to endocrine therapy, as in the case for breast cancer where the prognostic
significance of oestrogen responsive proteins such as oestrogen and progesterone
receptor, pS2 and Cathepsin D has been widely reported. These and other markers of
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hormonal sensitivity are discussed in further detail in the next section 1.3.1, under
Endocrine Regulation.
1.3 GROWTH REGULATION
The presence of specific receptors for hormones and growth factors suggests that the
growth of ovarian cancer cells may depend upon these agents. These factors have
been shown to be involved in the growth of breast cancer cells and the evidence that
ovarian cancer may be similarly regulated is discussed in detail below.
1,3,1 Endocrine regulation
(i) Introduction
As mentioned previously, epidemiological data suggests that hormones are involved
in the development of ovarian cancer. This evidence lends support to two hypotheses
for the possible development of this carcinoma: the 'gonadotropin hypothesis' and the
'incessant ovulation hypothesis' (reviewed in Piver et al., 1991). The first theory
speculates that a continuously high level of gonadotropins resulting from either
ovarian failure or a block in the regulatory ovarian/pituitary feedback mechanism, acts
on the ovary and leads to tumourigenesis (Gardner, 1948). At menopause the levels
of gonadotropins are high but then decline and the age-incidence of ovarian cancer
may reflect this pattern. Both pregnancy and the use of oral contraceptives lower
gonadotropin levels and suppress ovulation, and have been shown to reduce the risk
of ovarian cancer (Cramer et al., 1983a). The 'incessant ovulation theory' proposed
by Fathalla in 1971 postulates that continuous trauma to the ovaries caused by
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ovulation leads to the development of cancer. The disruption of the surface
epithelium after ovulation is repaired by rounds of cell division. It is thought that this
continual requirement for growth activity markedly increases the probability of
malignant transformation. Mutations are much more likely to occur in dividing as
opposed to quiescent cells. Most other mammals exercise their reproductive potential
to the full and experience few ovulatory cycles, but in humans ovulatory cycles are
experienced almost continuously from puberty to menopause (Fathalla, 1971).
Experimental support for this hypothesis comes from studies in hens in which
frequent ovulatory activity (induced by artificial lighting) was associated with almost
a 100% incidence of ovarian cancer as compared to no incidence in hens kept in
normal lighting which ovulate seasonally (Wilson et al., 1958). Ovarian cancer is
thought to arise most frequently in surface epithelial inclusion cysts resulting from the
proliferation of surface epithelium cells which either invade or are trapped within the
cortex during ovulation (Hamilton, 1992, Radisavljevic, 1976). It has been postulated
that oestrogens then promote proliferation and increase the possibility of malignant
transformation (Cramer and Welch, 1983b).
Recent experimental evidence supports Fathalla's theory. Surface epithelial cells
isolated from rat ovary were subjected to prolonged cell division in vitro by repeated
subculturing. Cells acquired multiple features associated with the transformed
phenotype including ability for substrate independent growth, loss of contact
inhibition and the ability to form ovarian serous tumours when injected into nude
athymic mice (Godwin et al., 1993).
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Early animal studies directly implicated hormones in ovarian malignancy. Chronic
administration of oestrogens, progestins and androgens have resulted in ovarian
tumours (Jabara, 1962, Gardner, 1958, Horning, 1959, Biskind and Biskind, 1944).
Additionally, exposure to diethylstibestrol (DES) can induce cystadenocarcinoma in
utero (Walker, 1984). In humans, a two-three fold excess of ovarian carcinoma has
been found with women who were exposed to multiple ovulations as a result of
treatment with fertility drugs (Whittemore, 1993).
The main aim of this thesis is to investigate the role of oestrogen in the growth
regulation of ovarian cancer, so the actions of this hormone are discussed in further
detail.
1.3.2 Steroid hormones
(i) Chemistry and biosynthesis
Steroids are naturally occuring lipids with a common ring structure consisting of three
six-membered rings plus one 5-membered ring. They are synthesised mainly by the
adrenal glands, testis and ovary from the precursor cholesterol which is derived
mainly from low density lipoprotein (LDL) in the circulation, (reviewed in Ganong,








Biosynthesis of steroid hormones (Adapted from Ganong, 1989)
The two main functions of the ovary are (i) to produce ova and (ii) to synthesize three
categories of steroid hormones; oestrogens, progesterone, and androgens. Oestrogens
are secreted by the theca interna and granulosa cells of the ovarian follicle and by the
corpus luteum. In addition, the placenta secretes oestrogen and some small quantity is
also produced by the adrenal glands. The corpus luteum and placenta also secrete
progesterone. The production of ovarian steroids is under the control of two
hormones produced by the anterior pituitary gland; follicle-stimulating hormone
(FSH) and luteinizing hormone (LH). These in turn are under the control of
leuteinizing hormone releasing hormone (LHRH) produced by the hypothalmus.
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Oestrogen and progesterone levels influence these control mechanisms by a series of













Summary of positive and negative feedback mechanisms in the control of normal
ovarian steroid secretion during the menstrual cycle. Solid lines represent stimulatory
effects and dashed lines inhibitory effects.
The major secreted oestrogen is 17 P-oestradiol (E2) which is in equilibrium with
oestrone (Ei) in the circulation. Oestrone in turn is metabolised to oestriol which is
the least potent of the three. There are two peaks of oestrogen secretion during the
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menstrual cycle; one before ovulation and the other during the mid-luteal phase. After
the menopause oestrogen secretion declines to low levels. The main effects of
oestrogen are to facilitate growth of ovarian follicles, increase motility of uterine
tubes and increase uterine blood flow. They also produce duct growth in the breasts
and have a multiple role in development of female secondary sex characteristics
during puberty. Progesterone is responsible for cyclical changes in the cervix and
vagina. It also decreases the number of oestrogen receptors in the endometrium and
increases the conversion of 17 P-oestradiol to other less potent oestrogens.
(ii) Mechanisms of action
Oestogen exerts its major effects through interaction with a specific oestrogen
receptor (ER) which resides mainly in the nucleus (King 1986, 1987a, Welshons and
Gorski, 1986). There is considerable data concerning the structure of the ER. The
human ER gene was originally cloned from cDNA libraries prepared from the MCF-7
breast cancer cell line (Green and Chambon, 1986, Greene et al., 1986). The resultant
ER protein has a molecular weight of 66kDa and is composed of 595 amino acids.
The protein consists of several functional domains which have been elucidated from
DNA sequencing data used to predict amino acid composition (Figure 1.3).
The hydrophobic steroid-binding region is situated at the carboxy-terminal end of the
protein and is separated from the hydrophilic DNA binding domain by a 'hinge
region', the physiological relevance of which is not understood. The DNA-binding
region which is rich in cysteine residues is thought to attach to chromatin DNA via
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'zinc finger' projections from the protein. These are loops created by the










Structure of the human oestrogen receptor (Adapted from Ali et al, 1993)
Although homologies are high between the steroid and DNA-binding regions of
different steroid receptors, there are important differences which determine specificity
of function. Genetically engineered receptors which contain the steroid binding
domain ofER and the DNA binding domain of the glucocorticoid receptor (GR) will
evoke a glucocorticoid-like response in the presence of oestradiol (Green and
Chambon, 1987). The third functional domain of the ER is located at the amino
terminus and is involved in transcriptional activation.
The unoccupied ER has a sedimentation constant of 8S which changes primarily to a
5S nuclear form after oestrogen binding (reviewed by King, 1989). This 5S form is
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generated by the dimerisation of two 4S ligand binding units. The 8S form is an
oligomeric complex consisting of the 68kDa oestradiol binding unit plus other
proteins including the 90kDa heat shock protein, HSP90. It is thought that HSP90
may perform a role in preventing the unoccupied receptor binding to its target genes.
This observation comes from evidence that after dimerisation the affinity of the DNA
binding domain increases subsequent to the loss of the HSP90 protein (Chaumbraud
etal., 1990).
The oestrogen receptor complex binds to DNA at a site 5' to the structural gene. This
region contains cis-acting enhancer sequences termed oestrogen-response elements
(ERE's) which are highly specific for ER. Two regions of the ER termed
transactivating functions (AF's, formerly TAF's) are able to stimulate gene
transcription. AF-1, located in the N-terminal region, is able to stimulate transcription
constitutively (Kumar et al., 1987, Webster et al., 1988, Tora et al., 1989) whilst
AF-2, located in the hormone binding domain requires the binding of oestrogens for
its activity (Kumar et al., 1986, 1987, Tora et al., 1989, Webster et al., 1988). AF-1
and AF-2 can both induce transcription independently in a promoter and target cell
specific manner.
Binding of the receptor to DNA alone is insufficient to activate transcription. This is
indicated from observations that tamoxifen-receptor complexes and unliganded
receptor can bind to ERE's without activating them (Webster et al., 1988).
Phosphorylation of multiple serine residues is required for optimal transcription.
Experiments in which serine 118 in the N-terminal region of the human ER was
30
mutated to an alanine residue caused a significant reduction in transcriptional
activation, but DNA binding properties and nuclear binding were not altered (Ali et
al., 1993).
Anti-oestrogens such as 4-hydroxytamoxifen (OHT) and ICI 164,384 antagonize
oestrogenic effects by competing for receptor binding. However, OHT and other
tamoxifen derivatives have partial agonist activity in that although they cannot
activate AF-2 they allow the ER to bind to ERE's and transcription to commence
through activation by AF-1 (Berry et al, 1990). Recent studies to explain this
(Tzukerman et al., 1994) have suggested that AF-2 may act as a transcriptional
facilitator in that it is not required with certain promoters. In this context the AF-2
function may be provided by a separate transcription factor bound to the promoter.
AF-1 thus acts independently of AF-2 and this may allow tamoxifen and its
derivatives to exert partial agonist activity. The ICI compound is a complete
antagonist which inhibits transciptional activation by both AF-1 and AF-2 (Metzger et
al., 1992 ). Both these anti-oestrogens also induce ER phosphorylation but to a lesser
degree than oestrogen (Ali et al., 1993).
1.3.3 Effects of oestrogen on growth
(i) Breast cancer
Many studies have reported the effects of oestrogen in breast cancer. It is the most
important endocrine influence for the development and control of this carcinoma.
Studies have been facilitated by the establishment of numerous oestrogen-responsive
breast cancer cell lines such as MCF-7, T-47-D and ZR-75-1 (Brooks et al., 1973,
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Lippman et al., 1976, Engel et al., 1978). Oestrogen is a growth stimulator for the
first two and an absolute growth requirement for ZR-75-1 (Darbre and Daly, 1989).
These cell lines possess ER and are growth stimulated by physiological doses of
17 P-oestradiol (Lippman et al., 1976, Weischselbaum et al., 1978, Darbre et al.,
1983, Berthois et al., 1986, Darbre et al., 1989, Godden et al., 1992). This growth
may be inhibited by anti-oestrogens such as tamoxifen (Lippman et al., 1983, Jordan,
1984, Marth et al., 1984) which are used routinely for the treatment of malignant
breast disease.
(ii) Ovarian Cancer
Several ovarian carcinoma cell lines have been characterised in the literature (Sinna et
al., 1979, Buick et al., 1985, Benard et al., 1985) but there have been few studies
looking at hormonal sensitivity. Part of the reason for this is the sparsity of cell lines
with moderate valid ER levels. The BG-1 ovarian carcinoma line which has a
relatively low ER value of 23 fmol/mg protein was demonstrated to be growth
stimulated by 17 P-oestradiol (Geisinger et al., 1990, Pavlik et al., 1991,
Galtier-Dereure et al., 1992). Another ovarian carcinoma cell line, BR, is also
stimulated by oestrogen but the ER status of this line was not determined
(Wimalasena et al., 1993). A lack of an oestrogen growth response was initially
observed in the NIH:OVCAR-3 cell line which possesses an ER value of 28 fmol/mg
(Nash et al., 1989a), however, a later study using this cell line demonstrated that
oestrogen causes a slight increase in growth if cells are incubated initially with
tamoxifen (Chien et al., 1994). In addition, oestrogen caused an increase in c-myc
mRNA expression. Neither oestrogen nor tamoxifen have any effect on the growth of
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the SK0V3 ovarian adenocarcinoma cell line although it expresses ER mRNA and
protein (Hua et al., 1995).
1.3.4 Oestrogen-regulated proteins
(i) Introduction
As part of its growth effect in breast cancer cells, oestrogen induces many enzymes
involved in nucleic acid production such as DNA polymerase and uridine and
thymidine kinases (Aitken, 1983, 1985). It also stimulates the turnover of
phosphatidyl inositol in MCF-7 cells (Freter,1986) and induces progesterone receptor
(Horwitz and McGuire, 1978a), and other proteins such as plasminogen activator
(Barkley-Butler et al., 1979), pS2 (Masiakowski et al., 1982), HSP27 (Ciocca et al.,
1983) and cathepsin-D (Westley and Rochefort, 1980). Recently, oestrogen has been
demonstrated to induce retinoic acid receptor-a mRNA, another member of the
steroid hormone receptor superfamily (Roman et al., 1993, Rishi et al., 1995).
Some of these oestrogen-regulated responses are discussed in further detail below,
with reference to their role in both breast and ovarian cancer.
(ii) Steroid Receptors
Oestrogen receptors can be detected in approximately 60-70% of breast tumours
(McGuire, 1978) and are an important parameter in determining the hormonal
sensitivity of the tumour and its likely response to endocrine therapy. The
progesterone receptor is one of a number of proteins induced by oestrogen (Horwitz
and McGuire, 1978a) and assessment of both the ER and PR status of breast tumours
may improve the clinical management of the disease. Patients with both ER and PR
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show a good response to endocrine treatment, whilst those lacking both receptors
gain little benefit (Clark and McGuire, 1989).
The presence of oestrogen receptors (ER) in ovarian cancers also implicates
oestrogen in this disease, and progesterone receptors may be indicative of oestrogen
sensitivity. Oestrogen receptors are found at low levels in normal human ovarian
surface epithelium with progesterone receptors being more prevalent (reviewed in
Leake and Owens, 1990). However in ovarian cancer, incidence of PR is generally
lower whereas ER increases (Quinn et al., 1982, Spona et al., 1983). A review of 52
reports by Slotman and Rao, (1988) revealed that ER were present on 63% of
ovarian tumours, PR on 48% and ER and PR together on 34% of the tumours.
Neither were detected in 25% of cases. In addition androgen receptors were present
on 69% of tumours. A relationship between endometrioid tumours and PR status has
been reported, often in conjunction with ER (Freidman et al, 1979, Ford et al., 1983,
Sutton et al., 1986). Serous tumours are often ER-positive (Quinn et al., 1982) whilst
mucinous and clear cell tumours possess lower amounts of steroid receptors (Quinn
etal., 1982, Ford et al., 1983).
As in breast cancer, ER presence in ovarian cancer has been linked with a good
prognosis (Creasman et al., 1981, Kauppila et al., 1983, Bizzi et al., 1988, Kieback et
al., 1993a,b) although others have not found any correlation (Sevelda et al., 1990,
Rose et al., 1990). Inconsistencies in results may be due to differences in
methodologies or cut-off values, and recently studies have used the CARL value
(Composition Adjusted Receptor Level) which takes into account the cellular
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heterogeneity within tumours (Kieback et al., 1993 a), or obtained an immunoreactive
score comprising both the percentage of cell staining positively for ER and the
staining intensity (Kieback et al., 1993b). Both these methods have shown an
asssociation between ER positivity and improved survival (Kieback et al., 1993a,b).
A similar relationship between PR positivity and survival has been reported (Iversen
et al., 1986, Sevelda et al., 1990, Harding et al., 1990, Kommoss etal., 1992a).
As mentioned previously, several ovarian cancer cell lines possessing low levels ofER
have been described which vary in their growth responses to oestrogen (Nash et al.,
1989a, Galtier-Dereure et al., 1992, Chien et al., 1994). Oestrogen induction of
progesterone receptors has been demonstrated in the NIH:OVCAR-3 ovarian cancer
cell line (Nash et al., 1989a) and in vivo (Hamilton et al., 1984).
(iii) pS2 (pNR-2)
a) Structure and function
The pS2 protein (also known as pNR-2) is one of a series of oestrogen-inducible
proteins and has been cited as a possible predictive marker of endocrine response in
human breast carcinomas. pS2 was first characterised in the breast cancer cell line
MCF-7 from cDNA sequences (Masiakowski et al., 1982) corresponding to an
mRNA which was specifically increased by oestrogen treatment. Cloning of the gene
revealed that the full non-polyadenylated transcript is 490 nucleotides in length and
organised into three exons (Jeltsch et al., 1987) which encode a small pre-protein of
84 amino acids (Jackowlev et al., 1984), leading to a mature secreted protein of 60
amino acids (Rio et al., 1988a). The gene has been mapped to chromosome 21q22.3
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(Moisan et al., 1988). Berry et al., (1989) demonstrated that when isolated, the
transcriptional enhancer oestrogen-responsive element of the gene can confer
oestrogen inducibility to the rabbit P-globin gene promoter, an action which is inibited
by anti-oestrogens. Further studies have also revealed that enhancer regions flanking
the 5' region of the gene are responsive to TPA, EGF and the c-H-ras and c-jun
proto-oncogenes (Nunez et al., 1989).
The function of the pS2 protein has yet to be elucidated but it shows some structural
similarities to small peptide growth factors such as human IGF-I and IGF-II. There is
also a high degree of homology between the pS2 protein and a group of peptides
which include the porcine spasmolytic polypeptide, PSP and spasmolysin, a repetitive
protein isolated from Xenopus skin (reviewed in Rio and Chambon, 1990).
b) Distribution
A wide screen by immunohistochemistry of normal tissues including colon, pancreas,
liver, lung, prostate, kidney, endometrium, ovary and pituitary gland detected no
expression of pS2 protein (Rio et al., 1988b). Flowever the protein has been detected
in normal gastric mucosa, small intestinal mucosa and breast epithelium (Rio et al.
1988b, Piggott et al. 1991), and in a variety of malignant tissues including gastric
carcinomas, breast and gynaecological tumours (Luqmani et al., 1989, Rio et al.,
1987, Wysocki et al., 1990, Henry etal., 1991b).
c) Prognostic value
pS2 expression correlates predominantly with ER-positive breast tumours (Rio et al.,
1987, Foekens et al., 1990a, Henry et al., 1991a, Schwartz et al., 1991, Thor et al.,
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1992, Stonelake et al., 1994). It has also been associated with later recurrence and
death when analysed by immunoradiometric assay (Foekens et al., 1990a), with
overall survival being greatest in ER/PR/pS2-positive tumours. However, other
groups using immunohistochemistry found no association between pS2 expression
and overall survival or time to first relapse (Henry et al., 1991a, Thor et al., 1992,
Dookeran etal., 1993).
Using immunohistochemistry, Henry et al., (1991b) detected pS2 expression in
benign and malignant ovarian epithelial tumours, with a strong correlation with the
mucinous subtype. Wysocki et al., (1990) also demonstrated pS2 mRNA in ovarian
carcinomas and noted a correlation with ER status although this was not statistically
proven. However Foekens et al., (1990b) found no expresssion of pS2 in ovarian
tumours using a radiometric immunoassay.
(iv) HSP27
a) Structure and function
HSP27 is a 27kDa member of the heat shock protein (HSP) family which is induced
in response to oestrogen and has been cited as a possible prognostic marker in breast
cancer. It was first reported as a 24,000 molecular weight protein, 'p24', which was
induced in MCF-7 breast cancer cells in response to oestrogen (Edwards et al.,
1980). It was also induced by heat shock in this cell line (Fuqua et al., 1989). Several
other investigators were also simultaneously looking at the protein. Thor et al.,
(1991) described srp27 expression in human breast carcinomas and Coffer and King,
(1988) detected a cytoplasmic phosphoprotein, 'p29' with an antibody, D5, raised
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against partially purified human myometrial ER. Using immunocytochemical and
immunoblot techniques, Ciocca and Luque, (1991) identified p29 as HSP27.
The human HSP27 gene has been characterised (Hickey et al., 1986). From this and
other studies it was noted that HSP27, like other small HSP's, shares a striking
homology with a-crystallin lens proteins. HSP gene regulation has been well
documented and involves two heat shock factors, HSF1 and HSF2 in humans
(Rabindran et al., 1991, Schuetz et al., 1991). Heat shock-induced transcription is
activated by binding of HSF(s) to the heat shock element (HSE) of the HSP gene. It
is thought that hormonal activation ofHSP's may be similar to a system described in
Drosophila whereby P-ecdysone binds to a distinct promoter region, different to the
heat shock element. The p-ecdysone response element shows similarities to the
mammalian oestrogen response element (Riddihough and Pelham, 1987).
In addition to being induced by oestrogen, HSP27, as its name suggests, is induced by
heat shock and other environmental stresses such as viral or microbial infections,
exposure to oxidants and heavy metals (reviewed in Ciocca et al., 1993). Besides its
role in thermotolerance, HSP27 is also thought to act as a molecular chaperone and
play a role in signal transduction. In addition, recent studies have implicated it in the
development of drug resistance in a number of cell types (Huot et al., 1992) including
breast cancer cell lines (Ciocca et al., 1992, Oesterreich et al., 1993).
b) Distribution
The heat shock family are found in nearly all living cells, both eukaryote and
prokaryote. In human tissues, HSP27 has been detected in muscle, nervous and
connective tissue (Ciocca et al., 1983). It is expressed in higher amounts in oestrogen
target organs of the female reproductive tract, including the uterus, vagina and
fallopian tubes (Ciocca et al., 1983, reviewed in Ciocca et al, 1993).
c) Prognostic value
It is unclear how HSP27 may predict for prognosis in breast cancer. There has been
conflicting data regarding its utility in this disease. Certain groups have reported an
association with more aggressive breast tumours (Chamness et al., 1988, Tandon et
al. 1990) and a short disease free survival (Thor et al., 1991, Love and King, 1994).
However Seymour et al., (1990) reported an improved outcome in HSP27 positive
tumours. There have been no reports of its presence in ovarian cancer.
(v) Cathepsin D
Cathepsin D was first described in the oestrogen-receptor positive breast cell lines
MCF-7 and ZR-75-1 where it was secreted as a 52kDa protein into the culture
medium after oestrogen treatment (Westley and Rochefort, 1980). The 52kDa protein
was later purified and shown to be a precursor, approximately 55% of which is
secreted while the rest is processed into a 48kDa form and a 34kDa plus 14kDa
protein. The exact function of this protein is unknown but evidence points to it
playing a role in mammary carcinogenesis perhaps by enhancing tumour invasion
(Rochefort et al., 1987). Purified Cathepsin D is able to stimulate oestrogen-deprived
MCF-7 cells by activation of latent forms of growth factors, and at acidic pH can
degrade the extracellular matrix, suggesting it may mediate the effects of oestrogens
on tumour growth and invasion.
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Cathepsin D has been detected in breast biopsies and has been demonstrated to be
independent of steroid receptor status (Cavailles et al., 1987). It is constitutively
overexpressed in ER-negative breast cells (Rochefort et al., 1990) and linked in a
number of studies to increased risk ofmetastasis (Thorpe et al., 1989, Spyratos et al.,
1989, Tandon et al., 1990b). Recent studies have demonstrated its modulation by
oestrogen in several ovarian cancer cell lines (Galtier-Dereure et al., 1992, Hua et al.,
1995). Production of this protein by some ER-negative cells (Rochefort, 1994)
suggests that it will not be a useful marker of hormonal sensitivity in ovarian cancer.
Cathepsin D has been detected in some ovarian tumour cytosols and higher levels
have been observed in omental metastases than primary tumours but its presence
analogous to the situation found in breast cancer does not correlate with ER or PR.
(Scambia et al., 1991, 1994).
1.3.5 Growth factors
(i) Introduction
Growth factors are polypeptides that in a normal context act as extracellular agents to
modulate cell function or induce quiescent cells to proliferate or differentiate (Roberts
and Sporn, 1989). Smith et al., (1971) proposed that growth factors cancel certain
restriction points within the cell cycle and allow it to progress. In human cancer the
expression and function of peptide growth factors and/or their receptors are
frequently deranged leading to the overexpression of normal or mutated forms and
resulting in the development of malignancies (Roberts and Sporn, 1989, Dickson,
1990). Growth factors exert their biological effects on target cells following
interaction with specific receptors which then trigger a series of enzymatic and
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biological events, ultimately leading to DNA synthesis and effects on cellular kinetics.
They may act on the same cell which secreted them (autocrine regulation), or on
neighbouring cells (paracrine regulation) or on distant cells (endocrine regulation)
(see Figure 1.4).
There is an increasing amount of evidence to suggest that autocrine mechanisms are
important in the growth control of ovarian cancer. The major autocrine influences are
probably effected though members of the epidermal growth factor/transforming
growth factor-alpha (EGF/TGF-a), insulin-like growth factor (IGF) and TGF-P
families (Kohler et ah, 1989, Owens et ah, 1991a, Stromberg et al., 1992, Hurteau et
al., 1994). Data from breast cancer cell lines indicates that oestrogen may mediate its
mitogenic effects through growth factors which include TGF-a and IGF-I (Dickson et
ah, 1986, Bates et ah, 1988, Huff et ah, 1988). Several reports also suggest this may
be true in ovarian cancer; both TGF-a mRNA and several IGF binding proteins are
modulated by oestrogen (Nash et ah, 1989b, Krywicki et ah, 1993).
The role of oestrogen and its effects on EGF, TGF-a, and IGF-I receptor expression
in ovarian cancer cell lines is examined in this thesis, and so these growth factor
families are discussed in further detail.
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Possible growth regulation pathways
(ii) Structure and synthesis of Epidermal Growth Factor (EGF)
Epidermal growth factor was first discovered by Stanley Cohen over thirty years ago
as a contaminant of nerve growth factor (1962). It was originally distinguished for its
ability to open the eyelids of newborn mice and accelerate the eruption of mouse
teeth, and was found in abundance in mouse salivary glands. This source enabled the
purification and elucidation of its amino acid structure (reviewed in Burgess, 1989).
Gregory, (1975) realised that murine EGF was very similar in structure to a human
urinary protein responsible for the inhibition of gastric acid secretion, 3-urogastrone,
which his group had recently purified. Both factors have 37 amino acids (out of 53) in
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common and each contains 3 disulphide bonds at similar positions. He concluded that
human EGF and urogastrone were 'one and the same'.
EGF is synthesised as a 1217 amino acid precursor which is modified to a mature 53
amino acid form with a molecular weight of 6045 (Gray et al., 1983, Scott et al.,
1983). Originally thought to have limited expression it was found from sections of
whole newborn mice that EGF is expressed in a wide variety of tissues (Rail et al.,
1985) although the only concentrated source in the mouse is the male submaxillary
glands (Byyny et al., 1972). Here the precursor is broken down to the 53 amino acid
mature form which associates with several binding proteins in cytoplasmic granules
(Kasselberg et al., 1985).
EGF has many varied biological actions both in vivo and in vitro. In particular it has
proliferative effects on fibroblasts, keratinocytes and epithelial cells (reviewed in
Burgess, 1989). In humans, EGF is found in a variety of fluids including breast milk,
colostrum and urine (Jaspar and Frankchimont, 1985) and is located in a wide variety
of epithelial cells including those from lung, stomach, kidney, pancreas, skin, breast,
ovary, uterus and placenta (reviewed in Modjtahedi and Dean, 1994). It has been
shown to promote the proliferation of human mammary epithelial cells in culture
(Ethier et al., 1991) as well as a number of other normal and tumour cells.
(iii) Structure and synthesis ofTransforming Growth Factor-alpha
(TGF-a)
Transforming growth factors were originally discovered by De Larco and Todaro,
(1978) in the conditioned media of murine sarcoma virus-transformed mouse 3T3
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fibroblasts and provided evidence that expression of a viral oncogene could turn on
production of a cellular growth factor. The 'factor' involved was initially called
sarcoma growth factor (SGF) and had the ability to cause a phenotypic
transformation of cells; conditioned medium from the transformed cells induced a
reversible change in the morphology of normal fibroblasts (NRK cells) to a
transformed appearance, caused loss of contact inhibition of cells in monolayer
culture and induced anchorage-independent colony formation in soft agar (De Larco
and Todaro, 1978, Roberts et al., 1983). This data provided the first evidence for the
autocrine secretion of growth factors being a causative factor in malignant
transformation (Sporn and Todaro, 1980). When SGF was purified this transforming
activity was found to be the result of two growth factors, TGF-a and TGF-p.
Originally thought to be a property of transformed cells, it was discovered that these
two growth factors could also be extracted from normal cells (Roberts et al., 1981,
Sporn et al., 1986).
Human TGF-a cDNA was first isolated and characterised from a library prepared
from a human renal carcinoma cell line (Derynck et al., 1984). It was found that the
mRNA of approximately 4.8Kb encoded a 160 amino acid polypeptide anchored to
the cell surface via its C-terminus, from which the 50 amino acid biologically active
form derives (Bringman et al., 1987). In addition to this, higher molecular weight
forms are also released from the precursor. The portion ofTGF-a attached to the cell
membrane is palmitoylated and it has been suggested that this may allow for more
efficient cleavage of the precursor by slowing down its passage through the golgi and
cell surface membranes. Possibly the membrane-bound TGF-a molecule plays a role
in cell-cell signalling. TGF-a shows considerable structural and biological homology
with EGF and binds to the EGF receptor with similar affinity (Todaro et al., 1980,
Carpenter et al., 1983). TGF-a may play an important role in foetal development and
tissue regeneration (Derynck, 1992). Moreover, many studies also indicate that
human cancer cells produce and release TGF-a, and possess functional receptors for
the peptide (Todaro et al, 1980, Roberts et al., 1980, reviewed in Modjtahedi and
Dean, 1994).
(iv) Structure of the Epidermal Growth Factor Receptor
The EGF receptor (EGFR) is possibly one of the most studied tyrosine kinase
receptors and is found in a wide variety of tissues and cell types with the exception of
haemopoietic cells. It belongs to the Type I tyrosine kinase growth factor receptor
family which includes the products of the c-erbB-2 (also known as neu/HER-2),
c-erbB-3 and c-erbB-4 proto-oncogenes (Coussens et al., 1985, Yamamoto et al.,
1986, Kraus et al., 1989, Plowman et al., 1993). The gene for the EGFR, c-erbB-\ is
located on chromosome 7 (reviewed in Hsuan et al., 1989). This name derives from
the original sequencing experiments of the cloned receptor which revealed a high
level of sequence homology with the erb-B oncogene of the avian erythroblastosis
virus (AEV) (Ullrich et al., 1984). It is overexpressed in many malignancies including
some lung cancers, gastric carcinomas and breast cancer (Gullick et al., 1991). It was
first cloned and sequenced in 1984 (Downward et al., 1984, Ullrich et al., 1984). The
protein consists of a single polypeptide chain of 1186 amino acids, divided into two
domains separated by a hydrophobic membrane-spanning region. During its
biosynthesis N-linked oligosaccharide chains are added co-translationally to a 135kDa
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polypeptide core and a 24 amino acid leader sequence removed to give rise to a
160kDa precursor molecule, a process inhibited by tunicamycin. Further modification
of the oligosaccharide chains yields the mature 170kDa receptor (Mayes and
Waterfield, 1984). These oligosaccharide chains have been shown to confer ligand
binding ability to the receptor as tunicamycin-treated cells lack this facility. The
extracellular domain contains 621 amino acids and is responsible for binding the
ligand. It is folded into 4 domains termed LI, L2, SI and S2, the two L-domains
being folded together to form a (3-barrel superstructure which binds the ligand and is
supported by the S domains (Bajaj et al., 1987). These two S domains contain a high
cluster of cysteine residues (51 out of 621 amino acids) and are probably involved in
the formation of disulphide bonds. The transmembrane region of the receptor consists
of 23 uncharged hydrophobic residues and is held in its position by a highly-basic stop
transfer sequence. The exact function of this region has not been determined but
experiments in which the lipid environment of cell lysates is modifed can alter both
ligand binding and kinase activity (Downward et al., 1985). The intracellular region
of the receptor is responsible for the tyrosine kinase activity and consists of about 250
amino acids leading from a 50 amino acid juxta-membrane sequence. The catalytic
domain is linked to an autophosphorylation domain of about 150-200 amino acids.
After binding, receptors dimerize and rapidly become phosphorylated on tyrosine
residues in the C-terminal autophosphorylation domain. Recent work implicates
growth factor receptor-binding protein 2 (GRB2) as a primary signal transduction
protein involved in EGFR siganalling (Rozakis-Adcock et al., 1993, Egan et al.,
1993). GRB2, in a heterodimer complex with mSOS protein, binds to the
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phosphorylated EGFR; this complex then binds the ras-GDP complex (Chardin et al.,
1993). This leads to the activation of raf kinase probably through the binding of
c-raf-1 proto-oncogene (Zhang et al., 1993, Warne et al., 1993) and serves to
activate the MAP kinase cascade (Kyriakis et al., 1992). Targets for MAP kinase
include nuclear transcription factors c-myc and c-jun (Alavrez et al., 1991, Pulverer
et al., 1991) and these in turn influence cell cycle regulation. As well as acting as a
receptor for EGF and its related polypeptide TGF-a, the EGFR can also bind several
virally encoded growth factors such as those produced by Vaccinia (Brown et al.,
1985, Stroobant et al., 1985), and amphiregulin, a growth factor first identified in
breast cancer conditioned medium (Shoyab et al., 1988, 1989). More recently a new
epidermal growth factor-related protein has been described (Ciccodicola et al.,
(1989). Cripto-1 (CR-1) is a 188 amino acid protein which shares a cysteine rich
motif in common with the other members of the EGF family. It is overexpressed in
many colorectal and gastric carcinomas (Ciardiello et al., 1991, Kuniyasu et al.,
1991), and in pancreatic cancer (Freiss et al., 1994). However, recent work suggests
that it functions as a growth factor in an EGFR-independent pathway (Brandt et al.,
1994).
(v) Implication of the EGF/TGF-a family in ovarian cancer
Evidence is accumulating for growth factor involvement in the proliferation of
ovarian cancer. The presence ofEGFR have been detected by both ligand binding and
immunohistochemistry in between 33 and 75% of ovarian cancers (Bauknecht et al.,
1989, Morishige et al., 1991a, Owens et al., 1991b, Jindal et al., 1994) and appear to
be higher in malignant cells as compared to benign or normal ovary, implying a role
for EGFR in carcinogenesis (Owens and Leake, 1993, Berns et al., 1992). TGF-a has
been reported to be present in 50-100% of ovarian tumours (Owens et al. 1991a,
Morishige et al., 1991, Kommoss et al., 1990b). EGF has also been confirmed in
between 28-71% of ovarian tumour samples (Owens et al., 1991a, Stromberg et al.,
1994) and the presence of amphiregulin and cripto has also been reported (Stromberg
et al., 1994). The majority of studies report that the presence of EGFR is associated
with poor prognosis in malignant ovarian tumours, (Bauknecht et al., 1989, Battaglia
et al., 1989, Berchuck et al., 1991, Scambia et al., 1992) although this is not
universally observed (Van der Burg et al., 1993, Bauknecht et al., 1990).
C-erbB-2 is overexpressed in about 20-30% of ovarian tumours and is associated
with poor prognosis, similar to EGFR (Slamon et al., 1989, Berchuck et al., 1990a).
A recent study also reported the presence of the c-erbB-3 receptor in 89% of
malignant ovarian tumours, with a strong correlation between overexpression and
borderline and early invasive tumours (Simpson et al., 1995).
Several studies have demonstrated the presence ofEGFR and TGF-a production in a
range of ovarian carcinoma cell lines, and observations that neutralising antibodies to
TGF-a inhibit proliferation support the view of an EGFR/TGF-a autocrine loop in
ovarian cancer (Morishige et al., 1991b, Stromberg et al., 1992, Jindal et al., 1994).
A similar finding was noticed with an ovarian cell line developed in vivo (Kurachi et
al., 1991), and in primary human adenocarcinomas (Morishige et al., 1991a).
Berchuck et al., (1990b) demonstrated that addition of epidermal growth factor
(EGF) induced growth in several ovarian cancer cell lines but transforming growth
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factor-beta (TGF-P) caused an inhibition. Most of the cell lines were also found to
produce TGF-P, but not EGF. Bartlett et al., (1991, 1992) have demonstrated
varying expression of both TGF-a and TGF-P mRNA's in the series of ovarian lines
described in this thesis. Three of these same cell lines possess EGFR and are growth
stimulated in response to exogenous EGF and TGF-a (Crew et al., 1992a). In one of
these ER-positive ovarian cancer cell lines, PE04, oestrogen has been shown to
increase TGF-a mRNA levels, (Nash et al., 1989) and to downregulate levels of
EGFR (Crew et al., 1992b). There is also evidence that oestrogen may modulate
TGF-a in vivo, from data showing that higher levels of TGF-a are found in
ER-positive/PR-positive ovarian tumours (Leake et al., 1995).
(vi) Insulin-Like Growth Factors
The insulin-like growth factors IGF-I and II are low molecular weight peptides which
are structurally similar to pro-insulin and are believed to play a role in cyclic ovarian
follicular development (Giordano et al., 1992, reviewed in Giudice, 1992). The IGF-I
receptor is the main mediator of IGF activity although IGF's can also act through the
insulin receptor. The growth stimulatory potential of IGF's is modulated by binding
proteins (IGFBP's) which may target them to specific tissues (Jones and Clemmons,
1995). Alternatively IGFBP's may inhibit the effects of IGF's by complexing with
them. They have been implicated in the autocrine regulation of a number of tumour
cell lines (Macaulay, 1992), and evidence is accumulating to suggest that oestrogen
may exerts part of its actions through modulation of IGF's. In the ER-positive breast
cancer cell line MCF-7, oestrogen has been shown to upregulate the IGF-I receptor
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(Stewart et al., 1990), and Briinner et al., (1993b) showed that oestrogen treatment
of human breast tumour xenografts grown in nude mice correlated with IGF-II
expression. IGF-I, and its receptor are expressed in several ovarian carcinoma cell
lines (Yee et al., 1991a) and Resnicoff et al., (1993) have shown that growth of the
OVCAR-3 and CaOV-3 ovarian carcinoma cell lines is stimulated by IGF-I.
Furthermore, antisense oligonucleotides against the IGF-I receptor inhibit
proliferation of OVCAR-3. A number of IGFBP's (IGFBP2 to IGFBP-6) are also
expressed by ovarian carcinoma cell lines (Yee et al., 1991a, Hofmann et al., 1994)
and have been found in malignant ovarian cyst fluid (Kanety et al., 1996). Data
regarding oestrogen modulation of the IGF family in ovarian cancer is sparse,
although Krywicki et al., (1993) have shown that oestrogen downregulates the
expression of IGFBP3, but upregulates IGFBP5 in the PE04 ovarian cell line.
(vii) Summary
Thus, an increasing amount of evidence suggests that growth factors are implicated in
the growth of ovarian cancer cells. Moreover, oestrogen may influence the growth of
hormonally-sensitive ovarian cancer cells through the regulation of these factors. A
diagram illustrating some of the possible response pathways through which oestrogen




A summary diagram illustrating some of the possible mechanisms by which oestrogen
may regulate growth in a hormonally sensitive ovarian cancer cell.
1.4 Aims of the study
As described in this introduction, there is both epidemiologcal and direct evidence to
suggest that at least a percentage of ovarian cancer is under the control of oestrogen.
The aims of this study were to obtain direct evidence of oestrogen regulation in
ovarian carcinoma cells and to define further oestrogenic mechanisms of growth
control. To facilitate this, a series of ovarian carcinoma cell lines established and
characterised within the Edinburgh Medical Oncology Unit were employed in
experiments. These ovarian cell lines possess a range of oestrogen receptors and
include the first ovarian cancer cell lines described with substantial levels of ER.
Using these cell lines the role of the hormone oestrogen was to be assessed by
determining :
a) the effects of oestrogen on the growth of human ovarian cancer cells in culture and
relating this to ER content.
b) which factors may be putative markers of hormonal sensitivity in these lines.
c) whether the effects of oestrogen on growth may be mediated through the action of
growth factors.
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2. MATERIALS AND METHODS
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2.1 MATERIALS
The sources of materials used in the experiments discussed in this thesis are listed in
the following section according to experimental technique.
2.1.1 Cell culture
(i) In vitro cell lines
a) Ovarian cancer cell lines
The serous adenocarcinoma ovarian cell lines were derived from ascitic fluids as
previously described (Langdon et al., 1988) and brief characterisation details are
given in Table 2.1. The cis-platinum (CDDP) resistant subline PE01cddp was derived
from the PEOl cell line by the continuous culture of the parent line in increasing
concentrations of CDDP from 5 x 10"9M to 10"6M over a six month period. The
cytology and karyotype of the subline is similar to the parent line but the doubling
time is shorter, plating efficiency is higher and resistance to CDDP is five-fold greater
than that observed for the parental PEOl cell line when assessed by MTT assay.
b) Breast cancer cell lines
Two breast cancer cell lines, ZR-75-1 and MDA-MB-231 were incorporated into the
studies for comparison. The ZR-75-1 line is an extensively studied ER-positive breast
cancer cell line first characterised by Engel et al., (1978). It was derived from the
malignant ascitic effusion of a 63 year old women suffering from an infiltrating duct
carcinoma of the right breast. The woman at the time had received 3 months of
chemotherapy including tamoxifen and fluoxymesterone. The MDA-MB-231 breast
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carcinoma cell line was derived from a pleural effusion, (Cailleau et al., 1974), and is
ER-negative (Horwitz et al., 1978c).
c) Materials for in vitro cell culture experiments
The following materials were used in the routine culture of the in vitro cell lines
Cell Scrapers Costar Corp.
Activated charcoal Sigma
Dimethyl Sulphoxide (DMSO) BDH Analar
Dextran T70 Pharmacia
DMEM media with/without phenol red GIBCO Paisley, UK
EDTA Sigma
Foetal Calf Serum GIBCO Paisley, UK
L-glutamine Sigma
17 p- oestradiol Sigma
Penicillin / Streptomycin GIBCO Paisley, UK
Phenol red Flow Laboratories
Phosphate Buffered Saline (PBS) Oxoid
RPMI 1640 media with/without phenol red GIBCO Paisley, UK
Sulphatase Sigma
Tissue culture flasks, multi-well plates Corning, Falcon
Trypsin GIBCO Paisley, UK
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Table 2.1 Characterisation of cell lines
CELL LINE ORIGIN OF CELL LINES INDICATING
CLINICAL CHARACTERISTICS AND

















Breast cancer cell lines
zr-75-1
mda-mb-231
Derived from the peritoneal ascites (PA) of a DB
patient with a poorly differentiated serous
adenocarcinoma following treatment with
CDDP, 5-FU and chlorambucil
Derived from PA in the same patient following
the development of drug resistance
Derived from PA in the same patient prior to
death
Derived from in vitro culturing of PEOl cell line
in increasing concentrations of CDDP
Derived from a pleural effusion of a patient with MK
a poorly differentiated adenocarcinoma. No
treatment
Derived from the PA from the same patient,
MK after relapse from cisplatin and
prcdnimustinc therapy
Derived from the PA of a patient with a poorly ER
differentiated serous adenocarcinoma after
radiotherapy
Derived from the PA of a patient with a well EM
differentiated serous adenocarcinoma prior to
treatment
Derived from the PA of the same patient, EM
collected on relapse after cisplatin and
chlorambucil therapy










a ER status of routinely cultured ovarian cell lines. Values shown are the mean of three
measurements determined by a ligand binding assay or sucrose density gradient assay (Langdon et
al., 1990) b Long et al., (1992) c Horwitz et al., (1978c) ND = Not determined
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Figure 2.1
Photograph of the PEOl ovarian carcinoma cell line in mid-log phase (x 125)
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Figure 2.2
Photograph of the PE04 ovarian carcinoma cell line in mid-log phase (x 125)
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Figure 2.3
Photograph of the PE014 ovarian carcinoma cell line in mid-log phase (x 125)
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(ii) In vivo experiments
The two ovarian cancer xenograft models, PE04 and HOX60, and two breast cancer
xenografts, ZR-75-1 and T1068 discussed in this thesis were established in female
nude (nu/nu) mice acquired from OLAC, Oxford, UK.
17 P-oestradiol slow-release pellets were obtained from Innovative Research of
America.
2.1.2 Oestrogen receptor (ER) / Progesterone receptor (PR)
measurements
Tris buffer





FACScan flow cytometer Becton Dickinson
(i) pS2 measurements
Anti-pS2 antibody
Sheep anti-mouse FITC conjugate
Tween 20
(ii) IGF-I receptor measurement
Anti-IGF-I Receptor antibody
Sheep anti-mouse FITC conjugate









2.1.4 Radioimmunoassay (RIA) of TGF-a and EGF










Phenyl methylsulphonyl fluoride (PMSF)
TGF-a RIA kit
Human recombinant TGF-a
Dr H Gregory, ICI (kindly supplied by Dr F.Habib
Western General Hospital, Edinburgh)















Microtitre Immulon 4 96-well plates

















96 multi-well microtitre plates








2.2.1 Routine culture of cell lines in vitro
(i) Growth of cell lines.
Ovarian cancer cells were routinely maintained at 37°C in a humidified atmosphere of
5% CO2 in Roswell Park Memorial Institute (RPM3) 1640 media containing phenol
red indicator. This was supplemented with 10% heat-inactivated foetal calf serum
(FCS; heat inactivated for 20 minutes at 56°C), streptomycin (100pg/ml) and
penicillin (100 IU/ml).
ZR-75-1 and MDA-MB-231 breast cancer cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) with phenol red indicator and supplemented with
the above additives plus 2 mM L-glutamine.
(ii) Harvesting of cell lines
Cells at 70-80% confluence in 175cm2 flasks were harvested by removing spent media
and washing monolayers twice with pre-warmed PBS. Cells were then removed by
addition of a 1:1 solution of trypsin (0.25% w/v in Gibco solution A) and versene
(ImM EDTA in PBS, 0.5% v/v phenol red). This solution was deactivated after
approximately 5 minutes by the addition of a small quantity of the appropriate media
containing 10% FCS. Cells were passed through either a 19.5 (PE014) or 21.5 gauge
needle to produce a single cell suspension and then seeded into new flasks.
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(iii) Freezing and storage of cells
Cells were frozen for later use in the following way: at 80-90 % confluence cells were
trypsinised as described above and a single cell suspension produced. An aliquot was
removed for counting by haemocytometer and the suspension centrifuged at lOOOg
for 10 minutes. The pellet was resuspended in ice cold 10% v/v DMSO/newborn calf
serum at a concentration of 5xl06 cells/ml. Aliquots (1ml) were kept at -80°C
overnight before final storage in liquid nitrogen.
Cells were recovered by thawing aliquots rapidly in warm water and the DMSO/cell
suspension placed into either RPMI or DMEM containing 10% FCS, followed by
centrifugation at lOOOg for 10 minutes. Cell pellets were resuspended in the
appropriate media and seeded into 25cm2 flasks which were incubated for 24 hours to
allow attachment. Fresh medium was added after washing monolayers with PBS to
remove dead cells. Cells for experiments were used at similar passage numbers.
(iv) Removal of oestrogens from culture media
For all in vitro experiments, cells were cultured in conditions free from oestrogens.
The pH indicator in tissue culture medium, phenol red, has been previously shown to
have weak oestrogenic effects (Berthois et al., 1986), consequently cells were fed
with phenol red-free media, either RPMI or DMEM which was supplemented with
streptomycin (100pg/ml), penicillin (100 IU/ml), 2 mM L-glutamine and 5%
double-charcoal stripped FCS.
63
Steroids were stripped from FCS as follows using a method adapted from Stanley et
al., (1977):
For 100ml of heat-inactivated FCS, a suspension of Ig charcoal/5mg dextran T70 in
10ml distilled H20 (dH20) was prepared and stored at 4°C until use. The FCS was
incubated with 250 units of sulphatase in a 37°C water bath for 2 hours. The pH of
the serum was then adjusted to 4.2 with 2M HC1 followed by addition of 5ml of the
charcoal/dextran solution. This was stirred overnight at 4°C and then the
dextran/charcoal removed by centrifugation at 18,000g for 20 minutes. The remaining
5ml of dextran/charcoal was added and the method repeated. The pH of the FCS was
adjusted to 7.2 with 2M NaOH and sterilised by passing through 0.22pM filters. The
double charcoal-stripped FCS was stored at -20°C until required.
2.2.2 Establishment of cell lines in vivo
Female nude (nu/nu) mice were maintained on a standard diet in negative pressure
isolators (La Calhene, Cambridge, UK). Animals were at least 8 weeks old when
experiments commenced. Xenografts were initiated from the PE04 ovarian and
ZR-75-1 breast cell lines by s.c. injection of cells into the flanks of female nude mice
and once established used at passages 3-10 for experiments. The HOX60 xenograft
originated from a patient with ovarian endometrioid adenocarcinoma and the T1068
xenograft was derived from a breast adenocarcinoma.
The ZR-75-1 xenograft was grown in the presence of a 1.7 mg 60 day-release
17 P-oestradiol pellet but the other xenograft models were maintained without
supplement.
2.2.3 Growth studies
(i) Measurement of the effects of oestrogen on cell growth in vitro
The effects of 17 P-oestradiol on cell proliferation were determined in the nine
ovarian and two breast cancer cell lines. Cells growing in mid-logarithmic phase were
harvested by trypsinisation and a single cell suspension made in RPMI (ovarian lines)
or DMEM (breast lines) media. Cells were plated using a 12ml Eppendorf multi-
dispensor at densities of either 2.5 x 104 cells/well (PE014) or 5 x 104 cells/well in
24-well plates. After 24 hours the media was removed, each well gently washed with
warmed PBS and the media changed to phenol red-free RPMI or DMEM containing
5% double charcoal stripped FCS. In order to reduce effects of any remaining phenol
red or steroids from FCS, plates were incubated for a further 24 hours. Subsequently
(this time was designated day 0), the medium was replenished to that with or without
17 P-oestradiol at a range of concentrations from 10"12M to 10"5M. A stock solution
of 17 P-oestradiol was prepared in absolute ethanol (10"2M) from which successive
dilutions were made up in the appropriate media. The trace amounts of ethanol in the
experimental doses have no effect on the cell lines (Langdon et al., 1990). The
medium was renewed after 3 days with fresh media containing the required
conditions. Quadruplicate wells were set up for each condition. On days 0, 3 and 6,
cells were trypsinised and counted by Coulter counter.
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a) Measurement of cell numbers
Counting of cell numbers was performed with a ZF Coulter Counter fitted with a
200|iM probe.
Counting pots containing 9.8ml NaCl (0.9%) were prepared and bubbles allowed to
disperse whilst cells were being trypsinised. Media was removed from plate wells and
each one washed gently with PBS. A solution of trypsin/versene was added
(250pl/well) and cells incubated for approximately 5 minutes at 37°C until detached.
A single cell suspension was produced by passing cells through a 19.5 (PE014) or
21.5 gauge needle (all other cells). An aliquot (200pl) was removed from each well
and added to a counting pot containing 9.8ml ofNaCl and the solution mixed. 500pl
of this cell suspension was counted by the Coulter counter. Triplicate counts were
recorded from each suspension. Cell number was calculated by multiplying the mean
of triplicate counts by a dilution factor of 25 to give the number of cells per well.
Final values for each experimental condition were determined from the mean number
of cells in four wells.
(ii) Measurement of the effects of oestrogen on cell growth in vivo
To determine the effects of oestrogen on the growth of ovarian cancer cells in vivo,
fragments of either the PE04 or F1OX60 xenografts were implanted subcutaneously
into mice and allowed to reach a mean volume of 32mm3 after approximately one
month. Animals (5-8) were allocated to either control or treatment groups and 30-day
slow-release pellets of 17 P-oestradiol (1.7mg) implanted into the opposite flank to
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that bearing the xenograft. Tumours were measured weekly using calipers and the
volume calculated in mm3 according to the formula;
volume (V) = ji /6 x / x w2
where / = the longest diameter and w = the diameter perpendicular to /.
2.2.4 Steroid receptor studies
(i) Effect of oestrogen on steroid receptors in vitro
Modulation of oestrogen receptors (ER) and progesterone receptors (PR) by
17 p-oestradiol was assessed in the nine ovarian and two breast cancer cell lines.
Media from mid-log phase cells growing in 175cm2 culture flasks were removed and
monolayers washed twice with pre-warmed PBS. Cells were fed with 50ml/flask of
either phenol red-free RPMI or DMEM media. After 24 hours (day 0) media were
replaced with phenol red-free media with or without 10"IOM 17 P-oestradiol. Cells
were refed on day 3 and harvested on day 6 by removing the media and adding a
small quantity of ice-cold PBS. Cells were then manually detached using a cell
scraper. The cell/PBS suspension was removed from one flask to another identical
flask and the procedure repeated until four flasks had been pooled. The cell
suspension was centrifuged at lOOOg for 10 minutes (4°C) to provide a single pellet
for analysis by an Abbott enzyme immunoassay kit.
(ii) Effect of oestrogen on steroid receptors in vivo
Fragments of the PE04 and HOX60 ovarian xenografts were implanted
subcutaneously into the flanks of adult female nude (nu/nu) mice and allowed to
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reach a mean volume of 32mm3 after approximately one month. Animals were
randomly assigned to either control or treatment groups (5-8 mice each). Treatment
consisted of subcutaneous implantation by trocar of a 1.7mg 17 fl-oestradiol
slow-release pellet into the flank of each mouse. After 60 days tumours were
removed and oestrogen and progesterone receptor levels analysed as described
below.
(iii) Enzyme immunoassay
ER and PR assays were kindly performed by Ann Tesdale and Tony Hawkins at the
Department of Surgery, Royal Infirmary, Edinburgh. Xenograft tissue and cellular
pellets were weighed and homogenised in buffer (10 mM Tris, 0.25 M sucrose, 1 mM
EDTA, 22°C, pH 8.0) plus v/v 1% monothioglycerol and 10% glycerol. Following
this, samples were centrifuged at 105,000g for 1 hour at 4°C. Cytosol protein
concentrations were determined by the method of Bradford, (1976). Samples were
analysed using Abbott ER and PR solid phase enzyme immunoassay kits according to
the manufacturers instructions.
2.2.5 Analysis of pS2 expression by flow cytometry
(i) Preparation of cells
Cells growing in mid-logarithmic phase were extracted by trypsinisation as described
previously. A single cell suspension was made and an aliquot counted using a
haemocytometer. Cells were plated in six well plates by Eppendorfmulti-dispensor at
densities of 105 cells/well (PE014) or 2 x 105 cells/well. After 24 hours media were
removed and wells washed gently with PBS. Fresh, phenol red-free medium was
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added and plates incubated for a further 24 hours. Cells were then treated with a
single concentration of 10"10M 17 P-oestradiol (day 0). Cells were either trypsinised
and analysed on day 3 or refed and analysed on day 6.
(ii) Analysis of pS2 by flow cytometry
After trypsinisation cells were fixed in 70% ethanol, 4°C for 30 minutes, and then
washed twice in PBS buffer containing 5% FCS/0.5% Tween 20. Anti-pS2 antibody
(lOOp.1) diluted 1:2 in buffer was added to cells on ice and left for 30 minutes. After
washing in buffer, cells were exposed to 100pl of a FITC-conjugated sheep
anti-mouse antibody (diluted 1:20 in buffer ) for 30 minutes. Cells were then washed
once in buffer, twice in PBS before being resuspended in PBS ready for reading by
flow cytometer (*see below). Samples were analysed using a FACScan instrument
(Becton Dickinson) equipped with an argon laser emitting an excitation wavelength
of 488nM. 10,000 events were collected for each sample and the data evaluated using
Lysys II software (Becton Dickinson).
2.2.6 Cell cycle analysis
* Cell cycle analysis was performed in conjunction with the pS2 experiments. Directly
before cells were analysed on the FACScan, 100pl of propidium iodide (lOOpg/ml)
was added and samples incubated at room temperature in the dark for 15 minutes.
Cells were then analysed by flow cytometer.
69
2.2.7 Analysis of IGF-I receptor modulation by oestrogen
The modulation of the IGF-I receptor by oestrogen was determined by flow
cytometry. Cells were prepared as described for analysis of pS2 expression. After six
days exposure to 10"10M 17 [3-oestradiol in six well plates, cells were detached by
trypsinisation, resuspended and fixed in 70% ethanol at 4°C for 30 minutes. Cells
were washed in cold PBS and incubated with lOOpl of anti-IGF-I receptor antibody
(diluted 1:10 in PBS/5%FCS/0.5% Tween 20 wash buffer) for 30 minutes on ice.
Samples were then washed once with the wash buffer and incubated with 100pl of a
sheep anti-mouse FITC-conjugate antibody for 30 minutes on ice. Cells were washed
twice in cold PBS and resuspended in 1ml of PBS for analysis using the FACScan
flow cytometer.
2.2.8 Analysis of HSP27 expression
(i) Preparation of pellets from routinely cultured ovarian and breast
cancer cell lines
To determine the HSP27 expression levels in routinely cultured cell lines, pellets were
prepared from cells growing at 70-80% confluency in 25cm2 flasks. Monolayers were
washed twice with PBS and cells manually removed in a small quantity of PBS using
a scraper. Samples were spun at lOOOg for 10 minutes at 4°C and the PBS removed.
Cell pellets were frozen at -80°C until required.
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(ii) Preparation of xenograft samples
PE04, HOX60, ZR-75-1 and T1068 xenografts were established as described
previously in female nude mice. Tumours were removed when approximately
1.5-2.Ocm diameter and frozen in liquid nitrogen until later use.
Cell pellets and xenograft samples were initially analysed for HSP27 expression by
Professor Roger King at the University of Surrey. Measurements of constitutive
HSP27 expression in the cell lines was confirmed when investigating the modulation
by oestrogen.
(iii) Modulation of HSP27 by 17 P-oestradiol in vitro
To investigate the effects of 17 P-oestradiol on HSP27 expression, cell lines growing
in mid-log phase in 175cm2 flasks were washed twice with pre-warmed PBS, and
media changed to phenol red-free media containing 5% dcsFCS. Cells were refed 24
hours later and exposed to a 10"10M concentration of 17 P-oestradiol. After 72 hours
cells were harvested as described previously by scraping, and then pelleted and stored
at -80°C until required.
(iv) Modulation of HSP27 by 17 P-oestradiol in vivo
Fragments of xenografts were subcutaneously implanted into the flanks of female
nude mice in a similar manner as that described for ER and PR analysis. When
tumours reached an approximate size of 32mm3 in volume, animals were allocated
randomly to control (receiving no treatment) or treated groups (17 P-oestradiol was
administered via a 60 day slow-release pellet). At the end of this period tumours from
control and treated animals were extracted and stored in liquid nitrogen until use.
(v) Cytosol preparation
HSP27 was determined in cytosols of cells pellets or xenografts prepared in the
following way:
Xenografts were weighed and homogenised with 5 volumes of Tris/EDTA buffer
(lOmM Tris/HCl, ImM EDTA, 2mM dithiothreitol, pH 7.4) on ice for 2 x 20 seconds
using a Silverson homogeniser, allowing cooling between bursts. Pellets from cell
lines were resuspended in 0.5ml of Tris/EDTA buffer and homogenised on ice by
hand using a glass homogeniser. Samples were then spun at 200,000# at 4°C for 1
hour, cytosols removed for analysis and the pellet discarded.
(vi) Protein concentration estimation
Cytosol protein levels were determined by a colourimetric assay (BioRad) adapted
from Bradford, (1976). Duplicate tubes were set up containing 20pl of either the
unknown sample or BSA protein standards ranging from 0.18-1.4 mg/ml. Two BSA
protein quality controls were also set up at 1:100 and 1:200 dilutions (0.8 and 0.4
mg/ml). BioRad Protein Dye assay reagent was diluted in distilled H20 (1:5), mixed
and filtered through Whatman No. 1 paper. The dye solution was then added to the
samples, lml/tube, and the solutions vortexed. Aliquots (200|il) from each tube were
loaded into a 96 flat-bottomed-well microtitre plate and read at 600nm using a
BioRad EIA plate reader which had been calibrated to zero. Protein concentrations
were determined by comparison with the standard curve readings. The mean of two
separate readings for each sample was calculated for use in the ELISA.
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(vii) Analysis by ELISA
HSP27 expression was detected in sample cytosols by an ELISA method (Cano etal.,
1986) using a monoclonal antibody D5, kindly provided by R. King, and
incorporating cytosolic myometrium (30, 20, 10, 5 pg/ml) and recombinant HSP27
(50, 25, 10 fig/ml) diluted in PBS as standards. Essentially, duplicate samples diluted
in PBS to give 40, 20 and lOpg/ml (ovarian cell cytosols) or 6.25, 5.00, 3.75 and 2.5
pg/ml (breast cell cytosols) were plated in Immulon 4 microtiter plates at 200p.l per
well and incubated at 37°C for 90 minutes. Plates were washed 3 times in PBS,
0.05% Tween buffer and then treated with either the D5 antibody (0.75pg/ml,
200|il/well) or 200pl PBS/Tween buffer (control wells) for 2 hours at 37°C. After
washing 3 times in buffer, wells were incubated with 200p.l of peroxidase-conjugated
rabbit anti-mouse immunoglobulin at 1:1000 at 37°C for 1 hour. Following further
washing, 200p.l of the peroxidase substrate, tetramethylbenzidine, was added to each
well for 4 to 10 minutes in the dark. The peroxidase substrate was aliquoted from a
stock solution containing lOOgl of tetramethylbenzidine (20 mg/ml in DMSO) per
20ml of substrate buffer (0.05M Na2HP04 (anhydrous) / 0.02M citric acid, pEl 5.0),
plus the addition of 14pl of 30% hydrogen peroxide when ready to use. Reactions
were terminated with 50(j.l/well of 0.5M sulphuric acid and plates read at 450nm
using a BioRad plate reader. Readings were calibrated by initially zeroing the reader
with a blank micro-titre plate.
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HSP27 expression was calculated in the unknown samples per p.g/protein by
quantifying against the value obtained for 1 pg of either a myometrial or recombinant
HSP27 protein standard run at the same time.
2.2.9 Measurement of EGF and TGF-a production by
radioimmunoassay
(i) Preparation of conditioned media
The effects of 17 P-oestradiol on the production of TGF-a and EGF by the cell lines
was determined using TGF-a RIA kits (Peninsula Labs Inc.) and an EGF
radioimmunoassay method adapted from McDonald et al., (1990). Conditioned
medium was prepared for analysis as follows: Cells growing in mid-logarithmic phase
in 175cm2 culture flasks were washed twice with pre-warmed PBS and 50ml per flask
of phenol red-free/serum-free media added. Flasks were incubated for 24 hours
followed by exposure to 50ml of fresh media containing 17 P-oestradiol (10"10M).
Cells were then incubated for 72 hours. After this time, media from the flasks were
removed and pooled to provide 100ml per condition. This was spun at 4°C, lOOOg for
10 minutes to remove any cells and subsequently transferred to round-bottomed
flasks on ice. Protease inhibitors were added to give final concentrations of 0.2mM
phenylmethanesulphonyl fluoride, ImM EDTA, 0.5 mg/L leupeptin and 0.7 mg/L
pepstatin A (adapted from Stromberg et al., 1992). Media were concentrated by prior
immersion in a methanol/CCL bath followed by freeze-drying using an Edwards freeze
drier. Once fully dry, samples were resuspended in dH20 to produce a 50x
concentrate. This was then dialysed in benzoylated cellulose dialysis membrane tubing
against PBS (2 L) for 24 hours at 4°C to remove excess salts with a molecular weight
of <1200. Concentrates were freeze-dried again and resuspended in an appropriate
volume of dH20 to produce a final concentration 100 times greater than that of the
original media before processing. Samples were dialysed again at 4°C for 48 hours,
renewing the PBS after 24 hours, and stored at -80°C before analysis.
(ii) Radioimmunoassay
a) Transforming Growth Factor-alpha (TGF-a)
Analysis of TGF-a was performed using a competitive radioimmunoassay kit
incorporating a rabbit anti-TGF-a (rat) antibody and rat TGF-a standard. A standard
curve was constructed using a concentration range of peptide from 1.0 to 128pg/tube
(lOOp.1). All samples were diluted in the RIA kit buffer. Unknown samples at lOOx
and 50x concentration (1:2 dilution of lOOx concentrate) were aliquoted (100pl/tube)
and 100pl of rabbit anti-TGF-a antibody added to both the standards and unknowns.
Tubes were vortexed and left at 4°C overnight.
The following day 125I-TGF-a stock was prepared in buffer to give a count of
10,000-15,000 cpm/sample. Tracer (lOOp.1) was then added to each sample, tubes
vortexed and left for a further 24 hours at 4°C. After this period, lOOpl of goat
anti-rabbit IgG serum was added to each tube, together with 100pl of normal rabbit
serum. Tubes were vortexed and incubated at room temperature for 90 minutes. RIA
buffer was then added to each tube (500|il), vortexed, and the samples centrifuged at
\100g, 4°C for 20 minutes to separate bound and free 125I-TGF-a. Tubes were
carefully aspirated by pasteur pipette and the pellet containing the bound 125I-TGF-a
counted for 1 minute on a Cobra AutoGamma counter (Packard Canberra).
Samples were determined in duplicate at each concentration and non-specific binding
(NSB) estimated in the absence of primary antibody and unlabelled TGF-a. Total
binding was determined by incubation of the tracer in the absence of cold TGF-a (ie.
sample or standard). Maximum binding (Bo) was calculated from this value minus the
NSB value. TGF-a activity in the samples was determined from a standard curve,
constructed by plotting %Bound/Bo against the log of the standard concentrations.
b) Epidermal Growth Factor (EGF)
Analysis ofEGF in conditioned media was determined by a liquid phase competitive
radioimmunoassay adapted from McDonald et al, (1990). All solutions were made
up in 0.01M PBS. A standard curve was prepared using EGF concentrations ranging
from 0.2-200 ng/ml. Samples were used at xlOO and x50 concentrations and human
urine incorporated as a quality control.
Standards or samples (lOOpl/tube) were aliquoted and to each tube was added lOOpl
of sheep anti-human EGF polyclonal IgG diluted to 1:30,000 and 100pl of 125I EGF
(15,000cpm). Tubes were vortexed and incubated at 37°C for 2 hours. Donkey
anti-sheep polyclonal IgG (diluted 1:20 in 1:200 normal sheep serum) (250pl) was
then added and the samples incubated overnight at 4°C. Following this, 500pl aliquots
of dH20 were added to each tube, the samples vortexed and centrifuged at 3500 rpm
to separate bound and free 125I EGF. Tubes were then carefully aspirated and the
pellet containing the bound I25I EGF counted for 1 minute in a Cobra AutoGamma
Counter.
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EGF activity was determined from a standard curve plot in a similar way to that




3.1 Modulation of growth by oestrogen
The following section describes the results from experiments designed to assess the
effects of oestrogen on the in vitro growth of nine ovarian carcinoma cell lines and to
determine any correlation between the oestrogen sensitivity of these lines and their
ER status. In addition, the effects of oestrogen on the growth of two ovarian
carcinoma xenografts, PE04 and HOX60 are presented.
The nine ovarian carcinoma cell lines possess a variety of oestrogen receptors (ER)
levels (Table 2.1) (Langdon et cil., 1990). Three of the lines, PE014, PE016 and
PE023 express receptor levels of less than 5 fmol/mg protein, the value considered to
be at the limit of detection. These lines are therefore regarded as ER-negative. The
remaining lines are ER-positive, ranging from relatively low levels of 12 to 23
fmol/mg protein for the cell lines PEA1 and PEA2, to moderate-high ER levels of 90
to 130 fmol/mg protein for the PEOl, PE04, PE06, cell lines.
3.1.1 Effects of oestrogen on proliferation in vitro
Growth response curves were initially produced for the PE04 and PEOl4 ovarian
cell lines, and two breast cell lines, ZR-75-1 and MDA-MB-231 using two
concentrations of 17 P-oestradiol (10"IOM and 10"8M), to confirm the ability of
oestrogen to modulate the growth of ER-positive cell lines but not ER-negative lines.
Secondly, the oestrogen sensitivity of eight of the ovarian cell lines was investigated
by exposing cells to a range of 17 P-oestradiol concentrations. Effects on cells were
examined in the absence of phenol red indicator and in the presence of 5% dcsFCS.
(i) Effects of oestrogen on cell growth rate
The effects of oestrogen on the in vitro growth of breast carcinoma cell lines has been
well recorded. Previous studies have shown the ER-positive ZR-75-1 cell line to be
growth stimulated by oestrogen, whilst the ER-negative MDA-MB-231 cell line is not
(Darbre and Daly, 1989, Lippman et al., 1976). These two lines were included in this
study to compare oestrogen effects between the two model systems, and to act as
positive and negative controls for oestrogen sensitivity together with the ER-positive
PE04 and ER-negative PE014 ovarian cell lines whose growth responsiveness to
oestrogen has also been shown to correlate with their ER status (Langdon et al.,
1990).
To determine whether the oestrogen growth responses of the PE04 and PE014
ovarian cell lines were typical of those described previously, cells were exposed to
10"10M and 10"8M concentrations of 17 P-oestradiol for six days. The breast cancer
cell lines, ZR-75-1 and MDA-MB-231 were similarly treated to determine their
oestrogen responsiveness. Growth was determined by changes in cell number.
a) ZR-75-1
Figure 3.1 illustrates the effects of 17 P-oestradiol on the growth of the ER-positive
breast cancer line, ZR-75-1. Oestrogen-deprived ZR-75-1 control cells showed little
growth in these conditions as demonstrated by the lack of any significant change in
cell number over the six day period. However, substantial growth modulations were
observed with both 10"10M and 10"8M concentrations of 17 P-oestradiol after three
and six days, producing a significant increase (p<0.001) in cell number as compared
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to cells grown in the absence of oestrogen over the period of study. This is in
agreement with previous data showing that this is an oestrogen sensitive cell line.
b) MDA-MB-231
The effects of 17 P-oestradiol on the growth of the ER-negative MDA-MB-231
breast carcinoma cell line after three and six days are shown in figure 3.2. There was
a progressive increase in the number of MDA-MB-231 control cells cultured
throughout the period of study. Treatment with either 10"10M or 10"8M concentrations
of 17 P-oestradiol had no significant effect on cell growth as compared to control
cells after either three or six days exposure. This result is consistent with the lack of
expression of ER and is comparable with the growth response curve for the
ER-negative PE014 ovarian carcinoma cell line (see figure 3.4).
c) PE04
Figure 3.3 shows a growth response curve, typical of three experiments, for the
ER-positive PE04 ovarian cell line after exposure to the two concentrations (10"10M
and 10"8M) of 17 P-oestradiol. In contrast to ER-positive ZR-75-1 breast cancer cells,
control PE04 cells (cultured without oestrogen supplement) progressively increased
in number over the six day period, showing a 30% increase after three days and rising
to 70% after six days. Both concentrations of 17 P-oestradiol stimulated cell growth
above that noted with control cells. A significant increase (p<0.001) in PE04 cell
number of approximately 70% was observed after three days exposure, rising to a
176 - 215 % increase after six days treatment; the 10"10M concentration causing a
slightly greater response. This result is comparable to previous reports of the
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oestrogen sensitivity in the PE04 cell line (Langdon et al., 1990), where an increase
in growth was noted after 4, 7 and 10 days exposure to both 10~10M and 10"8M
concentrations of 17 P-oestradiol. Dose response curves (see figure 3.6) indicated
that concentrations of oestrogen at 10"10M, 10"9M and 10"8M were equipotent in
producing a growth stimulation in PE04, and thus the small differences between dose
effects seen with the growth curves may be due to individual experiment variability.
This is confirmed by repeat experiments of the PE04 growth curve which show no
significant differences between the growth effects produced by 10"10M and 10"8M
17 P-oestradiol.
d) PE014
Figure 3.4 shows a growth response curve for the ER-negative PE014 ovarian cell
line after exposure to 10"10M and 10"8M 17 P-oestradiol over six days. Control
PE014 cells cultured in the absence of oestrogen increased in number after three days
culture but less of an increase was seen during the rest of the time course. In contrast
to ER-positive PE04 cells, treatment of PE014 cells with either concentration of
oestrogen produced no stimulation of growth above that seen in control conditions
after three or six days. This is in agreement with previous data, and is consistent with




Effects of exogenous addition of 17 p-oestradiol (E2) on the proliferation of the
ZR-75-1 cell line over a period of six days. Cells were cultured in phenol red-free
media supplemented with 5% dcsFCS and exposed to one of the indicated treatments
on day 0. Media was replenished after 72 hours. Cells were removed by trypsinisation
and counted by Coulter Counter after 0, 72 and 144 hours. Symbols represent the
mean of quadruplicate samples from one experiment which is typical of at least two
other experiments and bars represent standard error. *p<0.001 for the difference




Effects of exogenous addition of 17 (3-oestradiol (E2) on the proliferation of the
MDA-MB-231 cell line over a period of six days. Cells were cultured in phenol
red-free media supplemented with 5% dcsFCS and exposed to one of the indicated
treatments on day 0. Media was replenished after 72 hours. Cells were removed by
trypsinisation and counted by Coulter Counter after 0, 72 and 144 hours. Symbols
represent the mean of quadruplicate samples from one experiment which is typical of




Effects of exogenous addition of 17 P-oestradiol (E2) on the proliferation of the
PE04 cell line over a period of six days. Cells were cultured in phenol red-free media
supplemented with 5% dcsFCS and exposed to one of the indicated treatments on
day 0. Media was replenished after 72 hours. Cells were removed by trypsinisation
and counted by Coulter Counter after 0, 72 and 144 hours. Symbols represent the
mean of quadruplicate samples from one experiment which is typical of at least two
other experiments, and bars represent standard error. *p<0.001 for the difference




Effects of exogenous addition of 17 (3-oestradiol (E2) on the proliferation of the
PE014 cell line over a period of six days. Cells were cultured in phenol red-free
media supplemented with 5% dcsFCS and exposed to one of the indicated treatments
on day 0. Media was replenished after 72 hours. Cells were removed by trypsinisation
and counted by Coulter Counter after 0, 72 and 144 hours. Symbols represent the
mean of quadruplicate samples from one experiment which is typical of at least two
other experiments, and bars represent standard error.
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(ii) Effects of varying concentrations of 17 p-oestradiol on the growth of
ovarian carcinoma ceil lines
In order to obtain a more detailed profile of oestrogen sensitivity in ER-positive and
negative ovarian cell lines, eight ovarian cell lines were exposed to a range of
17 P-oestradiol concentrations (10_12M - 10_5M) over a six day period. Cells were
cultured in phenol red-free media supplemented with 5% stripped foetal calf serum
plus the addition of one of the above concentrations of 17 P-oestradiol, trypsinised
after six days and cell number determined by Coulter Counter.
a) PEOl cell line
The effects of oestrogen on cell number for the ER-positive PEOl cell line are
illustrated in figure 3.5. All concentrations of 17 P-oestradiol (1(T12 - 10"5M)
produced a significant increase (p<0.001) in the number of cells as compared to
control values. Concentrations from 10"12 to 10"10M produced a progressive increase
in cell number reaching maximum stimulation at 10"10M, approximately 140% higher
than control cells. Increasing concentrations from 10"9 to 10"5M produced a gradual
decline in stimulation, the 10"5M concentration producing the smallest increase in cell
number above the control.
b) PE04 cell line
Figure 3.6 shows the effect of 17 P-oestradiol on ER-positive PE04 cells.
Concentrations between 10"12M and 10"6M increased cell numbers significantly above
control levels (p<0.001). A gradual increase was observed with concentrations from
10"12 to 10"9M, with maximal stimulation of approximately 90% above control values
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at 10"10M and 10"9M concentrations. This result parallels the magnitude of stimulation
seen in the growth response curve for PE04 cells treated with 10"10M and 10"8M
17 P-oestradiol after six days, shown in figure 3.3.
A progressive decrease in growth stimulation was observed at concentrations higher
than 10"9M, with a concentration of 10"5M producing a significant decrease in cell
numbers to approximately 40% of control values.
c) PE06 cell line
The effects of 17 P-oestradiol on the ER-positive PE06 cell line are shown in figure
3.7. Concentrations between 10"12M and 10"7M produced a significant increase in cell
numbers which reached a maximum of approximately 40% above control cells with a
concentration of 10"10M 17 P-oestradiol. Similar to the PE04 cell line, growth
increases were less marked at higher concentrations (10"8 to 10"6M), and a significant
growth inhibition, 15% of the control value, was demonstrated with a concentration
of 1Q-5M.
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Figure 3.5
Effects of exogenous addition of 17 P-oestradiol (E2) on PEOl cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each sample being counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.001 for the
difference between the control and the group indicated, as evaluated by a Student's
/-test.
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Figure 3.6
Effects of exogenous addition of 17 P-oestradiol (E2) on PE04 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each of which was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p< 0.001 for the




Effects of exogenous addition of 17 [3-oestradiol (E2) on PE06 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each of which was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.001,
**p<0.05 for the difference between the control and the group indicated, as evaluated
by a Student's /-test.
91
d) PEA1 cell line
Figure 3.8 shows the effects of 17 P-oestradiol on the PEA1 cell line which expresses
only a low level of ER. At concentrations between 10"12M and 10"6M there was no
significant difference (p>0.05) between the number of treated and control PEA1 cells.
This differs from the responses noted in the moderate-high ER status PEOl, PE04
and PE06 cell lines which are growth stimulated by these concentrations. At the
lO^M and 10"5M concentrations of 17 P-oestradiol there appeared to be a decrease in
cell number, but this only achieved significance at the higher concentration, cell
number reaching only 30% of the control value.
e) PEA2 cell line
The effects of 17 p-oestradiol on the PEA2 cell line which expresses low levels ofER
is shown in figure 3.9. Concentrations of 17 P-oestradiol between 10"12M and 10"6M
caused no significant change in cell number. However, at the highest concentration,
10"5M there was a significant decrease in cell numbers to approximately 60% below
control values. These observations are comparable to the result obtained with the
PEA1 cell line.
The lack of response ofPEA1 and PEA2 to levels of oestrogen which are stimulatory
to both breast and ovarian carcinoma cell lines expressing moderate-high levels of
ER, (similar to that observed with ER-negative lines below), leads to the conclusion
that a certain level of ER expression is necessary in order to see growth stimulation
by oestrogen.
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f) PE016 cell line
The effects of 17 P-oestradiol on the ER-negative PE016 cell line are shown in figure
3.10. There was no significant effects (p>0.05) on cell number at concentrations
between 10"12M and 10'7M. However, the two highest concentrations of
17 P-oestradiol (10"6 and 10~5M) produced significant decreases in cell numbers. This
result is consistent with the lack of oestrogen sensitivity of ER-negative lines noted
previously with both the ER-negative PE014 ovarian line and the MDA-MB-231
breast carcinoma cell line (Figures 3.4, 3.2).
g) PE023 cell line
Concentrations of 17 P-oestradiol between 10"12 and 10"6M produced no significant
effects (p>0.05) on the growth of ER-negative PE023 cells (Figure 3.11). However,
a higher concentration of 10"SM caused a significant decrease in cell numbers as
compared to control cells. This is similar to the results obtained for the two low
ER-status cell lines, PEA1 and PEA2.
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Figure 3.8
Effects of exogenous addition of 17 (3-oestradiol (E2) on PEA1 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each of which was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.05 for the
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Figure 3.9
Effects of exogenous addition of 17 (3-oestradiol (E2) on PEA2 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each ofwhich was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.05 for the
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Figure 3.10
Effects of exogenous addition of 17 P-oestradiol (E2) on PE016 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each of which was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.05 for the
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Figure 3.11
Effects of exogenous addition of 17 (B-oestradiol (E2) on PE023 cell number. Cells
were grown in phenol red-free media supplemented with 5% dcsFCS and treated with
the concentrations of E2 indicated over a period of six days. The graph shows the
result from one experiment which is typical of at least three identical experiments.
Each value represents the mean of quadruplicate samples, each ofwhich was counted
in triplicate by Coulter Counter. Error bars denote standard error. *p<0.05 for the
difference between the control and the group indicated, as evaluated by a Student's
/-test.
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h) PE01cddp cell line
Figure 3.12 shows the effects of exogenous addition of 17 P-oestradiol on the
platinum resistant PE01cddp subline, after six days. The range of concentrations of
17 P-oestradiol (10"I2-10"5M) which caused an increase in cell number in the parental
PEOl line above control values, produced a significant decrease in numbers of
PE01CDDP cells, to approximately 40% below that of control cells, the highest
concentration (10"5M) producing the greatest inhibition. At lower concentrations of
17 P-oestradiol (10"13-10"16 M) a progressive decrease in inhibition was observed with
decreasing concentration such that at 10"16 M, cell numbers were similar to levels of
control cells cultured without oestrogen.
Figure 3.13 shows a more detailed growth response curve for the PE01cddp line after
treatment with varying concentrations of 17 P-oestradiol. After three days culture an
approximate four-fold increase in the number of untreated cells was seen. Cells
treated with the range of concentrations of E2 also showed an increase in number
over the three days. However, these numbers were below those seen for the control
and decreased in a dose-dependent manner, such that cells treated with the highest
concentration of E2, 10"5 M, showed only a 2.6 fold increase in number during this
time period.
Following a further three days culture, the number of control cells doubled, whereas a
much lower level of growth was seen with E2-treated cells, this being dose-dependent
at the four highest concentrations.
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Although PE01cddp cells express moderate-high levels of ER (see Table 3.1, p. 118)
these findings are in direct contrast to the positive growth effects caused by oestrogen
in the other cell lines with moderate-high ER levels. It may therefore be more
accurate to conclude from these experiments that substantial levels ofER expression
in ovarian carcinoma cell lines may indicate oestrogen sensitivity, characterised by a
change in growth pattern which may be an increase or a decrease in cell number.
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Figure 3.12
Effects of exogenous addition of 17 p-oestradiol (E2) on PE01cddp cell numbers.
Cells were grown in phenol red-free media supplemented with 5% dcsFCS and
treated with the concentrations of E2 indicated over a period of six days. The graph
shows the result from one experiment which is typical of at least three identical
experiments. Each value represents the mean of quadruplicate samples, each ofwhich
was counted in triplicate by Coulter Counter. Error bars denote standard error.
*p<0.005, **p<0.05 for the difference between control value and the point indicated,
as evaluated by a Student's /-test.
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Figure 3.13
Effects of exogenous addition of 17 (B-oestradiol (E2) on the proliferation of
PE01cddp cells over six days. Cells were grown in phenol red-free media
supplemented with 5% dcsFCS and treated with the concentrations of E2 indicated.
The graph shows the result from one experiment which is typical of at least one other
identical experiment. Each value represents the mean of quadruplicate samples, each
ofwhich was counted in triplicate by Coulter Counter.
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3.1.2 Effects of oestrogen on growth in vivo
Growth modulation by oestrogen was also examined in vivo in two ovarian xenograft
cell line models, PE04 and HOX60 which had previously been established in nude
mice. Receptor measurement demonstrated that PE04 was ER-positive (242 fmol/mg
protein) whilst the HOX60 xenograft expressed very low levels of ER (7 fmol/mg
protein), nearing the limits of detection. Tumours in the treatment group were
exposed to 1.7mg of 17 P-oestradiol in the form of subcutaneously implanted 30-day
slow-release pellets, and measured at least once a week. Figures 3.13 and 3.14 show
the mean tumour volume in the PE04 xenograft and the HOX60 xenograft, in
untreated and treated animals.
ER-positive PE04 xenografts without oestrogen supplement increased steadily in
volume during the time course. Conversely, there was no apparent change from the
initial tumour volume in xenografts which were treated with the 17 P-oestradiol
slow-release pellets. Values recorded during the second half of the time course were
significantly different to control measurements, (Figure 3.14). This is in sharp contrast
to the stimulatory action of oestrogen on proliferation in the in vitro PE04 model.
In mice bearing HOX60 tumours (Figure 3.15), the mean tumour volume of both
untreated and treated xenografts increased progressively with time but there was no
significant difference in the level of growth between the two groups. This observation
correlates well with findings with the in vitro ovarian cell line models which show a




Effect of oestrogen on the growth of the PE04 xenograft. Tumours were established
by subcutaneous implant into the flanks of nude mice and exposed to a 1.7 mg
17 P-oestradiol 30 day slow release pellet. Values represent mean relative tumour
volume (Vt/Vo) which is the ratio Vt, the volume at the time points indicated, to the
initial tumour volume,V0.(V calculated according to the formula described in the
methods). Each point is the mean value for 5-6 mice ± standard error. *p<0.05 for the





Effect of oestrogen on the growth of the HOX60 xenograft. Tumours were
established by subcutaneous implant into the flanks of nude mice and exposed to a
1.7mg 17 (3-oestradiol 30 day slow release pellet. Values represent relative mean
tumour volume (Vt/Vo) which is the ratio of Vt, the volume at the time points
indicated, to the initial tumour volume,V0 (V calculated according to the formula
described in the methods). Each point is the mean value for 5-6 mice ± standard error.
For each point p>0.05 for the difference between control and treated tumours, as
measured by a students /-test and an ANOVA test.
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3.2 Effects of 17 (3-oestradioI on the cell cycle
Results from experiments investigating the effects of oestrogen on the growth of
ovarian cells, described in the previous section, showed that 17 P-oestradiol caused a
growth stimulation in ER-positive lines, in a manner similar to reports in breast cancer
cell lines, but had no effect on the growth of cell lines which possessed low or
negative levels of ER. However, an exception to this was seen in the
cisplatin-resistant derivative of the PEOl line, PEOl00015, which showed a marked
growth inhibition in response to 17 P-oestradiol after six days despite being
ER-positive. It was of interest to perform cell cycle analysis to determine whether
oestrogen was affecting the distribution of cells within the cell cycle of the PE01CDDP
cell line. Six cell lines were investigated; PEOl, PE01cddp, PE04, PE014, ZR-75-1
and MDA-MB-231. Cell cycle measurements were taken from cells growing in
phenol red-free media supplemented with 5% dcsFCS after 0, 3 and 6 days exposure
to 17 P-oestradiol. Figure 3.16 shows representative cell cycle distribution histograms
for the PE04 cell line. Percentages of cells in each phase of the cell cycle were
calculated from the size of the peaks, using CellFIT cell cycle software.
3.2.1 PE01/PE01cddp
Figure 3.17 shows the distributions of PEOl and PEOlCDDP cens jn the cell cycle
which had been cultured with or without 17 P-oestradiol (10"10M) for six days. Only
minor differences were noted between the two cell lines: on day zero there were
slightly more PEOl cells in G0/Gi, and slightly more PEOlCDDp cej|s jn g_phase Qver
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the time point there was a small increase in the number of control PEOl cells in
S-phase, and a decrease in cells in G2/M. A reduction in the percentage of control
cells in G2/M was also observed with the PE01cddp cell line. Only small differences in
cell cycle distribution were noted in both cell lines with oestrogen-treated cells. There
were slightly higher percentages of oestrogen-treated PEOl cells in S-phase on day
three and day six as compared to untreated cells. Similarly, there was a higher
percentage of oestrogen-treated PE01cddp cells as compared to control cells in
S-phase on day six.
3.2.2 PE04
Figure 3.18 shows the cell cycle distribution of untreated and oestrogen-treated
PE04 cells. On day zero, the greatest percentage of cells were in G0/Gi (44%), the
remaining cells being equally distributed in S-phase and G2/M. A small increase in the
percentage of control cells was noted in G0/G1 after three days. This correlated with a
small decrease in the percentage of control cells in S-phase and G2/M. The percentage
of untreated cells in G0/G1 was lower on day six, with a slight increase in the
percentage of cells in S-phase. There were only small differences in the distribution of
oestrogen-treated cells as compared to control cells, most noticeable on day six;
approximately 10% more oestrogen-treated cells were measured in G0/G1, and 10%




































j l » i
a 423 5QQ
FL2-R
Day 6 Control Day 6 + E2
Relative DNA Content
Figure 3.16
Representative cell cycle distribution plots produced using CellFIT Cell cycle analysis
software. These figures show the cell cycle distribution ofPE04 cells after culture in
phenol red-free medium with or without 10"10M E2 for three and six days. The x-axis
is an arbitrary scale representing DNA content as measured by propidium iodide and
the y-axis indicates cell number. The largest peak shown is the Gi phase of the cell
cycle indicating cells which have a diploid (2N) content ofDNA, the smaller peak is
the G2/M phase representing cells with twice the DNA content (4N) as cells in Go/Gi




























































The effects of 17 {3-oestradiol on the distribution of cells in the cell cycle in the PEOI
and PE01cddp cell lines. Cells were cultured for a period of six days either in phenol
red-free media containing 5% dcsFCS alone (closed symbols, solid lines) or with the
addition of 10"10M 17 P-oestradiol (open symbols, dashed lines). Cell cycle analysis


















The effects of 17 (B-oestradiol on the distribution of cells in the cell cycle in the PE04
cell line. Cells were cultured for a period of six days either in phenol red-free media
containing 5% dcsFCS alone (closed symbols, solid lines) or with the addition of
10"10M 17 P-oestradiol (open symbols, dashed lines). Cell cycle analysis was




Figure 3.19 shows the distibutions of ER-negative PE014 cells in the cell cycle as
measured over six days. The highest percentage of cells were in Go/Gi on day zero
(approximately 66%), with the remainder of cells equally distributed between S-phase
and G2/M. A small increase (5%) in the numbers of control cells in G0/G1 was noted
after three days, corresponding to a 5% lower percentage of control cells in G2/M.
After six days there were no changes in these levels. The number of PE014 cells in
S-phase remained constant throughout the time course. The distribution of
oestrogen-treated cells was similar to control cells.
3.2.4 ZR-75-1
The cell cycle distribution of ZR-75-1 cells is shown in Figure 3.20. The majority of
cells (53%) were in G0/Gi when measured on day zero, with 37% of cells in G2/M
and 10% in S-phase. A slightly higher number of control cells were in Go/ Gi after
three days, but this level did not alter when measured after six days. This was
associated with a lower percentage of control cells in G2/M on day three. Numbers of
oestrogen-treated cells in G0/G1 were similar to control cells after three days, but
increased after a further three days so approximately 14% more oestrogen-treated
cells were in G0/G1 after six days as compared to control cells. This was associated
with a slight rise in the percentage of oestrogen-treated cells in S-phase, and a large
decrease of cells in G2/M after six days, so that there were approximately twice the
number of oestrogen-treated cells in S-phase as compared to untreated cells after six
days. Conversely there were approximately two-thirds more untreated cells in G2/M.
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3.2.5 MDA-MB-231
Figure 3.21 shows the cell cycle distribution for ER-negative MDA-MB-231 breast
cells. On day zero, the highest percentage of cells was measured in Go/Gi (66%). An
increase of cells in Go/Gi was noted after three days, and a further small increase was
noted on day six. This corresponded to a drop in the percentage of cells in S-phase
after three and six days culture. There was no difference in the distribution of
oestrogen-treated cells as compared to control cells when measured after three or six
days. Overall, the distribution of cells was similar to that observed with the
ER-negative PE014 ovarian cells over the time course.
Summarising the above data: there did not appear to be any major difference in the
cell cycle distribution of PEOlCDDP cells as compared to the parental line, PEOl,
either with control or oestrogen-treated groups of cells. Far greater numbers of both
these cell types, untreated and treated were measured in the S-phase of the cell cycle
at the three and six day time points than seen with the other cell lines analysed. In all
the cell lines, the majority of cells were found to be in Gi at the time points measured
and in the ER-positive lines, with the exception of the ZR-75-1 cell line, more cells
were found to be in the S-phase than G2/M. There appeared to be equal distributions
of ER-negative MDA-MB-231 and PE014 cells between these two phases. Only in
the ZR-75-1 cell line were any large differences noted between the percentages of
untreated and oestrogen-treated cells. Twice as many ZR-75-1 cells were measured in
S-phase after oestrogen treatment compared to the percentage of control cells, with






















































The effects of 17 P-oestradiol on the distribution of cells in the cell cycle in the
PE014 cell line. Cells were cultured for a period of six days either in phenol red-free
media containing 5% dcsFCS alone (closed symbols, solid lines) or with the addition
of 10"10M 17 p-oestradiol (open symbols, dashed lines). Cell cycle analysis was
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The effects of 17 P-oestradiol on the distribution of cells in the cell cycle in the
ZR-75-1 cell line. Cells were cultured for a period of six days either in phenol red-free
media containing 5% dcsFCS alone (closed symbols, solid lines) or with the addition
of 10"10M 17 P-oestradiol (open symbols, dashed lines). Cell cycle analysis was























































The effects of 17 P-oestradiol on the distribution of cells in the cell cycle in the
MDA-MB-231 cell line. Cells were cultured for a period of six days either in phenol
red-free media containing 5% dcsFCS alone (closed symbols, solid lines) or with the
addition of 10"10M 17 P-oestradiol (open symbols, dashed lines). Cell cycle analysis
was performed by flow cytometry at the time points indicated. The values shown are
from one experiment.
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3.3 Effects of oestrogen on oestrogen and
progesterone receptor (ER and PR) expression
It has been shown that culture of ER-positive breast cancer cells with oestrogen
causes a reduction in the levels of oestrogen receptor levels which are expressed
(Horwitz and McGuire, 1976). This is consistent with the notion that E2 is exerting its
effects through the ER. In addition, E2 increases the expression of another steroid
receptor, the progesterone receptor (PR) (Horwitz et al., 1978a). This is one of a
number of oestrogen-regulated proteins which may indicate functional ER and
therefore have utility as a marker for hormonally-sensitive ER-positive breast
tumours. It was therefore of interest to investigate the effects of 17 P-oestradiol on
ER and PR expression in the ovarian carcinoma cell lines.
3.3.1 Effect of oestrogen on oestrogen and progesterone receptor
expression in ovarian carcinoma cell lines in vitro
The ER levels of eight of the ovarian cell lines have been previously recorded
(Langdon et al., 1990) using a dextran-coated charcoal adsorption method (Hawkins
et al., 1975, 1981). PEOl, PE04 and PE06 possess moderate to high concentrations
of ER, whereas PEA1 and PEA2 have low levels, and PEOl4, PE023 and PEOl6
are ER-negative (Table 2.1). To investigate the effects of 17 p-oestradiol on ER and
PR expression, cells were grown in phenol red-free media supplemented with 5%
dcsFCS and exposed to a single concentration of 17 P-oestradiol (10"10M) for six
days. This concentration provided the maximum growth stimulation in the
ER-positive cell lines, PEOl, PE04 and PE06 (see section 3.1). Cells were refed
after three days and collected by scraping for analysis on day six. Receptor levels
were detected by enzyme immunoassay (EIA) performed by Dr Hawkins in the
Department of Surgery, Royal Infirmary, Edinburgh.
(i) Modulation of oestrogen receptor levels
The effect of 17 P-oestradiol on ER expression in the nine ovarian carcinoma cell
lines is shown in Figure 3.22, together with the two breast cell lines, ZR-75-1
MDA-MB-231 which were measured for reference. Absolute values, expressed in
fmol/mg protein are given in Table 3.1. A cut-off value of 5 fmol/mg protein has been
assumed, cells and tissues expressing ER values at or below this background level
being considered ER-negative.
Results in Table 3.1 show that of the cell lines investigated, three ovarian cell lines
demonstrated significantly (p<0.05) lower ER expression after six days exposure to
10"10M 17 P-oestradiol as compared to control cells which were cultured in
oestrogen-deprived media; PEOl cells expressed mean levels of 130 fmol/mg protein
when cultured in the absence of oestrogen, but when oestrogen was present, ER
expression was substantially lower (approximately three-fold). Levels for ER
expression in PE04 control cells were higher than PEOl control cells but a similar
three-fold level of reduction was noted when cells were cultured in the presence of
oestrogen. Likewise, PE01CDDP cells expressed moderate-high levels ofER expression
in the absence of oestrogen, compared to a three-fold reduction in levels when
exposed to oestrogen.
One other ovarian cell line, PE06, expressed moderate-high levels of ER. Untreated
PE06 cells expressed levels of ER at 81 fmol/mg protein. Mean ER values were
approximately 1.5 fold lower in oestrogen-treated PE06 cells, although this did not
achieve significance (p>0.05). Low or background levels of ER expression were
recorded in the remaining ovarian cell lines, PEA1, PEA2, PE014, PE016 and
PE023; and the ER-negative breast cell line, MDA-MB-231, and no significant
difference between expression in oestrogen-deprived or treated cells was found.
High levels of ER expression were measured in the ER-positive ZR-75-1 breast cell
line, comparable to those found with the PE04 cell line. Cells cultured without
oestrogen had a mean ER value of 271 fmol/mg protein, as compared to 131 fmol/mg




Effects of 17 (3-oestradiol on oestrogen receptor levels in ovarian and breast cancer
cell lines. Cells were grown in phenol red-free media, 5% dcsFCS with or without
10"10M 17 P-oestradiol for six days. Receptor levels were measured by enzyme
immunoassay and are expressed in fmol/mg protein. Each value is the mean of three
separate experiments ± standard error. (*p<0.05, representing a significant difference
between control and treated cells, as measured by a Student /-test.)
ER Concentration (fmol/mg protein)
Control + 10 10M E2
Ovarian Cancer Cell Lines
PEOl 129.7 ±3.7* 47.7 ±6.1*
PE04 208.7 ±21.3* 67.3 ± 6.9*
PE06 81.1 ± 19.4 55.4 ±12.9
PE01cddp 149.4 ±9.8* 56.5 ± 4.2*
PEA1 18.0 ±1.4 16.4 ±0.5
PEA2 7.7 ± 0.9 8.2 ± 0.5
PEOl4 5.3 ±0.9 4.3 ±0.3
PE023 8.0 ±1.0 7.0 ±1.0
PE016 7.7 ±0.9 9.2 ±0.9
Breast Cancer Cell Lines
ZR-75-1 271.0 ±73.6 131.3 ±22.8
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Figure 3.22
Effects of 17 (3-oestradiol (E2) on oestrogen receptor levels in nine ovarian and two
breast carcinoma cell lines. Cells were grown in phenol red-free media supplemented
with 5% dcsFCS and with or without 10"10M E2 for a period of six days. ER levels in
cell cytosols were measured by enzyme immunoassay and are expressed in fmol/mg
protein. Lighter shaded bars depict untreated cells and darker shaded bars represent
cells treated with 10"10M E2. Each value represents the mean of three independent
observations and error bars denote standard error. Where there is no apparent error
bar, the SEM is small. *p< 0.05 for the difference between the control and treated
group for the indicated cell line, as evaluated by a Student's f-test.
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(ii) Modulation of progesterone receptor levels
The effect of 17 P-oestradiol on the level of PR expression in the ovarian and breast
cancer cell lines is shown in Figures 3.23 and 3.24; values are recorded in Table 3.2.
Low levels of PR expression (2-5 fmol/mg protein) were recorded for all of the
ovarian cell lines, and for the ER-negative MDA-MB-231 breast cell line in the
absence of oestrogen. In contrast, the ER-positive ZR-75-1 breast cell line expressed
substantially higher levels ofPR.
Three of the ovarian cell lines, PEOl, PE04 and PE06, (high ER levels) showed
significant differences (p<0.05) in PR expression between the two treatment groups.
The biggest differences in PR expression between control and treated cells were
observed in the PE04 and PE06 cell lines, (see Table 3.2). However, a much smaller
difference in PR expression was noted in oestrogen-treated PEOl cells (5 fmol/mg
protein) as compared to the control, these values still being at background levels. The
increased level of PR expression seen in both PE04 and PE06 in response to
oestrogen is comparable to that seen with the ZR-75-1 breast cell line (Table 3.2),
which had higher control PR levels (212 fmol/mg protein) but displayed a similar
magnitude of increase in PR expression in treated cells (Figure 3.24). PR values for
the other ovarian cancer cell lines (PE01cddp, PEA1, PEA2, PEOl4, PEOl6 and
PE023) and the MDA-MB-231 breast cancer cell line were at the detection limits of
the assay in either treatment group. A small change in PR expression was noted in the
MDA-MB-231 cell line but the statistical significance could not be ^-tested as the
SEM of the values for both untreated and treated cells equalled zero.
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Table 3.2
Effects of 17 P-oestradiol on progesterone receptor levels in ovarian and breast
cancer cell lines. Cells were grown in phenol red-free media, 5% dcsFCS with or
without 10"10M 17 P-oestradiol for six days. Receptor levels were measured by
enzyme immunoassay and are expressed in fmol/mg protein. Each value is the mean
of three separate experiments ± standard error. (*p<0.05, for the difference between
control and treated values as measured by a Student f-test).
PR Concentration (fmol/mg protein)
Control + 10"10M E2
Ovarian cancer cell lines
PEOl 3.3 ±0.3* 4.7 ±0.3*
PE04 2.7 ±0.7* 20.3 ±6.3*
PE06 6.3 ±0.9* 29.0 ±6.4*
PE01cddp 3.7 ±0.3 3.3 ±0.3
PEA1 3.0 ±0.0 2.3 ±0.7
PEA2 2.3 ±0.3 2.3 ±0.3
PEOl4 2.0 ±0.0 3.0 ±0.6
PE023 7.7 ±5.3 4.3 ±2.4
PEOl 6 4.0 ±0.6 5.0 ±0.6
Breast cancer cell lines
ZR-75-1 212.0 ±23.1* 920.0 ± 200.4*
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Figure 3.23
Effects of 17 P-oestradiol (E2) on progesterone receptor levels in nine ovarian
carcinoma cell lines. Cells were grown in phenol red-free media supplemented with
5% dcsFCS and with or without 10"10M E2 for a period of six days. PR levels in cell
cytosols were measured by enzyme immunoassay and are expressed in fmol/mg
protein. Lighter shaded bars depict untreated cells and darker shaded bars represent
cells treated with 10"10M E2. Each value represents the mean of three independent
observations and error bars denote standard error. Where there is no apparent error
bar the SEM is small. *p<0.05 for the difference between the control and treated








Effects of 17 P-oestradiol (E2) on progesterone receptor levels in two breast
carcinoma cell lines. Cells were grown in phenol red-free media supplemented with
5% dcsFCS and with or without 10~10M E2 for a period of six days. PR levels in cell
cytosols were measured by enzyme immunoassay and are expressed in fmol/mg
protein. Lighter shaded bars depict untreated cells and darker shaded bars represent
cells treated with 10"10M E2. Values represent the mean of three independent
observations, error bars denote standard error. Where there is no error bar the SEM
is small. *p<0.05 for the difference between the control and treated group for the
indicated cell line, as evaluated by a Student's f-test.
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3.3.2 Effects of oestrogen on oestrogen and progesterone receptor
expression in ovarian carcinoma cell lines in vivo
The effect of 17 P-oestradiol on ER and PR expression was also investigated in vivo,
in the two ovarian xenograft models, PE04 and HOX60. Fragments of xenograft
were implanted subcutaneously into the flanks of nude mice and, once established,
animals were exposed to a 1.7mg 17 P-oestradiol slow-release pellet planted into the
opposite flank of each animal. Control animals did not receive pellets. After 60 days
xenografts were removed from both sets of animals and analysed for either ER or PR
by enzyme immunoassay.
(i) Modulation of oestrogen receptors
Levels of ER in control and oestrogen-treated ovarian xenografts are given in Table
3.3. The PE04 xenograft, grown without oestrogen supplement, has high levels of
ER (242 ± 41 fmol/mg protein), comparable to the value (209 ± 21 fmol/mg protein)
measured in the PE04 in vitro line from which it was derived. When treated with
17 P-oestradiol, ER levels are significantly reduced to approximately 10% of the
value (32 ± 2 fmol/mg protein) seen in control animals (see Figure 3.25). In contrast,
the HOX60 ovarian xenograft contains borderline levels ofER of 7 fmol/mg protein,
(the detection limit of the assay being 5 fmol/mg protein) which are not significantly
different from animals receiving oestrogen treatment. These observations parallel the
findings seen in vitro where ER levels are modulated by oestrogen in cell lines with a
moderate-high ER status, but there are no alterations in ER expression in cell lines
which contain low levels.
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(ii) Modulation of progesterone receptors
Figure 3.26 shows the effect of 17 P-oestradiol on PR expression in the two ovarian
xenografts. High PR levels were measured in the ER-positive PE04 xenograft, but
there was only a low level of expression (4 fmol/mg protein) in the ER-negative
HOX60 model. There was a marked significant difference in PR expression between
oestrogen-treated PE04 xenografts and those grown without supplement. Mean
levels of 87 fmol/mg protein were measured in control animals, but in the treated
group the mean value was 776 fmol/mg protein; a nine-fold difference in expression
(see Table 3.4). There was no variation in the low levels of PR expression between
HOX60 control and treated xenografts.
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Table 3.3
Effects of 17 P-oestradiol on oestrogen receptor levels in vivo in two ovarian
xenografts established in nude mice. Treated xenografts were exposed to a 1.7mg E2
slow-release pellet and excised after 60 days. Receptor levels were measured by
enzyme immunoassay and are expressed in fmol/mg protein. Each value is the mean of
three to six separate observations ± standard error. (p*<0.05 for the difference
between control and treated xenografts as measured by a Student's /-test.)
ER Concentration (fmol/mg protein)
Ovarian xenograft lines Control + 1.7mg E2
PE04 241.17 ±41.1* 32.3 ±1.9*
HOX60 6.7 ± 0.3 8.3 ± 0.3
Table 3.4
Effects of 17 P-oestradiol on progesterone receptor levels hi vivo in two ovarian
xenografts established in nude mice. Treated xenografts were exposed to a 1.7mg E2
slow-release pellet and excised after 60 days. Receptor levels were measured by
enzyme immunoassay and are expressed in fmol/mg protein. Each value is the mean of
three to six separate observations ± standard error. (p*<0.005 for the difference
between control and treated xenografts as measured by a Student's /-test.)
PR Concentration (fmol/mg protein)
Ovarian xenograft lines Control ± 1.7mg E2
PE04 86.8 ± 19.2* 776.3 ± 249.7*



























Effects of 17 P-oestradiol (E2) on oestrogen receptor levels in two ovarian
xenografts. Tumours were established in nude mice and treated animals exposed to
the presence of a 1.7mg E2 slow release pellet for a period of 60 days. Each value
represents the mean of 3-6 independent observations and error bars denote standard
error. Lighter shaded bars depict untreated xenografts and darker shaded bars
represent xenografts treated with E2. *p<0.05 for the difference between the control





























Effects of 17 P-oestradiol (E2) on progesterone receptor levels in two ovarian
xenografts. Tumours were established in nude mice and treated animals exposed to
the presence of a 1.7mg E2 slow release pellet for a period of 60 days. Each value
represents the mean of 3-6 independent observations and error bars denote standard
error. Lighter shaded bars depict untreated xenografts and darker shaded bars
represent xenografts treated with E2. *p<0.005 for the difference between the control
and treated group for the PE04, as evaluated by a Student's t-test.
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3.4 pS2 expression in ovarian and breast carcinoma
cell lines
pS2 is one of a number of oestrogen-regulated proteins which has been cited as
having prognostic significance in breast cancer, its expression being found
predominantly with ER-positive tumours (Rio et al., 1987, Foekens et al., 1990a,
Henry et al., 1991a). In addition, levels of pS2 have been shown to be increased in
17 3-oestradiol-treated MCF-7 breast cells (Masiakowski et al., 1982). However,
there have been few studies investigating pS2 expression in ovarian cancer and its
role as a marker of hormonal sensitivity is not well defined.
The expression of this protein was therefore investigated in the absence or presence
of oestrogen, in several of the ovarian cell lines (PEOl, PE04, PEA1, PE014 and
PE01CDDP) which express a range of ER levels. Samples were analysed for pS2
expression by flow cytometer after either 3 or 6 days exposure to 10"10M
17 P-oestradiol in phenol red-free media plus 5% dcsFCS, using an in-house protocol
which had been optimised for fixation procedures and antibody dilutions. Figure 3.27
shows a typical histogram obtained for ZR-75-1 cells incubated in the presence or
absence of oestrogen, showing traces for background staining (in the absence of







Typical histogram obtained for flow cytometric analysis of pS2 expression in ZR-75-1
cells cultured in phenol red-free media supplemented with 5% dcsFCS in the absence
or presence of 10"10M E2 for three days. Plots are shown for background staining (in
the absence of the primary antibody, anti-pS2), control cells and oestrogen treated
cells. The x-axis shows fluorescence intensity, (4 log decades), and the y-axis cell
number (linear scale).
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3.4.1 Effect of oestrogen on pS2 expression in ovarian cell lines
The following section describes the results of the effects of oestrogen on pS2
expression, values given being the mean of at least three independent observations.
Figure 3.28 shows the intensity of staining for pS2 expression in the five ovarian and
two breast cell lines after 6 days, with and without exposure to 10"10M
17 P-oestradiol. These data together with values after three days are summarised in
Table 3.5. pS2 expression as measured by staining intensity (mean increase in
fluorescence) was at a low level or background levels; i.e. around 1.0 (shown by the
dashed line in figure 3.28) at both the time points in all the cell lines which were
grown without oestrogen, although a small increase was noted in PEOl control cells
after six days as compared to the day three value. When staining intensity values for
oestrogen-treated cells were compared to those grown in the absence of the hormone,
the greatest differences were noted in the ZR-75-1 cell line. Levels were significantly
raised almost twofold after three days and three-fold by six days exposure. A smaller
difference was observed in the PEA1 cells after 3 days exposure to oestrogen
compared to cells grown without oestrogen, however the effect was not sustained
after six days treatment. Conversely, a slightly lower level of staining intensity was
noted in oestrogen-treated PEOl cells after six days.
pS2 expression was also measured in terms of percentage of cells stained, and Figure
3.29 shows values recorded after six days. A summary of the results is given in Table
3.6. Only a low number of the ovarian cells and the MDA-MB-231 cells stained for
pS2, in either control or oestrogen-containing conditions. However, a small
significant rise was noted in oestrogen-treated PEA1 cells as compared to the control
after three days; staining in control cells was at background levels but a number of
cells treated with oestrogen (5%) showed positive staining. In concordance with
results seen with staining intensity in this line, this effect was not sustained following
a further three days exposure. There was also a four-fold decrease in the mean level
of staining in PEOl cells exposed to oestrogen for six days as compared to control
cells, although again the absolute number of cells staining for pS2 was low. This
effect was not noted after three days exposure. This parallels the reduction in staining
intensity (Table 3.5) observed with this line.
Expression in control ZR-75-1 breast cells was at a low level, similar to the other cell
lines, although there appeared to be a small reduction in the number of positively
staining control cells during the time course. Significantly increased numbers of
ZR-75-1 cells staining for pS2 expression were measured in the presence of
17 P-oestradiol as compared to levels seen in ZR-75-1 cells growing without the




The effects of 17 p-oestradiol on the expression of pS2 in ovarian and breast cell lines
after 3 or 6 days exposure. Values are expressed in terms of increase in mean
fluorescence which is a ratio of sample mean fluorescence compared to background
values. Thus a value of 1.0 equals background fluorescence. Results shown are the
mean of at least three independent observations ± standard error. *p<0.05, **p<0.001
for the difference between control and treated values for the groups indicated, as
evaluated by a Student's /-test.
MEAN INCREASE IN FLUORESCENCE
(staining intensity)
(sample value/background value)
Cell line Day 3 Day 6
Control E* Control E2
PEOl 1.22 ±0.10 1.48 ± 0.10 1.65 ±0.15* 1.17± 0.03*
PE04 0.99 ± 0.23 1.48 ±0.10 1.03 ±0.07 0.98 ±0.12
PE06 1.24 ±0.03 1.28 ±0.05 1.13 ±0.20 0.69 ±0.16
PE01CDDP 0.87 ±0.30 0.54 ±0.02 1.21 ±0.08 1.02 ±0.10
PEA1 1.01 ±0.01* 1.43 ±0.13* 1.20 ± 0.11 1.33 ±0.10
PEOl 4 1.16 ± 0.17 1.06 ±0.11 1.32 ±0.05 1.33 ±0.09
ZR-75-1 1.36 ±0.02** 2.05 ±0.17** 1.12 ± 0.10** 3.12 ± 0.14**
MDA-MB-231 1.28 ±0.14 1.28 ±0.25 1.20 ±0.10 1.20 ±0.06
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Table 3.6
The effects of 17 p-oestradiol on the expression of pS2 in ovarian and breast cell lines
after 3 or 6 days exposure. Values given represent the % of cells stained above
background values. Results shown are the mean of at least three independent
observations ± standard error and represent values from one experiment typical of at
least three similar experiments. *p<0.05, **p<0.01 for the difference between control
and treated values for the groups indicated, as evaluated by a Student's t-test.
% OF CELLS STAINED FOR PS2
(sample value-background value)
Cell line Day 3 Day 6
Control e2 Control e2
PEOl 1.87 ± 1.09 7.84 ±3.32 5.00 ±0.98** 1.16 ± 0.17**
PE04 3.79 ±2.24 8.44 ±3.09 0.54 ±0.37 0.99 ±0.67
PE06 2.95 ±0.52 3.27 ±0.74 1.57 ±0.60 3.56 ±0.95
PE01CDDP 0.00 0.00 2.46 ±0.36 0.98 ±0.98
PEA1 0.00* 5.45 ±2.12* 2.54 ± 1.47 5.36 ± 1.33
PEOl4 1.16 ± 0.17 1.06 ±0.11 1.32 ±0.05 1.33 ±0.09
ZR-75-1 6.49 ± 1.12** 23.63 ±3.64** 2.60 ±0.47** 33.41 ±2.44**
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Figure 3.28
Effects of 17 P-oestradiol after six days on the expression of pS2 in ovarian and
breast carcinoma cell lines, measured in terms of staining intensity. Cells were grown
in phenol red-free media supplemented with 5% dcsFCS. Striped bars represent
control cells and shaded bars represent cells treated with 10"10M 17 P-oestradiol. The
results shown are the mean of at least three independent observations. The mean
increase in fluorescence is a ratio of the sample reading compared to the background,
where a value of 1 equals background fluorescence, indicated on the graph by a
dashed line. *p<0.05, **p<0.001 for the difference between control and treated





Effects of 17 (3-oestradiol after six days on the expression of pS2 in ovarian and
breast carcinoma cell lines, measured as a percentage of cells positively staining for
pS2 above background readings. Cells were grown in phenol red-free media
supplemented with 5% dcsFCS. Striped bars represent control cells and shaded bars
represent cells treated with 10"10M 17 P-oestradiol. The results shown are the mean of
at least three independent observations. *p<0.05, **p<0.01 for the difference




HSP27 is an oestrogen-regulated protein in breast cancer in which it is positively
associated with the presence ofER (King et al., 1987b). Its expression however, has
not been previously reported in ovarian cancer although one study has noted a lack of
expression in normal ovary (Ciocca et al., 1983). The expression of this small
member of the heat shock family was examined in the series of in vitro and in vivo
ovarian cell lines by an ELISA method developed by Prof. Roger King at the
University of Surrey. Initial ELISAs looking at constitutive expression were carried
out by Prof. King on cell pellets sent to him for analysis. The effects of oestrogen on
HSP27 expression in the cell lines was then examined, incorporating an adapted
ELISA method for use in-house.
3.5.1 HSP27 expression in vitro
Examination of basal levels of HSP27 in the nine in vitro ovarian cell lines was
initiated by collecting cell pellets from each of the cell lines grown routinely in phenol
red-containing media supplemented with 10% FCS. Cytosols were prepared from
these and analysed, the results of which are shown in Figures 3.30 (a) and (b), and
summarised in Table 3.7
HSP27 expression was detected by reading the optical densities (OD) at 450nM for
each sample dilution, produced by the chromogenic peroxidase substrate, TMB. The
intensity of the colour produced, and hence the OD, being proportional to the amount
of HSP27 protein present. Final OD readings were calculated by subtracting the
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appropriate background values; the OD for the sample minus D5 antibody, and the
difference in OD's obtained for a PBS sample incubated with and without D5. Values
in Table 3.7 represent the amount of HSP27 (ng/pg of sample cytosolic protein,
calculated from the absorbance at 450nM for lpg protein of sample) divided by the
absorbance / ng of recombinant HSP27 protein run in the same assay.
Varying levels of HSP27 expression were observed in the nine ovarian cell lines
ranging from background levels in the PEA2 cell line to 3.8 ng/pg in the PE04 cell
line. In general, expression levels appeared to correlate well with the ER status of the
cell lines; the highest concentration being noted in the PE04 cell line, followed by the
PE06 and PEOl cell lines, which contain moderate to high levels of ER. Lower
expression levels were observed in the PEA1, PEA2, PEOl6, PEOl4 and PE023 cell
lines which express low levels of ER. However, included within this group was the
PE01CDDP cell line which although expresses ER levels similar to the parent line
PEOl, contained HSP27 levels similar to PEOl6. HSP27 content was also measured
in the ER-positive ZR-75-1 breast cell line, which demonstrated almost tenfold higher
levels ofHSP27 expression than the highest levels found in the ovarian lines (PE04).
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Table 3.7
HSP27 expression in nine ovarian and one breast carcinoma cell lines growing in
routine culture conditions; RPMI 1640 containing phenol red and supplemented with
10% FCS. Results are expressed in ng and are calculated from the ratio of the
absorbances at 450nM of lpg of sample cytosolic protein with respect to lng of
recombinant HSP27. Values show the mean of 3 independent observations ± S.E.M.
Cell Line HSP27
(ng/pg cytosolic protein)






Cell Lines with low or negative ER expression
PEA1 0.3 ±0.1
PEA2 0 ± 0
PE016 0.1 ±0.1
PE014 0.4 ± 0.0
PE023 0.7 ±0.1
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PE01 PE04 PE06 PEOI/cddp PEA1 PEA2 PE016 PE014 PE023
Cell Line
Figure 3.30 (a)
HSP27 expression in nine ovarian carcinoma cell lines. ELISA analysis was
performed on cell cytosols, extracted from mid-log phase cells growing in 25cm2
culture flasks. Bars represent the mean of three separate observations ± SEM and are
expressed in ng of HSP27/|ig cytosolic protein, calculated from the ratio of the
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Figure 3.30 (b)
Figure showing HSP27 expression in the ovarian cell lines as compared to that seen in
the ZR-75-1 breast cell line.
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3.5.2 HSP27 Expression in xenografts
HSP27 expression was also examined in the two ovarian xenograft models, PE04
and HOX60, and the two breast xenografts, ZR-75-1 and T1068, established, as
previously described, in nude (nu/nu) mice. The ZR-75-1 model was grown in the
presence of additional oestrogen supplement in order to maintain its growth. Results
are illustrated in Figure 3.31 and summarised in Table 3.8. Again, consistent with the
type of expression observed in the in vitro cell lines, the concentration of HSP27 in
the xenografts appeared to correlate with their ER status. Thus, higher HSP27 levels
were noted in the ER-positive ZR-75-1 and PE04 xenografts as compared to their
ER-negative counterparts, T1068 and HOX60 which expressed very low levels of the
heat shock protein. The level of expression which was noted in the ER-positive breast
xenograft (60ng/pg), was much higher than that found in the ER-positive ovarian
model (1.8ng/pg), also similar to observations in vitro. The level of HSP27
expression in the ZR-75-1 in vivo model was approximately double that seen in the in
vitro cell line, and probably reflects the fact that the xenograft is grown in the
presence of additional oestrogen supplement, whereas, conversely, the PE04
xenograft expressed only 50% of the level observed in vitro.
142
Table 3.8
HSP27 expression in two ovarian and two breast carcinoma xenografts established in
nude (hu/nu) mice. The ZR-75-1 xenograft was established in the presence of a
1.7mg E2 slow-release pellet. Results are expressed in ng and are calculated from the
ratio of the absorbances at 450nM of lpg protein of sample cytosol with respect to 1
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Figure 3.31
HSP27 expression in two ovarian and two breast carcinoma xenografts. ELISA
analysis was performed on cell cytosols, extracted from tumours established in nude
(inu/nu) mice. Bars represent the mean of three separate observations ± SEM and are
expressed in ng of HSP27/pg cytosolic protein, calculated from the ratio of the
absorbances at 450nM of lpg protein of sample cytosol with respect to lng of
recombinant HSP27.
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3.5.3 Effects of oestrogen on HSP27 expression in vitro
An adapted ELISA method was used to investigate the modulation of HSP27
expression by 17 P-oestradiol in the ovarian in vitro and in vivo cell models.
(i) Validation of method
Before the ELISA was run routinely to detect HSP27 modulation, several aspects of
the method were investigated to determine optimum conditions.
a) Substrate optimisation
In previous studies, both o-phenylene diamine hydrochloride (OPD) and
tetramethylbenzidine (TMB) have been utilised as peroxidase substrates for the
HSP27 ELISA depending on the type of sensitivity required. TMB has been reported
to be the more sensitive of the two assay systems and more appropriate for use with
cell lines which may express lower levels of HSP27, as opposed to tumour material
which may express a large range of HSP27 concentrations (R. King, personal
communication). To determine which would be the one of choice for detecting
modulation in the ovarian cell lines, titrations of recombinant HSP27 protein
(r-HSP27) and cytosols prepared from human myometrial cells were run in an ELISA
with both substrates. Human myometrium expresses a high level ofHSP27 (Ciocca et
al., 1983), and has previously been used as a standard in ELISA's before the
availability of the recombinant protein. Studies with this ELISA had suggested
protein concentrations between 20 and 0.5 pg /ml protein would be a suitable range
for the myometrial standard. Routinely cultured ZR-75-1 and MDA-MB-231 cells,
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were also examined, at a range of dilutions; 5, 0.5, 0.05|ig /protein/ml, covering a
range suggested by previous work (Dunn et al,. 1993).
Figure 3.32 gives the results for the recombinant HSP27, myometrial and breast
samples which were incubated with both substrates for 10 minutes in the dark at
room temperature.
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Evaluation of two different peroxidase substrates, TMB and OPD, in the detection of
HSP27 expression by ELISA. Values represent the optical densities at the appropriate
wavelengths of the two substrates after 10 minutes incubation at room temperature in
the dark (TMB; 450nM, OPD; 492nM). Results are shown from one experiment
which was repeated again with similar findings.
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The results shown in Figure 3.32 are final OD values resulting from the subtraction of
background readings. Background OD's were obtained from cytosolic samples in the
absence of the primary antibody D5, and PBS samples +/- D5. From these results it
appeared that there was little difference in the two substrates, although slightly higher
OD readings were obtained using the TMB substrate, possibly suggesting that it was
more sensitive to the levels of recombinant HSP27 protein, (r-HSP27), and HSP27
expression in myometrium and breast samples. TMB was therefore incorporated as
the substrate in further studies as it might be more likely to detect any small changes
in HSP27 expression in the cell lines due to modulation by oestrogen.
b) Standard optimisation
Previous studies have incorporated human myometrium as a standard in HSP27
assays. However, as the recombinant protein has recently become available it seemed
appropriate to include this in these studies, to provide a reliable constant value.
Titrations of both standards were evaluated initially using the OPD peroxidase
substrate and the results from a single experiment are shown in Figure 3.33. The
concentrations used for the myometrial standard were 0.5, 2, 5, 20 and 40pg/ml of
protein, and for the recombinant HSP27 protein; dilutions from 128 - lng/ml. The
lowest concentrations of the myometrial sample (0.5 and 2pg/ml) gave readings
which were at background values. OD values for the recombinant HSP27 protein at
concentrations between 4.0-64.0ng/ml equated closely with each other when adjusted
on an absorbance per ng basis. The top concentration of 128ng/ml did not equate
closely, giving an OD reading of 6.96 and falling outwith the linear part of the curve.
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When myometrial OD readings were similarly equated to give an absorbance value
per pg, the readings did not equate as closely. This observation was confirmed when
TMB was used as the substrate. Both standards were incorporated into each ELISA
but the recombinant protein standard was used to equate values for the ovarian cell
lines. Using the recombinant protein also had the advantage of expressing values in ng




HSP27 expression measured by optical density at 492nM in titrations ofmyometrium
and recombinant HSP27. Results shown are from one experiment.
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c) Sample Dilution
A range of dilutions for each cell line cytosol was evaluated using the protein levels
calculated for each sample. Results following substrate optimisation determined
suitable protein ranges for ZR-75-1 cells. Figure 3.34 shows typical optical densities
obtained for a range of dilutions of both control and oestrogen-treated PE04 and
PE014 cells run in the ELISA using TMB as the peroxidase substrate. Also shown
are typical values for the recombinant HSP27 protein, and control and
oestrogen-treated ZR-75-1 breast cells. The graph shows that HSP27 expression in
the cell lines appeared to dilute similarly to the recombinant protein, although values
for the ZR-75-1 breast cancer cell line equated more closely than the ovarian cancer
cell line readings when adjusted per pg of protein. The recombinant HSP27 was run
in each assay at 50, 25 and lOng/ml to provide a range of OD readings. Protein
concentrations at 40, 20 and lOpg/ml were chosen for the ovarian and MDA-MB-231
cell lines, and 6.25, 5.0, 3.75, 2.5pg/ml for the ZR-75-1 cell lines which gave OD
values within the range for the recombinant protein, and falling within the linear range
of the titration curve. The internal myometrial standard was also incorporated in each
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Detection of HSP27 expression in two ovarian cell lines and the breast cell line,
ZR-75-1 at a range of protein concentrations. Cells were cultured in phenol red-free
media containing 5% dcsFCS in the presence (open symbols, E2) or absence (closed
symbols, C) of 10"10M 17 (3-oestradiol for three days. Cytosols were then extracted
and examined for HSP27 expression by ELISA. Results show typical optical densities
read at 450nM from one experiment after subtraction of background values.
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(ii) Effects of oestrogen on HSP27 expression in vitro
The effects of oestrogen on HSP27 expression were measured in several of the
ovarian cell lines (PEOl, PE04, PEOlCDDP and PE014), and the ZR-75-1 and
MDA-MB-231 breast cell lines. Cells were grown in phenol red-free media
supplemented with 5% dcsFCS either in the presence or absence of 10"10M
17 P-oestradiol. After three days cells were removed and cytosols prepared as
described in the Methods, section 2.28. Dilutions of samples were prepared as
described in the previous section and analysed by ELISA incorporating TMB as the
peroxidase substrate. Figure 3.35 illustrates the results of the analysis for the six cell
lines which are summarised in Table 3.9.
At higher protein concentrations a plateau effect was sometimes observed with the
dilution curve, therefore values for each cell line were calculated from the dilution
giving an OD reading which fell on the linear part of the curve and within the OD
range of the recombinant protein standard. This value was equated to an absorbance
for 1 pg of protein, and the concentration of FISP27 then calculated from the OD
reading for lng of standard.
HSP27 expression levels above background were detected in both control and
modulated groups of all the cell lines analysed. When considering either treatment
group, the greatest level of expression was noted in the ER-positive ZR-75-1 breast
cell line, this contrasting with the ovarian cell lines which expressed 3-8 fold lower
HSP27 levels, and the ER-negative breast line, MDA-MB-231 which had a very low
HSP27 content. In the ZR-75-1 line, the level of HSP27 expression was significantly
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increased (p<0.05) in cells exposed to oestrogen, as compared to control cells grown
in oestrogen-free conditions. Conversely, significant decreases in expression were
noted in oestrogen-treated PE04 and PE01CDDF ovarian cell lines as compared to
control cells. A slight increase in HSP27 content was observed in the PEOl cell line
in response to oestrogen but this proved to be non-significant. There was no change
in expression in the ER-negative PEOl4 or MDA-MB-231 breast cell line.
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Table 3.9
Effects of oestrogen on HSP27 expression in ovarian and breast cancer cell lines.
Results are expressed in ng and are equated against the mean absorbance for lng of
recombinant HSP27 standard run in each assay. Each value represents the mean of
nine separate experiments ± SEM. *p<0.05, **p<0.005 for the difference between
control and treated cells, evaluated using a paired Students /-test.
Cell Line HSP27 Concentration (ng/pg cytosolic
protein)
Control + 10 10M E2
peol 0.516 ± 0.114 0.754 ±0.197
pe04 1.270 ±0.112** 0.956 ±0.095**
peoicddp 1.340 ±0.151** 0.772 ±0.102**
peol4 0.558 ±0.101 0.455 ±0.061
zr-75-1 4.470 ± 0.470* 6.830 ± 0.766*









Effects of oestrogen on HSP27 expression in ovarian and breast cancer cell lines
cultured in phenol red-free media supplemented with 5% dcsFCS. Striped bars
represent cells which were grown in the absence of oestrogen and shaded bars
represent those grown in the presence of 10"10M 17 P-oestradiol (E2). Results show
the mean of nine separate observations ± SEM. *p<0.05 (ZR-75-1), **p<0.005
(PE04 and PE01cddp) for the difference between control and treated values,
according to a paired Student f-test.
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3.5.4 Effects of oestrogen on HSP27 expression in xenografts
The modulation of HSP27 expression was also investigated in the PE04 xenograft
model. Xenografts were established as described previously and treated tumours were
exposed to a subcutaneously implanted 1.7mg 17 p-oestradiol slow-release pellet for
60 days. Control tumours were grown without additional oestrogen supplement.
After this period, treated and untreated tumours were extracted and cytosols prepared
as for the in vitro cell lines. TMB was used as peroxidase substrate in the ELISA to
be consistent with in vitro experiments. Xenografts were initially titrated at a range of
dilutions (4, 2, 1, 0.2pg/ml protein) to determine a suitable concentration range.
Tumour samples appeared to dilute in parallel with titrations of the recombinant
protein (Fig 3.36). Results were calculated using the criteria established in the in vitro
experiments, i.e. dilutions which fitted the linear portion of the dilution curve and the
recombinant protein standard curve.
Results for the oestrogen modulated and unmodulated xenografts are shown in Figure
3.37. HSP27 levels in the xenograft control group had a mean value of 5.7 ± 0.4ng
and in the treated group, 5.1 ± 0.6ng, concentrations which were approximately
five-fold greater than those observed in the in vitro PE04 models (see Figure 3.35).
However, unlike the situation in vitro, HSP27 concentrations in the PE04 xenograft




Typical dilution curve showing the absorbances at 450nM for different concentrations
of untreated and oestrogen-treated PE04 xenograft cytosols, run in the HSP27





HSP27 levels in the PE04 ovarian xenograft model grown in the absence or presence
of a 60 day 17 (3-oestradiol slow-release pellet. The striped bar depicts xenografts
grown in the absence of oestrogen supplement, and the shaded bar represents
oestrogen-treated xenografts. Results show the mean ± SEM of 9 separate
observations and are expressed in ng HSP27/gg cytosolic protein, calculated from the
ratio of the absorbances at 450nM of lpg protein of sample cytosol with respect to 1
ng of recombinant HSP27.
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3.6 Modulation of TGF-a and EGF expression in
ovarian cancer cells
There is evidence from breast cancer studies to suggest that oestrogen may exert its
growth stimulatory effects partly through the action of one or more growth factors,
by altering their expression in target cells (Dickson et al., 1986, Bates et al., 1988,
Huff et al., 1988). In ovarian cancer, this may involve members of the EGF growth
factor family, such as TGF-a and EGF acting through the EGF receptor. Previous
studies have demonstrated the presence of EGF receptors in the PEOl, PE04 and
PE014 ovarian cell lines which are also growth stimulated by TGF-a and EGF (Crew
et al., 1992a). If these cells are shown to secrete these factors, an autocrine or
paracrine growth pathway may exist, which could be partly influenced by the action
of oestrogen.
To determine whether oestrogen modulates the secretion of TGF-a and EGF, levels
of these growth factors were measured in the conditioned media of PEOl, PE04,
PEOl4 and PE01cddp ovarian cancer cell lines growing in the absence or presence of
10"10M 17 P-oestradiol for three days. Cells were cultured in phenol red-free media
without serum. Growth factors were detected in the conditioned media using liquid
phase competitive radioimmunoassays (RIA) specific for human TGF-a and EGF.
Both assays are based upon the competition of labelled 125I-peptide and unlabelled




Analysis ofTGF-a was performed using TGF-a RIA kits obtained from Peninsula,
(i) Specificity
The Peninsula kit for TGF-a detection comes supplied with a rabbit anti-TGF-a (rat)
antibody which the manufacturers claim shows a similar level of cross-reactivity
(100%) for both human TGF-a and rat TGF-a, but shows no cross-reactivity with
human EGF. To confirm the cross specificity of the rat TGF-a antibody and the
suitability of the rat TGF-a standard in the assay, serial dilutions of human and rat
TGF-a standards (10pg/ml-1280pg/ml) were prepared and incubated with fixed
amounts of the TGF-a antibody, goat anti-rabbit IgG, 125I-TGF-a (rat) and normal
rabbit serum. In addition, a series of log dilutions of human EGF standard were also
tested with the supplied TGF-a antibody.
Figure 3.38 shows standard curves for the rat and human TGF-a, and human EGF,
generated from the concentration of each standard versus the % bound (B)/maximum
binding (Bo) of labelled peptide. A 100% value demonstrates maximum binding of
labelled peptide (125I-TGF-a) and indicates a low level (limit of detection) of
unlabelled standard. As the amount of unlabelled standard increases the %B/Bo value
decreases indicating the greater competition for binding by the cold competitor.
Similar curves were produced for both human and rat TGF-a standards denoting the
same level of reactivity with the rat anti-TGF-a antibody. The curves generated also
matched the standard curve profile provided with the kit. All dilutions of EGF
produced a %B/Bo value for the 125I-TGF-a of around 90-100% indicating very little
competition for binding from the EGF competitor, and thus little reactivity between
the anti TGF-a antibody and EGF.
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Figure 3.38
A standard curve calculated from the % bound (B) / maximum binding (Bo) of
125TGF-a (rat) for different concentrations of unlabelled human (open symbols) or rat
(closed symbols) TGF-a in a TGF-a radioimmunoassay. Readings were initially
measured as counts per minute. The % bound value (B) was calculated by subtracting
the non-specific background reading (binding of125 TGF-a in the absence of primary
antibody and unlabelled TGF-a) from each sample reading. Maximum binding, Bo,
was calculated from binding of 125TGF-a in the presence of both primary and
secondary antibodies but without unlabelled TGF-a. Values shown are the mean of
duplicate observations from one experiment, and bars represent SEM.
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(ii) Sample preparation
a) Effect of concentrating samples
Because secreted levels of TGF-a are extremely low it has usually been necessary to
concentrate and purity conditioned media samples by various methodologies in order
to detect the peptide by conventional assays. In order to determine whether this
would be necessary to detect secreted TGF-a in this study, conditioned media from
cultured cells was concentrated by freeze-drying, and dialysed against PBS. Table
3.10 shows the results from a TGF-a RIA for unprocessed and processed
(concentrated and dialysed) conditioned media samples from ZR-75-1 breast cells, as
well as concentrated conditioned media from two ovarian cell lines, PEOl and PE04.
Cell lines were grown in phenol red-free media in the absence of serum for three days,
after which media was collected and processed.
Assays of unprocessed conditioned media from ZR-75-1 cells gave binding values of
around 100%, which equated to a TGF-a concentration which was at the standard
curve limit. When the cell conditioned media was concentrated 25-fold, a binding
value of 88.8% was obtained, which fell within the range of the standard curve. After
taking the concentration factor into account, this gave a mean final concentration of
4.1pg/ml. However, conditioned media from the ovarian cell lines which was
concentrated 25-fold, had high %B/Bo values. TGF-a concentrations therefore could
not be calculated for PEOl or PE04 which gave readings at the limit of the curve.
These results suggested that media from the cell lines would have to be concentrated
further in order to obtain a reading from the standard curve. Ideally, readings should
164
be taken from the plot where the relationship between TGF-a concentration and
%B/Bo is linear. Conditioned media from the ovarian cell lines for subsequent
analysis were concentrated 100-fold which gave readings falling within this range.
Table 3.10
% B/Bo and TGF-a concentrations of conditioned media from ZR-75-1 cells which
was either unprocessed or concentrated 25 fold and dialysed. Also shown are values
for processed media from the PEOl and PE04 ovarian carcinoma cell lines. Values
shown are for duplicate measurements. Cells were cultured in phenol red-free media

















b) Effect of serum and protease inhibitors
Table 3.11 shows the % B/Bo values and concentrations of TGF-a like activity for
conditioned media collected from breast and ovarian cell lines cultured in the presence
or absence of 5% dcsFCS. Also shown are measurements for media alone which were
prepared in the absence or presence of serum and protease inhibitors (0.2mM
phenylmethanesulfonyl fluoride, ImM EDTA, 0.5mg/L leupeptin and 0.7mg/ml
pepstatin A).
Conditioned media from ZR-75-1 cells demonstrated TGF-a like activity both in the
presence and absence of serum when concentrated 25-fold and incubated with
protease inhibitors. Similarly, PEOl and PE04 cells grown in the presence of 5%
dcsFCS demonstrated binding activity which was within the range of the standard
curve, giving mean values of TGF-a-like activity of 3.95 and 4.32 pg/ml respectively.
However, there was no detectable TGF-a like material in conditioned media obtained
from PEOl or PE04 ovarian cells grown in the absence of serum.
Analysis with the non-cell conditioned media samples showed that RPMI or DMEM
culture media alone did not exhibit any TGF-a like activity. But when 5% dcsFCS
was present in the media, some TGF-a like activity was detected which was enhanced
in the presence of protease inhibitors. Maximum binding was observed in the RPMI
sample incubated just with protease inhibitors, suggesting that the inhibitors on their
own did not exert any binding activity, but enhanced the competition for binding from
any factors present in serum.
Because of the possibility of competition for binding in stripped serum, subsequent
experiments in the cell lines determining oestrogen modulation of TGF-a were
carried out in serum-free conditions. Conditioned media collected were incubated




(A) Shows the % B/Bo for conditioned media collected from ZR-75-1, PEOl and
PE04 cell lines cultured with or without serum for three days. Media was
concentrated 25-fold in the presence of protease inhibitors, and dialysed against PBS.
Key: S (5% dcsFCS), P (protease inhibitors). Values shown are the mean of duplicate
experiments ± SEM.




ZR-75-1+ P 88.77 ± 0.63 4.06 ±0.26
ZR-75-1 + S + P 86.89 ±1.91 4.79 ±0.75
PEOl + S + P 89.02 ±1.50 3.95 ±0.61
PEOl + P 95.50 ± 1.39 at curve limit
PE04 + S + P 88.11± 1.23 4.32 ±0.49
PE04 + P 95.76 ±0.59 at curve limit
(B) Media samples
RPMI only 99.96 ±0.54 at curve limit
DMEM only 100.4 ±0.4 at curve limit
RPMI + S 91.86 ±0.36 3.67 ±0.41
RPMI + S + P 85.10 ± 1.20 6.55 ±0.25
RPMI + P 108.65 ±2.95 at curve limit
3.6.2 Modulation of TGF-a secretion by 17 p-oestradiol
The level of TGF-a-like activity was examined in the conditioned media of four
ovarian cell lines, PEOl, PE01CDDP, PE04 and PEOl4 which were cultured in the
absence or presence of 10"10M 17 P-oestradiol, and in the absence of serum for three
days. Protease inhibitors were added to the conditioned media collected, which was
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concentrated 100-fold. At this concentration, detectable levels of TGF-a were
measured in conditioned media from the ovarian cell lines. Figure 3.39 shows typical
%B/Bo values obtained for the TGF-a RIA, and confirms the presence of TGF-a-like
activity in titrations of conditioned media from untreated and treated ZR-75-1 and
PE04 cells, which dilute in parallel with a typical standard curve of known
concentrations ofTGF-a.
Results of TGF-a RIA's for the untreated and treated ovarian and breast cell lines are
given in Figure 3.40 and are summarised in Table 3.12. TGF-a-like activity was
detected in the conditioned media from all the cells after 72 hours culture, but was at
an extremely low level in conditioned media from the ER-negative PE014 ovarian
cell line. Higher levels of TGF-a-like material were secreted by the ER-positive
ovarian cell lines, PEOl, PE04 and PEOl00015. Moreover, in two of these lines, PE04
and PE01CDDP, secreted levels were significantly increased from cells which were
exposed to 10"10M 17 (3-oestradiol as compared to cells cultured in oestrogen-free
conditions. Levels of TGF-a-like activity also appeared to be increased in the PEOl
cell line (near significance, p= 0.051). In addition, TGF-a-like material was detected
in the conditioned media of ER-positive ZR-75-1 cells, but there was no significant
difference in the levels of secreted TGF-a from either untreated or oestrogen-treated
cells. Cell counts of the above cell lines growing in serum-free conditions in 24 well
plates for 72 hours indicated that there was no significant increase in cell number over
this period (data not shown), thus suggesting that the increase in TGF-a in the
168
conditioned media of oestrogen-treated PE04 and cells was due to increased
secretion and not a greater number of cells producing the growth factor.
Table 3.12
Detection of TGF-a-like activity in the conditioned media of four ovarian and one
breast cell line. Cells were cultured in serum-free RPMI (or DMEM; ZR-75-1)
without phenol red in the absence or presence of 10"10M 17 (3-oestradiol (E2) for 72
hours. Conditioned media were then collected, concentrated xlOO and analysed using
a RIA specific for TGF-a. Results are expressed as pg of TGF-a/ml of media. Values
shown are the mean of three separate measurements ± SEM. *p= 0.051, **p<0.05
Cell Line TGF-a concentration (pg/ml)
Control cells + 10 loM E2
PE04 1.23 ±0.18** 4.93 ± 1.23**
PEGi001^ 1.55 ±0.12** 6.60 ± 1.09**
PEOl 0.87 ±0.19* 1.60 ±0.19*
PE014 0.24 ±0.15 0.23 ±0.12
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Figure 3.39
Typical displacement curves showing the presence of TGF-a like activity in serial
dilutions of conditioned media from untreated and oestrogen-treated PE04 and






TGF-a-like activity in the conditioned media of four ovarian and one breast cell line,
cultured in the absence or presence of 10"10M 17 (3-oestradiol for 72 hours.
Conditioned media was then collected, concentrated and analysed using a TGF-a
specific RIA. Lighter shaded bars represent untreated cells and darker shaded bars
treated cells. Values shown represent the mean of three separate observations and





The radioimmunoassay for EGF was adapted from a method described by McDonald
et al., (1990), incorporating a sheep anti-human EGF antibody which does not cross
react with murine EGF or human TGF-a. Initial experiments were set up to confirm
this by incubating both a series of human recombinant EGF and TGF-a standards
(0.2-200 ng/ml) with the anti-EGF antibody and 125I labelled human EGF. The results
shown in Figure 3.41, demonstrate that the EGF standards effectively compete out
binding by labelled EGF in a dose dependent manner. However, as indicated by the
maximum %B/Bo values, no competition for binding is exhibited by any of the
TGF-a standards.
(ii) Sample Preparation
a) Effect of concentrating samples
Previous reports with this assay have shown that concentration of conditioned media
was necessary in order to detect the low levels of EGF-like activity produced by a
prostatic cancer line, DU145 (McDonald et al., 1990). Therefore, initial RIA's were
performed with cell line conditioned media from ZR-75-1, and three ovarian cell lines
which had been cultured in the absence of serum Samples were incubated with
protease inhibitors and concentrated 25-fold. Results indicated that no detectable
EGF-like activity could be measured in these samples, implying further concentration
might be necessary to detect the presence of the growth factor.
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Figure 3.41
Graph showing specificity of the anti-human EGF antibody for human recombinant
EGF, but no cross reactivity with human recombinant TGF-a. Standards were
incubated with 125I EGF and sheep anti-human EGF antibody, followed by incubation
with donkey anti-sheep polyclonal IgG. Bound fractions were counted by gamma
counter, and from this %B/Bo values calculated as described previously.
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b) Effect of serum and protease inhibitors
RPMI media samples containing either 5% dcsFCS or protease inhibitors, or both
were run in the EGF assay to determine whether these factors elicited any binding
activity. In addition, conditioned media from ZR-75-1, PEOl, PE04 and PE014 cells
grown in the presence of 5% dcsFCS and protease inhibitors were also run. Samples
were concentrated 25-fold and dialysed against PBS. No detectable EGF-like activity
was seen in RPMI alone or with the addition of protease inhibitors. In contrast to the
TGF-oc RIA, the presence of 5% dcsFCS in media did not elicit any competition for
binding in the EGF RIA, either alone or with protease inhibitors. At 25-fold
concentration, conditioned media from any of the cell lines assayed did not contain
detectable levels of EGF activity when cells were grown in the presence of 5%
dcsFCS and protease inhibitors.
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3.6.4 Modulation of EGF secretion by 17 (3-oestradiol
The same conditioned media samples which demonstrated detectable TGF-a levels, at
100-fold concentration, were also analysed for EGF activity using the EGF specific
RIA. However, no EGF-like material could be detected in either untreated or
oestrogen-treated samples using the assay which is sensitive in the range 0.2 - 200
ng/ml.
To further test whether the cell lines produced any detectable EGF-like material, two
EGF standards used to create the RIA standard curve were diluted in the control
conditioned media from PE04 and PE014. However, as can been seen in Figure
3.42, no displacement of the standard curve was seen, suggesting that the cell lines
were secreting little or no EGF-like activity.
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Figure 3.42
EGF standard curve containing a range of concentrations of human EGF. Arrows
indicate where standards were spiked with conditioned media from PE04 and PE014
cells. Values shown are the mean of duplicate readings ± SEM.
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3.7 Analysis of IGF-I Receptor regulation by
oestrogen
Previous reports have implicated the insulin-like growth factors (IGF's) in the control
of breast cancer growth through autocrine and paracrine growth pathways, (Yee et
al., 1988, Osborne et al., 1989), and more recent evidence implies that they may also
be involved in the growth regulation of ovarian carcinoma. IGF-I and its receptor is
expressed by several ovarian carcinoma cell lines (Yee et al., 1991a), including
OVCAR-3 which is also growth stimulated by IGF-I (Yee et al., 1991a, Resnicoff et
al., 1993). The receptor has also been demonstrated in ovarian tumours (Foekens et
al., 1990b). Recent data by Krywicki et al., (1993) has shown that E2 can
downregulate the expression of IGF binding proteins in the PE04 ovarian cell line,
and suggested that this may make the cells more responsive to IGF-I. There is
however still a paucity of data on the regulation of the IGF family by oestrogen in
ovarian cancer and it was therefore of interest to examine whether the IGF-I receptor
is modulated by oestrogen in ovarian cell lines. The PEOl, PE04 and PE014 cell
lines all express mRNA for IGF-I and its receptor, and the presence of receptors has
been confirmed by immunohistochemistry, Bartlett et al., (1995).
Cell lines were grown in phenol red-free media supplemented with 5% dcsFCS and
exposed to 10"10 M E2 for six days, following which the IGF-I receptor levels were
measured by flow cytometry. Figure 3.43 shows the percentage of cells staining for
IGF-I receptor in the ER-positive PEOl, PE04 ovarian lines and the ER-negative
MDA-MB-231 breast cell lines in control and oestrogen-treated groups. Greater than
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90% of cells in the ovarian cell lines stained positively for presence of the receptor.
There was no significant difference between the percentage staining seen in the
oestrogen-treated PEOl and PE04 cells and that observed in control cells. A much
lower level of staining was seen in the ER-negative breast cell line with only
approximately 7% of cells in the control group showing positive staining for the
presence of the receptor. A smaller percentage of oestrogen-treated MDA-MB-231
cells had detectable IGF-I receptor (approximately 2%), although again this was
non-significant.
Figure 3.44 shows the intensity of staining for IGF-I receptor measured in the cell
lines calculated as a ratio of the mean fluorescence for each sample compared to the
background. Both the ovarian ER-positive cell lines demonstrated a six to seven fold
higher staining intensity than that seen in the ER-negative breast cell line. Intensity
levels seen in oestrogen-treated PE04 cells were significantly greater than PE04 cells
cultured without oestrogen. The mean staining intensity was also greater in
oestrogen-treated PEOl cells although this difference did not achieve significance.







IGF-I receptor expression in two ovarian and one breast cell line cultured in phenol
red free media supplemented with 5% dcsFCS. Darker shaded bars show cells which
were grown in the presence of 10"10M 17 (3-oestradiol for six days and lighter shaded
bars show cells which were untreated. Values are given for the percentage of cells







IGF-I receptor expression in two ovarian and one breast cell line cultured in phenol
red-free media supplemented with 5% dcsFCS. Darker shaded bars show cells which
were grown in the presence of 10"10M 17 (3-oestradiol for six days and lighter bars
show cells which were untreated. Values are given for the intensity of positive
staining for the IGF-I receptor and represent the mean of duplicate observations ±




4.1 Growth modulation by oestrogen
There has been increased interest in recent years in the potential role of hormones in
ovarian cancer. The majority of human ovarian adenocarcinomas are oestrogen
receptor (ER)-positive (reviewed in Slotman and Rao, 1988) and there have been
reports of some responses with hormonal therapy, such as the anti-oestrogen,
tamoxifen (Myers et al., 1981, Hatch et al., 1991), which has been successful for a
number of years in the treatment of breast cancer. It is likely therefore that a subset of
ovarian carcinomas are oestrogen-regulated but their characteristics are undefined.
Knowledge of the role of oestrogens in breast carcinogenesis and tumour progression
has been greatly enhanced by use of a number of oestrogen-sensitive breast cancer
cell lines, such as the MCF-7 and ZR-75-1 lines (Soule et al., 1973, Engel et al.,
1978). However, a lack of similar models for ovarian cancer has meant there is less
insight into hormonal influences in this disease. Despite several ovarian cell lines
being derived and established in recent years (Fogh et al. 1977, Buick et al., 1985,
Sinna et al., 1979) there have been few studies describing hormonal sensitivity. In
part this is because little attention has been paid to the steroid receptor content of
these lines, and if assayed for the presence of ER, the majority of the cell lines have
proven to be receptor-negative (Woods et al., 1979, Benard et al., 1985). Thus, there
has been a lack of clinically relevant experimental models.
This study has incorporated a number of ovarian carcinoma cell lines with varying
levels of ER, amongst them the first recorded cell lines (PEOl, PE04 and PE06)
with moderate/high levels of ER of approximately 100 fmol/mg protein, as detected
previously by the dextran-coated charcoal ligand binding assay (Langdon et al.,
1988). Evidence from breast cancer studies suggests that higher ER values (greater
than 100 fmol/mg protein) are associated with a greater response rate to endocrine
therapy (McGuire, 1978), whereas the response rate is much lower with decreased
levels of ER. Thus, these ovarian cell line models may be more representative of a
clinically responsive tumour phenotype than those previously described by other
groups. The other cell lines studied have lower ER values; PEA1 and PEA2 have an
ER content of 23 and 12 fmol/mg respectively, whereas the remaining cell lines,
PE014, PE016 and PE023 are ER-negative. Cell lines were deemed ER-negative if
their receptor levels were less than 5 fmol/mg protein, the ER assay detection limit.
In addition, a further cell line, PE01cddp was also investigated. This cell line, which
has not been previously described in the literature, is a cisplatin-resistant subline,
derived by continuous culture of PEOl cells in increasing concentrations of cisplatin
for six months and is approximately 5-fold more resistant to cisplatin than the parent
line, PEOl (Langdon, personal communication). PE01cddp therefore provided a
useful model to compare with the PEOl and PE04 cell lines which were derived from
the same patient before and after the onset of clinical resistance to cisplatin
combination therapy. These two lines have LD50 values of 0.064pM and 0.2p.M
respectively (Wolf et al., 1987).
The series of ovarian cell lines described in this thesis are amongst the few reported
with positive ER levels (Langdon et al., 1988, 1990). Two other established
ER-positive ovarian cell lines have been previously described. The NIH:OVCAR-3
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cell line, established from the malignant ascites of a patient with a poorly
differentiated ovarian adenocarcinoma, was the first ovarian cell line reported to
contain steroid receptors, expressing both ER and AR (androgen receptors) at 28 and
30 fmol/mg protein respectively, (Hamilton et al., 1983). The lower limit of ER
values in breast tumours which may be hormonally sensitive is usually taken to be
20-30 fmol/mg protein, thus, the receptor level in the NIH:OVCAR-3 line just
borders on the clinically significant. The other ER-positive ovarian cell line, BG-1,
was characterised by Geisinger et al. (1989), and has a slightly lower ER content of
23 fmol/mg protein. A recent study by Hua et al., (1995) has shown that the SKOV3
ovarian carcinoma cell line also has detectable levels of ER as measured by Western
blotting.
The PEO series of cell lines, therefore provides a good experimental system with
which to assess the effects of oestrogen, representing primary ovarian tumours with
both lower and higher levels ofER. Two breast cancer cell lines were also included in
this study; ZR-75-1, an ER-positive breast cell line, and MDA-MB-231, an
ER-negative cell line, so that comparisons could be made between observations with
the ovarian cancer cell lines and already established oestrogenic effects in breast
cancer. The hormonal growth sensitivity of the PEOl, PE04 and PEO 14 had
previously been characterised by Langdon et al., (1990) but effects of oestrogen on
the other cell lines had not been described before. To determine the effects of
oestrogen on growth, all experiments were conducted in oestrogen-depleted
conditions. Previous studies have shown that there are substantial levels of oestrogens
in commercial foetal calf sera (FCS) (up to lOnM concentration) (Esber et al., 1973),
as well as sulphate conjugates, and other steroids. These can be removed by using
dextran-charcoal treated FCS (Stanley et ah, 1977, Darbre et al., 1983). In addition,
the pH indicator phenol red, normally present at high concentrations in culture media,
is a weak oestrogen which can bind to the ER with an affinity 0.001% that of
oestradiol (Berthois et ah, 1986). All experiments therefore, were carried out using
phenol red-free media supplemented with double charcoal-stripped sera.
Under these conditions, growth of PE04 and PE014 cells has been shown to be
reduced as compared to cells growing in normal culture media (Crew, personal
communication). The absence or presence of phenol red indicator does not seem to
make any difference to growth rates when cells are grown in charcoal-stripped serum
(Langdon et ah 1990), thus this effect appears to be due to growth promoting agents
being removed from the sera. One of these components is likely to be oestrogen as
this can increase the growth rate in PE04 cells when added back to the culture media
(see next paragraph), however as the same effect is not observed with PE014 cells, it
would appear that other growth promoting agents such as other steroids or growth
factors are removed as well.
Growth curves for the ER-positive PE04 and the ER-negative PE014 in the
presence and absence of serum were initially reproduced to verify previous reports of
their oestrogen sensitivity/insensitivity, and compared with the response of an
ER-positive and ER-negative breast cancer cell line, ZR-75-1 and MDA-MB-231 to
oestrogen. Both concentrations of 17 P-oestradiol used (10"10M and 10"8M) produced
significant increases in growth over six days in the ER-positive PE04 cell line as
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compared to control cells, which was comparable to previous findings. There was
also a 70% increase in growth of PE04 cells in the absence of oestrogen over the
time course. This might possibly be due to residual oestrogens in the culture media
through insufficient stripping of sera, or inadequate washing with PBS. However as
tamoxifen has previously been shown not to inhibit this growth (Langdon et al.,
1990), it appears that this residual growth activity is not due to oestrogenic
stimulation. This suggests that the growth of PE04 cells may be influenced by other
mitogenic factors, additional to oestrogen, which are present in the culture medium.
The magnitude of growth response observed with oestrogen-treated PE04 cells was
comparable with that of the ER-positive ZR-75-1 breast cancer cell line which was
significantly stimulated by the two concentrations of 17 (3-oestradiol, consistent with
previous observations that this is an oestrogen-sensitive cell line (Darbre et al., 1983).
However, very little growth was observed with control ZR-75-1 cells over the six
days, a finding which is in keeping with reports that ZR-75-1 cell line is an
oestrogen-dependent line (Glover et al., 1988). This group found that there was some
growth of ZR-75-1 cells in short term culture in oestrogen-free conditions
(phenol-red free media plus 5% stripped FCS), but basal growth was reduced to zero
after prolonged culture (2 weeks or more). If oestrogen was added back to the
culture, basal cell growth returned, suggesting that growth of ZR-75-1 cells is
dependent upon oestrogenic stimulation. They suggested that any residual growth
which was seen in short term culture without the presence of oestrogens could have
been due to a steroid "memory effect". No significant increase in growth was noted
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with the control ZR-75-1 cells described in this thesis, suggesting that all oestrogens
had been removed from the media.
Consistent with its lack of ER, there was no effect of oestrogen on PE014 cell
numbers. However, both control and treated cells increased approximately three-fold
in number over the six days, a growth rate greater than that observed with control
PE04 cells which in normal culture conditions (phenol red, 10% FCS) have a shorter
doubling time than PE014 (Langdon et al., 1988), suggesting that growth promoting
factors for PE014 are still present in dcsFCS. This response was similar to that seen
with the ER-negative MDA-MB-231 breast cancer cell line which showed a four-fold
increase in number over the six days.
The effect of varying concentrations of oestrogen on cell numbers was examined in
eight of the ovarian cell lines to determine the range of hormonal sensitivity.
Significant increases in growth were observed in the PEOl, PE04 and PE06 cell
lines between the oestrogen concentration range lO12 and 10"6M, maximal
stimulation being obtained in the range 10"10 to 10"8M. This is in agreement with
Nash et al, (1989a) who compared the oestrogen sensitivities ofNIH:OVCAR-3 and
PE04 lines, reporting the PE04 line to be growth stimulated by concentrations of
oestrogen between 10"12 and 10"8M, with maximal effects at 10"10M.
The increase in growth stimulation gradually fell between 10~8M and 10"6M, possibly
caused by a down-regulation of ER. This is similar to oestrogen-sensitivity profiles
obtained with ER-positive breast cancer cell lines (Lippman et al., 1976, Darbre et
al., 1983). Sensitivities at concentrations lower than 10"12M were not examined
except in the PEOlCDDP line (see below), but Langdon et al., (1993) has shown that
the PE04 cell line is not significantly growth stimulated by a dose of 10"13M
oestrogen. This sensitivity to oestrogen is consistent with the presence of
moderate-high levels ofER in these lines (around 100 fmol/mg protein). Conversely,
no increase in cell numbers was seen in response to oestrogen treatment in the PEA1
or PEA2 cell lines, which although being ER-positive, contain much lower levels of
ER; 18 and 8 fmol/mg protein respectively when measured by enzyme immunoassay
(see next section of discussion). This observation is compatible with reports in breast
cancer which suggest that ER values greater than 20-30 fmol/mg protein delineate
tumours which are likely to be hormonally sensitive (Jensen et al., 1976). As might be
expected with a lack of ER, there was no growth stimulation in either the
ER-negative PE016 or PE023 cell lines.
There are only a few reports of oestrogen effects on the growth characteristics of
other ovarian carcinoma cell lines. The BR ovarian carcinoma cell line in which the
ER status is unknown is stimulated by several concentrations of oestrogen
(Wimalasena et al., 1993). Of the previously reported ER-positive lines, only the
NIH:OVCAR3 and BG-1 lines show an increase in growth in response to oestrogen.
Chien et al., (1994) showed that the NIJEOVCAR-3 cell line was growth stimulated
by oestrogen in contrast to an earlier finding by Nash et al., (1989a), and effects of
oestrogen on the proliferation of ER-positive BG-1 ovarian cells were noted by
Galtier-Dereure et al., (1992), who demonstrated that the growth of BG-1 cells was
significantly increased after exposure to 17 (3-oestradiol for 5 days. However, despite
having detectable levels of ER, oestrogen has no effect on the growth of the SKOV3
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line, (Hua et al., 1995). Therefore, cell lines with low levels of ER around 20-30
fmol/mg protein such as BG-1 and NIH:OVCAR-3 may be oestrogen responsive. A
report by Lazo et al., (1984) showed that in clonogenic assays of cells taken directly
from clinical ovarian samples, 2 out of 4 samples with an ER value of greater than 30
fmol/mg protein responded to the anti-oestrogen tamoxifen, but none of the samples
with levels lower than 30 fmol/mg protein showed a response, again suggesting that
cells with moderate to high levels ofER are more likely to be oestrogen sensitive.
An interesting observation was noted when the platinum-resistant subline PE01cddp
was exposed to oestrogen. Although this line contains ER levels similar to the
parental line PEOl, and these are down-regulated by 10"10M 17 P-oestradiol to a
similar degree (see section 4.2), concentrations of oestrogen which were stimulatory
to the parent line caused a decrease in PE01CDD1 cell numbers. The magnitude of this
inhibition gradually decreased at lower concentrations, until cell number was
comparable with the control at a concentration of 10"16M. The inhibitory effects of
oestrogen on PE01CDDI cells is not simply a cytostatic effect. Cell numbers increase
after plating in both control and treated groups, but the rate of growth in treated cells
appears to be less than those not exposed to oestrogen. After three days culture there
is evidence of a growth inhibition in a dose dependent manner and following a further
three days of oestrogen-exposure this is even more pronounced. Oestrogen is possibly
causing a down-regulation of growth stimulatory mechanisms, or an up-regulation of
growth inhibitory mechanisms.
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This finding is certainly not consistent with the positive growth effects observed in the
other cell lines with high levels of ER. The concentrations of oestrogen responsible
for the inhibition were also not at levels which have previously been reported as being
toxic to cells. In all the other cell lines, except PEOl, cytotoxic and cytostatic effects
were only apparent with the highest concentration, 10"5M, and also at a concentration
of lO^M in PEOl6. Although a concentration of 10"5M produced a growth
stimulation in PEOl, cytotoxic effects in PEOl have been seen with a concentration
of 10"4M (Crew, personal communication). This is similar to observations by Reddel
and Sutherland, (1987) who reported a 50% inhibition in the ER-positive MCF-7
breast cell line with 5 x 10"6M 17 P-oestradiol, and suggested that high concentrations
of oestrogens caused specific changes in cell cycle parameters. There appeared to be
differences between different breast lines in that the ER-positive T47-D breast cancer
cell line showed less sensitivity to inhibition by high dose oestrogen. However, they
also noted that these observations were not limited to ER-positive lines in that an
inhibitory effect was also noticed in the ER-negative cell line, MDA-MB-330
although the level of sensitivity was reduced. Likewise, there were no specific
differences in cytotoxicity between ER-positive and ER-negative ovarian cancer cell
lines in the present study, so it would seem that these effects are independent of the
ER.
A report by Vickers et al., (1988) observed that generation of drug resistance in
human MCF-7 breast cancer cells by increasing concentrations of a drug such as
adriamycin can lead to a loss of mitogenic response to oestrogen. This is associated
with a loss ofER and other estrogen responses such as PR induction. In contrast, ER
expression is high in the PEOlCDD>> cell line5 but it may be possible that these
receptors are dysfunctional, and the normal positive growth regulatory pathways are
abrogated in some manner. As discussed later, PR levels are not induced in this line
but other oestrogen modulated proteins such as HSP27 and TGF-a are. In addition,
ER levels are downregulated, suggesting that the receptors are functional in
PE01cddp cells.
Inhibitory effects of E2 on growth have been observed in other ER-positive cell lines,
including an MCF-7 variant (Bronzert et al., 1984) and growth inhibition by
oestrogen, at levels stimulatory to ER-positive breast cancer cell lines, has also been
noted in human mammary epithelial cells, and ER-negative MDA-MB-231 breast
cancer cells which have been transfected with a recombinant ER (Zajchowski et al.,
1993, Jiang and Jordan, 1992). Both these groups reported an increase of cells in the
Go/Gi phase of the cell cycle, and a decrease in the S-phase cell population after E2
treatment, increasing the cell doubling time. This could be noted as early as 12 hours
in the transfected mammary line B5-ER (Zajchowski et al, 1993) and was observed
after six days of treatment with 10"8M E2 in the transfected MDA-MB-231 cell line
(Jiang and Jordan, 1992). The growth inhibition was blocked by the anti-oestrogen
ICI 164,384 in both the transfected human mammary line, B-E23 (Zajchowski et al.,
1993), and the ER-transfected MDA-MB-231 (Jiang and Jordan, 1992). It was
proposed that this growth effect may be attributable to the intolerance of ER
overexpression in constitutively ER-negative cells. The inhibitory effects seen in
PE01cddp are unlikely to be due to high ER expression as the parental PEOl cells
express similar levels of the protein. However, Jiang and Jordan (1992), suggested
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that the anti-proliferative effects seen in the MDA-MB-231 transfectant may be due
to an alteration in growth factor expression. Alternatively, Lottering and co-workers
(1992) have suggested that growth inhibition by oestrogen could be the result of
enhanced production of 2-methoxy-17 (3-oestradiol, a product of E2 metabolism,
which may be responsible for the cytotoxic effects seen with pharmacological
concentrations ofE2 (Seegers et al., 1989).
Previous reports suggest that oestrogens stimulate growth proliferation by shortening
both Gi and S-phases (reviewed by Sutherland et al., 1983), and thus reducing the
doubling time of the cells. Cell cycle measurements performed in the present study did
not reveal any large differences between the distribution of cells in the parental PEOl
line following oestrogen treatment and the PE01cddp cell line, over a six day period.
Slightly lower numbers of oestrogen-treated PEOl cells were seen in Go/Gi, and
higher numbers were observed in S-phase and to a lesser extent in G2/M as compared
to untreated cells, but these differences were minimal and were also observed in
oestrogen-treated PE01cddp cells. Notably, there were far greater numbers of PEOl
and PE01cddp cells in S-phase from both treatment groups than in the other cell lines.
Reddel and Sutherland, (1987) reported a large decrease of cells in Gi following high
doses of diethylstilbestrol (2.5 xlO"6M) or E2 (5 xlO"6M) for 48 hours, and
accumulation of cells in the S and G2/M phases of the cell cycle in both MCF-7 and
T47-D cells, with the appearance of polyploid cells. A similar finding, which was also
probably a consequence of high concentrations of E2, was reported in ER-positive
breast xenografts which were growth inhibited by E2 at serum concentrations of
approximately 10"7M (Brunner et al., 1983). No accumulation of treated PE01cddp
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cells was observed in G2/M, and this suggests that the growth inhibition by E2 in
PE01cddp is through another mechanism than that observed with pharmacological
concentrations of oestrogens.
When MCF-7 cells are exposed to the lower concentration of 10"8M E2, a similar
reduction in Gi and increase in the S-phase population is seen although the
percentage of cells in G2/M remains steady, (Jiang and Jordan, 1992). Weichselbaum
et al., (1978) also reported an increase in the numbers ofMCF-7 cells in S-phase after
treatment with 10"9M E2 during a 30 hour period, but noted a decrease in the S-phase
with a higher dose (10"7M). Bezwoda and Meyer (1990) reported an increase of
MCF-7 cells in S-phase after 48 and 72 hours of treatment but not at 24 or 96 hours.
All these studies note large differences in the cell populations between control and
treated cells unlike those noted here, in both the PEOl pair of lines and the other
ovarian cell lines examined. These studies suggest that further detailed examination of
cell cycle data by examining earlier time points may reveal differences between cell
cycle kinetics both in PEOl and PE01cddp cells, and the PE04 and PEOl4 ovarian
cell lines. At present there appears to be little published literature on cell cycle
analysis in other ovarian carcinoma cell lines.
The largest cell cycle changes were noted in the ZR-75-1 breast cell line. The
percentage of oestrogen treated cells in G2/M was much lower than control cells after
six days, and this was concomitant with higher levels of treated cells in S and Gi.
Similar but less pronounced differences were noted after three days. This increase in
the S-phase population is consistent with the MCF-7 cell line data discussed above,
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although these report a decrease in the percentage of treated cells in Go/Gi. Recent
data from Launoit et al., (1991) showed an initial decrease in cells in Gi following
exposure of ZR-75-1 cells to 10"10M E2 for 24 hours. After further exposure, the
number of cells increased again and stayed constant, suggesting that certain changes
in the cell cycle in this cell line may be apparent earlier than assayed in this study.
Growth inhibition by oestrogen was observed when the PE04 cell line was grown as
a xenograft in nude mice. The mean residual volume of tumours which were not
exposed to an exogenous 17 P-oestradiol pellet increased over a 75 day period but
the volume of treated tumours virtually remained static. This study was carried out in
mice which were not ovariectomised, so both control and treated groups were
exposed to background levels of endogeneously produced oestrogens. PE04
xenografts are growth inhibited in ovariectomised mice, compared to growth of
xenografts in intact mice (Langdon, et al., 1993) and this is consistent with a report
by Sawada et al., (1990) who noted decreased growth of the ER-positive OXA-5
ovarian xenograft in untreated male mice as compared to oestrogen-treated animals.
Growth of PE04 xenografts in ovariectomised mice supplemented with oestrogen is
also inhibited compared to that seen in unsupplemented intact animals (Langdon et
al., 1993) and it is possible, therefore that endogenous oestrogen levels are sufficient
for growth of PE04 xenografts, whereas additional oestrogen supplement raises
concentrations to a level which is inhibitory, similar to observations in vitro with high
concentrations of oestrogen. This is borne out by observations that serum oestrogen
concentrations in ovariectomised mice have been shown to be similar to that of male
mice (approximately half that seen in intact mice), but levels are raised approximately
10-fold in both normal and ovariectomised mice with 17 P-oestradiol implants
(Langdon et al., 1993). Brunner et al. (1983) also reported that growth of T61 breast
carcinoma xenografts was oestrogen inhibited.
HOX-60, an ER-negative xenograft, was not growth inhibited by treatment with
oestrogen, and therefore it is unlikely that the effects on the PE04 xenograft are due
to general cytotoxicity. Alternatively, oestrogen may be influencing the action of
other factors such as gonadotropins present in the in vivo situation which may
override stimulatory effects on growth. The endogenous oestrogen levels in the mice
were not sufficient to stimulate growth of the ER-positive ZR-75-1 breast carcinoma
model which requires exogenous oestrogen (Osborne et al., 1985).
4.2 Effects of oestrogen on oestrogen and
progesterone receptor levels
In clinical studies, Clarke and McGuire, (1989) have reported ER to be present in
50-85% of all breast cancers, assuming a value of greater than 3 fmol/mg protein to
be positive. ER expression is now widely used to predict the responsiveness of breast
tumours to hormonal therapy, however about half of ER-positive tumours do not
respond to treatment, suggesting that ER's in these cases are either not functional, or
other signalling pathways are dominant. Further markers of oestrogen sensitivity have
been sought. Progesterone receptors (PR) are induced in response to oestrogen
(Horwitz and McGuire, 1978a) and are now used in conjunction with ER as a
predictive marker in breast cancer. Tumours expressing both receptor types have a
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70-75% response rate whereas less than 10% of tumours without ER respond to
treatment (Brooks et al., 1980).
A summary of receptor data from a number of studies reviewed by Slotman and Rao,
(1988) suggests that 63% of ovarian tumours contain ER while PR are present in
48%. However, very little experimental data concerning these receptors exists, partly
due to the paucity of receptor-positive cell lines, as explained before.
Levels of ER decreased in response to oestrogen in PEOl, PE04, PE06 and
PE01cddp (the ovarian cell lines with substantial levels of the receptor), and also in
the ER-positive ZR-75-1 breast line. This observation is compatible with the idea that
oestrogen is acting through the ER, which is rapidly processed once occupied with
ligand (Horwitz and McGuire, 1978b, Saceda et al., 1988, Berkenstam et al., 1989),
and is similar to responses previously noted in breast cancer cell lines. Levels ofER in
the PEA1 and PEA2 cell lines were near background and apparently unaffected by the
addition of oestrogen. Although these cell lines are ER-positive, levels are low, and
probably insufficient to elicit a mitogenic response. This is also consistent with the
observation that oestrogen does not elicit a growth response with these two lines,
unlike the cell lines with higher levels of ER. Likewise no change was observed in ER
levels in the ER-negative PEOl4, PEOl6 and PE023, values remained at the limit of
detection.
As might be anticipated, oestrogen induces levels of PR in the PEOl, PE04 and
PE06 cell lines, although it is doubtful whether the change is meaningful in PEOl,
these values being at the limit of detection. A similar observation was noted in
ZR-75-1 breast cells, and although PR levels were far greater than those seen with the
ER-positive ovarian cell lines, there was a similar fold induction in both ZR-75-1 and
PE06. These observations contrast with the previous findings of Nash et al., (1989a)
who despite observing a growth modulation by oestrogen, did not see PR induction in
PE04. This might be due to differing assay procedures, (Nash used sucrose density
gradient analysis) or culture conditions. PR have also been shown to be induced in
response to oestrogen in the ER-positive NIH:OVCAR-3 cell line (Hamilton et al.,
1984), which is growth stimulated by oestrogen.
No induction of PR expression was noted in either PEA1 or PEA2, or the PE01cddp
cell lines. This is not unexpected for PEA1 and PEA2 if an increase in PR expression
is indicative of oestrogen sensitivity; these two show no growth response to
17 P-oestradiol, or down regulation of ER. However, this is not true for the
platinum-resistant cell line, where oestrogen causes a growth response, albeit an
inhibition rather than a stimulation. As ER levels are reduced in response to oestrogen
this indicates a direct effect of oestrogen acting through the ER. It is therefore
possible that certain oestrogenic effects such as PR induction are only associated with
a growth stimulation. However, PR levels are also induced in the ER-positive PE04
xenograft which is also growth inhibited by oestrogen. The ER-negative HOX60
ovarian xenograft did not display any significant variation in either ER or PR levels,
suggesting that 17 P-oestradiol again has a direct effect on PE04 cells in the in vivo
model, mediated through the ER, which is downregulated. These findings together
with the previous data on the NIH:OVCAR-3 cell line (Hamilton et al. 1984) suggest
that PR induction is an indicator of oestrogen sensitivity but not necessarily growth
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stimulation. However in addition, as shown by the results obtained with the PEOl cell
line, a lack of significant PR induction does not necessarily indicate that a cell type is
not hormonally sensitive.
In the PE01CDDP drug resistant model, oestrogen effects also do not appear to be
coupled to an alteration in PR expression, values in both control and treated groups
being at the limit of detection. It seems unlikely that this is a result of cisplatin
selecting out a subpopulation of resistant cells with uncoupled PR responses as PR
values were similar to the levels found in the parent PEOl line, and thus these
responses may be inherent to this line. Jiang and Jordan, (1992) previously noted that
subclones of MCF-7 produce low levels of PR in response to oestrogen. However,
the PE04 cell line in which PR levels were induced by oestrogen was derived from
the same patient as PEOl but at a later stage in the progression of the disease
following the onset of drug resistance. This model may represent a drug-selected
subpopulation of cells demonstrating a different phenotype to PEOl, in which
oestrogen effects are coupled to PR induction, or may be representative of a more
advanced stage of the disease. As PEOl is not a clonal line, the PE04 cell phenotype
may have been masked by a larger population of cells, although the observations with
PE01cddp cell line suggest that exposure to a selective pressure such as cisplatin does
not favour the predominance of the PE04 phenotype. Alternatively, it is possible that
repeated culture of the PEOl cell line in vitro has lead to the selection of a particular
population of cells with uncoupled PR responses, from which the PE01cddp cell line
was derived, whereas, the PE04 cell line model may be more representative of the
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original tumour phenotype. This is readily testable by looking at oestrogen responses
in early passage PEOl cells.
Observations with these cell line models suggest that there is a need to delineate
further markers of hormonal sensitivity, since lack ofPR expression is not necessarily
a sign of low hormonal responsiveness. This is also reflected clinically in breast
tumours. A recent trial of patients with ER-positive, PR-negative (<10 fmol/mg
protein) metastatic breast cancer demonstrated a 43% response rate to tamoxifen
(Ravdin et al., 1992). However, this study confirmed the value of elevated PR levels
and emphasised the importance of use other predictive factors in conjunction with
steroid receptor status.
4.3 Effects of oestrogen on pS2 expression
Several oestrogen-inducible markers have been described which may act as predictors
of hormonal responsiveness in breast cancer. Amongst these is the pS2 protein, of
unknown function, which is secreted by the ER-positive breast cancer cell line,
MCF-7 (Nunez et al., 1987). A number of reports have shown it to be positively
correlated with the presence of ER (Rio et al., 1987, Schwartz et al., 1991, Henry,
1991a, Thompson et al., 1993) and overall survival in breast tumours (Gion et al.,
1993, Besse et al., 1994) although this is not always the case (Wysocki et al., 1994).
There have been few reports of pS2 expression in ovarian cancer, probably due to
only a recent interest in hormonal regulation of this disease and none of these have
investigated its regulation in cell line models. pS2 expression and its possible
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modulation by oestrogen was examined in five of the ovarian cell lines with varying
ER levels. However, only a small level of staining (< 3%) was observed in both
control and treated groups after three or six days in experimental conditions. Some
small changes were observed in staining intensity between control and treated PEOl
and PEA1 cells but as these values were just above the background level of 1.0, they
are unlikely to represent a major effect. In contrast, pS2 expression was seen in
ER-positive ZR-75-1 breast cells, similar to previous reports by Darbre and Daly,
(1990). Moreover, levels were increased about 3 fold after oestrogen treatment.
These findings are in agreement with a study by Foekens et al., (1990b) who found
no pS2 expression in a sample of 26 advanced ovarian tumours, and together suggest
that pS2 may have no utility as a predictive marker in ovarian cancer, unlike the
situation for breast cancer. Interestingly, pS2 staining has not been found in a variety
of normal tissues including ovary and endometrium (Rio et al., 1988b).
However, reports of positive expression in ovarian cancer have been recorded.
Wysocki et al., (1990) detected pS2 mRNA in 6 out of 29 primary ovarian
carcinomas. Expression appeared to be correlated with histological subtype, as four
of these tumours were mucinous cystadenocarcinomas, this group exhibiting a much
stronger pS2 band than the one serous cystadenocarcinoma which was positive.
Tumour numbers were not high enough for this to prove statistically significant. A
similar and significant result was obtained by Henry et al., (1991b) who found 6 out
of 9 pS2-positive ovarian tumours were of the mucinous subtype, and a more recent
study by Dante et al., (1994) has also confirmed a relationship between the mucinous
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subclass and pS2 expression. This group also examined pS2 expression in ovarian
cystadenomas, and again found the positive correlation with mucinous histotype. No
expression was observed in serous cystadenomas.
Expression of pS2 in Wysocki's study did not appear to correlate with ER which is in
conflict with the majority of breast cancer data. Dante also suggested that pS2
expression was not oestrogen-dependent having found pS2 mRNA in oestradiol-free
ascitic fluid from mucinous cystadenomas. It is possible that in these tissues pS2
expression is independent of oestrogen regulation. pS2 levels have been shown to be
induced by a number of factors including epidermal growth factor (Nunez et al.,
1989), and so expression may regulated differently in individual tissues. Some
evidence from breast cancer also indicates that pS2 may be hormone independent.
Johnston et al., (1995) found that a set of breast tumours which had progressed on
tamoxifen therapy were ER-negative, but still expressed pS2 and PR, possibly due to
elevated levels of a variant form of ER, and Briinner et al., (1993a) showed that a
series of hormone independent MCF-7 sublines had high pS2 expression compared to
parental cells. Evidence suggests that pS2 may be a growth factor (Rio et al., 1987)
and its constitutive expression may be important in oestrogen independent growth.
The presence of pS2 may also be related to the production of mucin. In addition to
Dante's and Wysocki's findings, high levels of pS2 have been found in stomach
mucosal cells (Rio et al., 1988b), and strong positivity is found in mucinous (colloid)
breast carcinomas (Henry etal., 1991a).
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The ovarian cancer cell lines in this study were derived from serous ovarian
carcinomas, and are representative of the majority of diagnosed cases which are of
this histological category. There is no mention of the ovarian tumours' histology in
Foeken's report (1990b) so no conclusions can be drawn as to the lack of expression.
Further studies are needed to help define the function of the pS2 protein. It has some
characteristics similar to IGF-I and other small peptide growth factors (reviewed by
Rio et al., 1990), and has close homology with porcine pancreatic spasmolytic
peptide which causes a growth stimulation in breast cancer cells (Hoosein et al.,
1989). However, Neri et al., (1991), have suggested that pS2 may have a function
other than as a growth regulator from studies which noted a lack of close association
between pS2 expression and proliferation in MCF-7 cells. So far in ovarian cancer
there is no evidence that it may serve as a predictive marker for hormonal sensitivity,
but it may have limited use as a specific marker for mucinous carcinomas.
4.4 HSP27 expression and its modulation by
oestrogen
Interest in HSP27 has mounted over the last ten years as evidence accumulates to
support its role as a predictive marker in breast and endometrial cancer (reviewed by
Ciocca et al., 1993). Furthermore, recent data suggest an involvement in drug
resistance (Oesterreich et al., 1993). This study is the first report of HSP27
expression in ovarian cancer. In order to determine a relationship between HSP27
levels and hormonal responsiveness, expression was investigated in routinely cultured
cells and after oestrogen treatment.
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In the majority of cell lines HSP27 expression correlated with the presence ofER and
oestrogen responsiveness, levels being highest in the PEOl, PE04 and PE06 cell
lines which have a moderate to high ER status and are growth stimulated by E2. This
is similar to data obtained with breast tumours (King et al., 1987b, Dunn et al.,
1993). However, only a low level of expression was observed in the cisplatin resistant
PE01cddp cell line although this expresses similar levels ofER to that of the parental
PEOl cell line. This may be a consequence of drug selection, however, when grown
in 5% dcsFCS, HSP27 expression in PE01cddp is comparable with PE04. Whelan
and Hill, (1993) have shown that ER-positive MCF-7 cells which are selected for
resistance to vincristine lose expression of HSP27 and pS2. However, unlike
PE01cddp cells they also show no detectable ER expression either. These changes
were accompanied by overexpression of the P-glycoprotein and a classical multi-drug
resistance phenotype, which is not involved in cisplatin resistance. It is feasible,
however, that downregulation of pS2 and HSP27 expression occurred as a result of
loss of the ER in these cells, and not as a direct consequence of drug resistance or
MDR1 expression.
However, there is evidence to suggest that HSP27 may be important in resistance to
certain types of drugs. Huot et al., (1991) have shown that Chinese hamster ovary
cells which overexpress transfected human HSP27 are resistant to doxorubicin,
colchicine and vincristine but not 5-flurouracil or the nitrosoureas. In addition, heat
shock induction of HSP27 in MCF-7 and MDA-MB-231 cells also renders them
resistant to doxorubicin, although not to other agents (Oesterreich et al., 1993).
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HSP27 expression may have relevance to in vivo derived clinical resistance in ovarian
cancer. The cell lines, PEO1, PE04 and PE06 were all derived from the same patient
but levels of HSP27 protein in the PE04 and PE06 cell lines which were derived
after onset of resistance were two to four fold higher than PEOl. Moreover, HSP27
levels are significantly higher in primary ovarian tumours which progress on therapy,
as compared to ones which are static or responsive (Langdon, personal
communication).
Positive associations between ER and HSP27 expression were also observed in vivo,
when levels of the protein were examined in ER-positive ZR-75-1 breast and PE04
ovarian cell lines grown as xenografts. Both these models expressed higher levels of
HSP27 than the ER-negative HOX60 and T1068 xenografts. Expression in vivo
appeared to be comparable with levels observed in the in vitro cultured lines,
although the higher expression in the ZR-75-1 xenograft may reflect higher levels of
oestrogen administered to the tumour in the in vivo situation (as a result of an
oestrogen pellet being necessary to sustain growth of the xenograft).
A further connection between ER and HSP27 expression was noted when levels of
the protein were examined after cells had been treated with oestrogen. Differences in
expression were noted only in the ER-positive cell lines, although levels were
downregulated in the PE04 and PE01cddp lines but upregulated in ZR-75-1. This
latter response is in line with previous reports which have shown HSP27 to be
upregulated both at the mRNA and protein level in MCF-7 and ZR-75-1 cells (Fuqua
et al., 1989, Ciocca et al., 1983 Ciocca et al., 1992). HSP27 may be differentially
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regulated in breast and ovary, however, an upward trend in expression was also noted
in the PEOl cell line after E2 treatment and although this proved non-significant it
may delineate certain differences in the oestrogen response pathway between itself
and the PE04 and PE01cddp cell lines. Expression was not significantly altered by
oestrogen treatment in the in vivo PE04 model. However, as these experiments were
performed in non-ovariectomised animals, circulating oestrogens may modulate
HSP27 expression, such that no further change in levels are seen in xenografts
exposed to E2 supplement.
4.5 Effect of oestrogen on growth factor expression
The exact mechanism by which oestrogen regulates growth in ovarian cancer is still
undefined although characterisation of oestrogen response pathways in breast cancer
suggest that it may mediate part of its action through the modulation of growth
factors in an autocrine or paracrine manner. Expression of TGF-a and IGF-I are both
increased by oestrogen treatment in MCF-7 cells (Bates et al., 1988, Huff et al.,
1988). EGF receptors are commonly expressed in ovarian cancer (Bauknecht et al.,
1988, Battaglia et al., 1989, van der Burg et al., 1993) and increasing evidence is
revealing the importance of autocrine mechanisms in the growth of this carcinoma.
The production of TGF-a and EGF by oestrogen-treated and untreated cells grown in
serum-free media was measured by radioimmunoassay. Production of TGF-a was
detected in the conditioned media from all of the ovarian cell lines (PEOl, PE04,
PE01cddp and PEOl4) but was highest in the PE01CDDP line. Leake et al., (1995)
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have recently shown that the TGF-a levels found in cytosolic fractions of PEOlCDDP
are also greater than in PEOl and PE04 cytosols, fitting in with observations in this
thesis. Although the concentrations of TGF-a detected were low, they were similar to
the lower end of a range of levels detected in a series of ovarian cell lines described
by Stromberg et ah, (1992). Values were also uncorrected for assay efficiency and so
are likely to be lower than actual levels of secreted TGF-a. Additionally, it is possible
that levels of secreted TGF-a may be an underestimate of endogenously produced
growth factor since TGF-a may exist as a membrane-bound biologically active
precursor molecule (Wong et al., 1989, Rainer et ah, 1991). Consistent with previous
reports of oestrogen modulation of TGF-a in ER-positive breast carcinoma lines
(Dickson et al., 1986, Bates et ah, 1988, Kenney et ah, 1993), an increase in TGF-a
expression was noted in both ER-positive PE04 and PE01cddp lines which were
exposed to oestrogen. A similar increase was noted in the ER-positive PEOl cell line
although this was at borderline significance (p=0.05), but no change was noted in
expression in the oestrogen unresponsive ER-negative PEOl4 cell line. When
normalised against cell number the difference in expression between treated and
untreated cells is still observed and shows that the increase in TGF-a secretion is not
purely an effect of increased cell number, and in fact there is slightly reduced growth
of cells in serum-free conditions.
Crew et ah, (1992a) have shown growth stimulatory effects of TGF-a in the PEOl
and PE04 cell lines, and taking this data into account there is a strong suggestion that
TGF-a may play an important role in the mediation of oestrogen-stimulated growth
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responses in ER-positive ovarian cell lines. Growth of the ER-negative PE014 was
also shown to be stimulated by TGF-a and this is consistent with the fact that all
three cell lines possess EGF receptors (Crew et al., 1992a). A low level of TGF-a
was detected in the culture medium of PE014 and suggests that this growth factor
may also be involved in the growth regulation of this line, in an
oestrogen-independent mechanism. There are an increasing number of reports in the
literature to support the role of TGF-a in the growth regulation of ovarian cancer.
Several groups have noted the growth stimulatory action of TGF- a in ovarian cancer
cell lines (Morishige et al., 1991b, Zhou et al., 1992, Stromberg et al., 1992).
Moreover, Stromberg et al., (1992) and Morishige et al., (1991b) have both reported
the production of TGF-a in EGF-R positive ovarian cancer cell lines and growth
inhibition with neutralizing antibodies against TGF-a. Similar observations are noted
with primary human ovarian cancer models and in xenografts providing further
evidence for an autocrine growth mechanism in ovarian cancer (Kurachi et al., 1991,
Morishige et al., 1991a).
There was no change in the expression of TGF-a in ER-positive ZR-75-1 breast cells
which had been oestrogen-treated, although this line produced the greatest detectable
amount of the growth factor, twice as much as PE01cddp. Expression of TGF-a
mRNA has previously been described in ZR-75-1, although at a level less than that
seen in ER-negative MDA-MB-231 breast cells (Bates et al., 1988) who noted that
basal expression of TGF-a appears to be unrelated to ER status. An increase in
TGF-a expression by oestrogen in a clone of ZR-75-1 has been reported by Dickson
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et al., (1986), although the level of induction was lower than that seen in MCF-7
cells. Kenney et al., (1993) have suggested that oestrogen-modulation ofTGF-a is an
important mechanism in the growth of ZR-75-1 cells by showing that
oestrogen-stimulated growth is inhibited by infection with an antisense TGF-a
retroviral vector. Why no modulation of TGF-a expression was observed in the
present study is unclear, although clonal selection can not be ruled out.
No EGF production could be detected in conditioned media from any of the cell lines
either treated or untreated, and it is possible that the radioimmunoassay used was not
sensitive enough to detect EGF levels present, operating in the nanomolar range. As
such, EGF may have been detected if further concentration of conditioned media
(greater than xlOO) was carried out. However, EGF may be only a minor element in
growth regulation of these ER-postitive cell lines, with the main effector being
TGF-a. Crew et al., (1992a) have shown that PEOl, PE04, and PE014 are also
growth stimulated by EGF to a similar degree as TGF-a. Similar findings were
described by Berchuck et al., (1990b) who found that although the OVCAR 429 and
433 cell lines showed a growth response to EGF, there was no EGF-like activity in
the conditioned medium from these cells. Evidence of a TGF-a-predominant growth
regulation pathway was also noted by Morishige and co-workers, (1991b) who found
no EGF expression by either northern blotting or immunohistochemistry in the
SHIN-3 ovarian carcinoma cell line, but detected TGF-a and EGFR expression by
both techniques. Fitting in with this observation, they also found that monoclonal
antibodies directed against EGF did not inhibit the growth of SHIN-3 cells, in
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contrast to significant growth inhibitions observed with antibodies against TGF-a or
EGF-R. Leake et al., (1995) found that only a minority of ovarian tumours contained
measurable levels of EGF, whereas over 80% contained TGF-a, implying that EGF
may be of less importance in the growth regulation of this cancer.
The evidence that oestrogen produces an increase in TGF-a production in the
PE01cddp cell line is interesting in the light of the fact that this is concomitant with
growth inhibition, suggesting perhaps that in this cell line the normal oestrogen
regulated TGF-a pathway is abrogated, possibly by factors downstream of receptor
activation. Oestrogen induces an increase in TGF-a mRNA expression in
MDA-MB-231 cells stably transfected with a wild type ER expression vector, and
this is also associated with a growth inhibition (Jeng et al., 1994). More recent work
has shown that addition of TGF-a to PE01cddp cells also causes growth inhibition, in
contrast to the parental line in which there is growth stimulation (Simpson, personal
communication). Furthermore, using a neutralising monoclonal directed against the
EGF receptor, these effects on growth can be partially reduced in the order of
40-80%. There is some evidence to suggest a link between growth factor receptor
expression and drug sensitivity. Christen et al, (1990) have reported that treatment of
two human ovarian carcinoma cell lines with EGF sensitises the cells to cisplatin, and
sensitization is both dependent on EGF-R numbers and concentration in mouse
fibroblasts expressing transfected EGF-R. EGF did not enhance the cisplatin
sensitivity of CDDP-resistant 2008 ovarian cells which express 3 fold fewer EGF-R
than sensitive 2008 cells, and they suggested that the resistant phenotype was
associated with a defect in the signal transduction pathway. In contrast, increased
levels of EGF-R have been found in multi-drug resistant Chinese hamster and mouse
tumour cell lines (Meyers et al., 1986). In addition, there is data to support an
association between drug resistance and c-erbB2 expression. Overexpression of this
receptor is known to be associated with poor outcome in ovarian cancer (Slamon et
al., 1989, Berchuck et al., 1990a) and recent work shows that antibodies against
c-erbB2 can block DNA repair after cisplatin treatment, and increase the cisplatin
sensitivity of both SKBR3 cells which constitutively overexpress c-erbB2, and
2008/C13 CDDP-resistant ovarian cancer cells which overexpress c-erbB2 as a result
of infection with a retroviral construct containing full length human c-erbB2 (Pietras
et al., 1994). These data do not suggest that overexpression of c-erbB2 can cause
increased drug resistance as there was no difference in the cisplatin sensitivity of C13
vector alone controls and c-erbB2 overexpressing cells, although transfection of
MCF-7 breast cells with c-erbB2 does decreases sensitivity to cisplatin (and
tamoxifen) (Benz et al., 1991). Langton-Webster et al., (1994) have shown that when
SKOV-3 ovarian carcinoma cells which constitutively overexpress c-erbB2 are made
resistant to cisplatin there is a reduction in c-erbB2 expression, and therefore it may
be interesting to evaluate levels of c-erbB2 in PE01cddp as compared to PEOl to
determine whether there is decreased c-erbB2 expression in the resistant subline.
There are varying reports of TGF-a and EGF-induced cell inhibition, and several
studies suggest that the action ofEGF or TGF-a on cells may depend on the levels of
c-erbB2 receptor present. Mills et al., (1992) have shown that both these growth
factors increase proliferation in two ovarian cancer cell lines (OCC1 and OCC3)
which overexpress c-erbB2, whereas there is decreased growth in two other lines
(0CC2 and HEY) which expresss normal levels of the c-erbB2 receptor. C-erbB2 is
thought to potentiate the EGF signal and becomes rapidly phosphorylated when
certain cell types are treated with the EGF (GrausPorta et al., 1995). When tyrosine
kinase activity was assessed in the OCC1 and HEY ovarian cell lines, it was noted
that the level of tyrosine phosphorylation of the EGF-R was similar in the two lines,
but c-erbB2 phosphorylation was observed only in the OCC1 cells, consistent with
the observation that OCC1 cells have higher levels of c-erbB2 as compared with the
HEY cell line (Mills et al., 1992). Other workers have shown that EGF has converse
effects on cell proliferation depending on the level of EGF receptors. Addition of
EGF to tumour lines A431 and MDA-MB-486 which overexpress EGF-R cause a
growth inhibition, whereas other cell lines expressing moderate levels of EGF-R are
growth stimulated (Filmus et al., 1985, Gill and Lazar, 1981, Barnes, 1982). The
growth inhibition in A431 has been shown to be associated with a sustained increase
in p21(WAF-l/cipl) and reduced cyclin-dependent kinase-2 (CDK2) activity
associated with a Gi arrest, (Fan et al., 1995). Gulli et al., (1996) have suggested that
this growth inhibition is dependent on the level of EGF-R autophosphorylation in
A431: high levels being associated with growth inhibition, whereas lower levels, a
result of reduced availability of ligand, are associated with a growth proliferation.
Additionally, Chen and Lin, (1993) have previously reported that growth inhibition in
A431 is associated with increased tyrosine kinase activity as compared to the EGF
growth-stimulated A431-4 subline which expresses lower levels of EGF-R.
Interestingly, recent data shows that tyrosine kinase activity is highest in the
PE01cddp cell line as compared to PEOl or PE04, is associated with raised levels of
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TGF-a, and is further increased by 17 p_0estradiol (Leake et al, 1995), although the
level of EGF-R expression in PEOlCDDP has not been determined. Potentially, an
abnormal level of tyrosine kinase activity induced by TGF-a may alter the normal
signal transduction pathway in PE01cddp possibly bringing into effect elements of a
negative feedback pathway involving other growth factors which may inhibit growth.
A number of other growth factors are implicated in the progression of ovarian cancer
and amongst these, the importance of the IGF family of growth factors in ovarian
cancer is now emerging. IGF's are major determinants of paracrine control of normal
ovarian function, but less is known about their role in ovarian cancer, and whether or
not they are influenced to any extent by hormones such as oestrogen. When levels of
IGF-I receptors were measured in PEOl and PE04 cell lines, a small but significant
increase in expression levels was noted in PE04 cells which had been exposed to
oestrogen treatment as compared to untreated controls. A similar response was
observed in PEOl. This finding is consistent with reports in breast cancer cell lines
where IGF-I receptors are also up-regulated by oestrogen (Stewart et al., 1990), and
a previous study by Wimalasena et al., (1993) who saw an increase in IGF-I receptors
after oestrogen treatment in an ovarian cancer cell line. It has been recently confirmed
that both the PEOl and PE04 cell lines express mRNA for IGF-I, are stimulated by
the growth factor, and also contain receptors for IGF-II (Bartlett et al., 1995). In
addition, both the cell lines are stimulated by insulin, but not IGF-II, despite
possessing receptors for the latter. This data cumulatively points to IGF-I being a
regulator of growth in PEOl and PE04, and oestrogen may possibly effect growth
responses through modulation of these factors.
IGF-I receptors have been shown to be expressed in a number of ovarian cell lines
and several are growth stimulated by IGF-I (Yee et al., 1991a, Resnicoff et al.,
1993), however data on the effects of oestrogen modulation are sparse. Krywicki et
al. (1993) have shown that oestrogen can modulate the expression of certain IGF
binding proteins (IGFBP's) in PE04; mRNA levels for IGFBP-3 are decreased, as are
IGFBP-2, -4 and -6 although to a lesser extent, whereas IGFBP-5 levels are
increased. However, they also showed that IGF-I mRNA was not altered by
oestrogen. IGF's associate with IGFBP's and modulate the level of ligand/receptor
interaction (De Mellow and Baxter, 1988) and it is possible that reduced levels of
binding proteins after oestrogen treatment in PE04 may make the cells more
responsive to IGF-I (Krywicki et al., 1993), and this may agree with an increase in
the levels of IGF-I receptors following oestrogen treatment. In MCF-7 breast cancer
cells, 17 P-oestradiol increases the sensitivity of the cells to the growth stimulatory
effects of IGF-I (Thorsen et al., 1992). This effect has also been noted by
Wimalasena et al., (1993) who showed that oestrogen could enhance the growth
effects of IGF-I in ovarian cancer cells. IGFBP-2 may be one of the more important
regulators of IGF activity in ovarian cancer. Krywicki et al., (1993) showed it to be
preferentially expressed in a series of ovarian tumour samples, and it is elevated in
cyst fluid and serum from patients with malignant ovarian tumours as compared with
benign neoplasms (Karasik et al., 1994, Kanety et al., 1996). IGFBP-2 is induced by
oestrogen in ER-positive breast cancer cells (Yee et al., 1991b) and a correlation
between oestrogen and IGFBP-2 content of cyst fluids from ovarian tumours has
been noted (Karasik et al. 1994).
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The effect of steroid hormones on the IGF family in breast cancer is better
understood. Oestrogen up-regulates the IGF-I receptor in breast cancer cells (Stewart
et al., 1990, van den Berg et al., 1996) and a positive correlation between ER and
IGF-I R has been shown (Pekonen et al., 1988, Railo et al., 1994). Oestrogen also
induces the levels of IGF-II mRNA in the T47-D and MCF-7 breast cell lines (Myal et
al., 1984, Yee et al., 1988). In addition it has been shown that anti-oestrogens can
influence the levels of circulating IGF-I and expression of IGFBP's (Pratt and Pollak
et al., 1993, Lahti et al., 1994). Levels of IGF's may be involved in the growth
inhibition observed in T61 breast xenografts seen after treatment with both oestrogen
and tamoxifen. Brtinner et al., (1993b) reported that IGF-II mRNA was down
regulated by both treatments in the xenograft. A monoclonal antibody against the
IGF-I receptor also inhibited growth, implicating IGF-II in the growth of the
xenograft. As such, a change in IGF expression may also be partly responsible for the
oestrogen-induced growth inhibition observed in PE01cddp cells.
4.6 Conclusions and Future Work
Data presented in this thesis have shown that the growth of in vitro and in vivo
ovarian cell lines which possess moderate to high levels of oestrogen receptors can be
modulated by oestrogen, whereas ovarian cell lines which express lower levels of
oestrogen receptor (< 20 fmol/mg protein) are not. These effects on growth may be
mediated through the regulation of TGF-a and members of the IGF family, possibly
in an autocrine and/or paracrine pathway (see Figure 4.1). Furthermore, these growth
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effects are associated with increased levels of other proteins, PR and HSP27 which
are putative markers of hormonal sensitivity in breast cancer.
As the majority of ovarian tumours possess ER, it seems plausible that anti-oestrogen
therapy may be of benefit in the treatment of this cancer, however there have been
only a limited number of trials conducted so far. This study suggests that a certain
subset of patients with moderate to high levels ofER may be responsive to treatment
strategies involving the anti-oestrogen tamoxifen, or one of the newer pure
anti-oestrogens. In addition, HSP27 and PR may have value as predictive markers of
endocrine response in ovarian cancer similar to reports in breast and endometrial
carcinoma, and aid selection of treatment strategy. Alternatively, drugs directed
against the downstream target of oestrogen, for example growth factor receptors,
may also be of benefit.
A clinical study investigating the use of tamoxifen in the treatment of ER-positive
ovarian tumours will soon be initiated in the Edinburgh Medical Oncology Unit.
Based on some of the observations described in this thesis, patients will be selected
for treatment on the basis ofmoderate-high levels of ER. Several markers which may
be related to response will be measured and include PR, HSP27 and the EGFR.
Further work with the cisplatin resistant derivative of PEOl will help determine the
mechanisms whereby oestrogen elicits a growth inhibition, and answer several
important questions which may have relevance for treatment of resistant tumours in
the clinical setting. More detailed flow cytometric analysis may help elicit which cell
cycle changes are occurring and whether this an increase in apoptosis or a reduction
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in the mitotic index in this cell line. In addition, does tamoxifen or other
anti-oestrogens reverse the effects of oestrogen, or also cause a growth inhibition? As
oestrogen induces a growth inhibition in ER-transfected breast cells it may be of
interest to see whether parallel changes occur in ovarian cancer. In vivo models
derived from PEOlCDDP may also aid characterisation of this cell lines phenotype in a
more realistic environment.
Evidence presented in this thesis suggests that the oestrogen-induced growth
inhibition ofPEOlCDDI is possibly due to a modified growth pathway involving one or
more growth factors. If this model of drug resistance is typical of the clinical situation




Schematic summarising the results in this thesis, showing the effects of oestrogen on
the expression of certain proteins, and the possible pathways by which it may mediate
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The Regulation of Growth and Protein
Expression by Estrogen In Vitro: A Study of
8 Human Ovarian Carcinoma Cell Lines
S. P. Langdon,1* G. L. Hirst,1 E. P. Miller,1 R. A. Hawkins,2 A. L. Tesdale,2
J. F. Smyth1 and W. R. Miller1
'ICRF Department of Medical Oncology, Edinburgh EH4 2XU and *Department of Surgery, Royal Infirmary of
Edinburgh EH3 9YW, U.K.
The effects of 17 /?-estradiol (E,) on the growth and the levels of estrogen receptor (ER), progesterone
receptor (PR) and pS2 protein were examined in a range of 8 ovarian carcinoma cell lines. E,
stimulated growth of the 3 cell lines with an ER content of 80-220 fmoi/mg protein but not the 5 cell
lines with ER concentrations less than 20 fmol/mg protein. After exposure to E,, ER concentration
in 2 of the 3 responsive cell lines was decreased relative to untreated cells and in 2 lines, progesterone
receptors were increased. No change in steroid receptor levels was observed in cell lines with low
or negligible levels of receptors. The pS2 protein was not induced by E, in the 5 ovarian carcinoma
ceil lines examined. These results indicate that E2 can stimulate the growth of some ER-positive
ovarian carcinoma cells and that these effects may be associated with changes in the cellular levels
of steroid hormone receptors.
J. Steroid Biochem. Molec. Biol., Vol. 50, No. 3/4, pp. 131-135, 1994
INTRODUCTION
The majority of human ovarian adenocarcinomas are
estrogen-receptor (ER)- positive (reviewed in Slotman
and Rao, 1988 [1]) and experimental evidence is ac¬
cumulating to indicate that, at least a proportion of,
these tumours are estrogen-responsive [2-5]. This is
consistent with the clinical observation that a subset of
ovarian cancer patients are responsive to the anti-estro¬
gen tamoxifen [6-8]. To define those characteristics
that determine sensitivity to estrogen (and therefore
anti-estrogens) in this disease, we have developed a
series of ovarian cancer cell line models [2, 9], Using
these models, we have previously demonstrated that
growth of the ER-positive ovarian carcinoma line PE04
line is modulated by 17 ^-estradiol (E,) in vitro and
in vivo, while growth of the ER-negative PE014 line is
not [2, 3], In addition to growth responses, we are also
attempting to define proteins whose expression is under
estrogen control. The identification of estrogen-regu¬
lated proteins should lead to an improved understand¬
ing of the mechanisms of estrogen (and anti-estrogens)
in this disease and provide possible indicators of hor¬
*Correspondence to S. P. Langdon.
Received 14 Jan. 1994; accepted 7 Mar. 1994
monal sensitivity in clinical specimens. In breast can¬
cer, estrogen-regulated markers, which have been
shown to have utility, include the progesterone recep¬
tor (PR) [10, 11], the pS2 (or pNR-2) protein [12, 13]
and procathepsin D [14, 15], This last protein has
already been demonstrated as being increased in ER-
positive ovarian cancer cells after exposure to E, [5, 16].
In the present study, we have investigated the ability
of E2 to influence the growth of a series of ovarian
carcinoma cell lines with moderate-high leveis of ER
(PE04, PE01, PE06) and with low or negligible levels
of ER (PEA1, PEA2, PE014, PE023, PE016) [2]. The
levels of ER, PR and pS2 have been measured after
culture in the absence and presence of E2 treatment in
these lines to determine whether these proteins are
modulated and might function as markers of estrogen
sensitivity. Comparisons are made with the ER-posi-




The human ovarian carcinoma cell lines (PE01,
PE04, PE06, PEA1, PEA2, PE014, PE023 and PE016)
were established and characterized as described
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previously [9]. Cells were routinely maintained at 37°C
in a humidified atmosphere of 5% CO, in air in RPMI
1640 (Gibco) containing 10% heat-inactivated foetal
calf serum (FCS) and supplemented with streptomycin
(100/jg/ml), penicillin (100 IU/mi) and glutamine
(2 mM). The breast carcinoma cell lines (ZR-75-1 and
MDA-MB-231) were maintained in DMEM (Gibco)
containing FCS and the same additives as for the
ovarian carcinoma lines.
Growth studies
Exponentially growing ceils were harvested by
crypsinisation and plated in 24-well plates (Falcon) at
densities of 2.5-5 x 104 ceils/well (4 wells/experimental
condition) in RPMI 1640 containing phenol red and
10% FCS. After 24 h, to allow for attachment, the
medium was removed and phenol red-free RPMI 1640
containing 5% charcoal-stripped FCS [17] was added.
The cells were incubated for a further 24 h and the
media were removed. RPMI 1640 containing 5% char¬
coal-stripped FCS, with or without E,, at concen¬
trations ranging from 10"12 to 10"SM was added.
Medium, with or without E,, was replenished 3 days
later. Cells were trypsinized from wells after a total of
6 days exposure and counted using a Coulter Counter.
Determination of ER and PR by enzyme-immunoassay
Mid-log phase cells growing in 175 cm2 flasks were
treated with or without 10"'°M E, for 6 days as
described in the growth experiments. After 6 days
treatment, medium was removed and cells were har¬
vested by scraping. The contents from 4 identical flasks
were pooled to give each pellet and these were stored
at — 80°C until use. Cell pellets (50-200 mg) were
weighed and homogenized in buffer (10 mM Tris,
0.25 M sucrose, 1 mM ethylene diammine tetraacetate,
pH 8.0, plus 1% v/v monothioglvcerol and 10% v/v
glycerol) as previously described [18, 19]. After cen-
trifugation at 105,000 g, the supernatant cvtosol was
assayed using the ER-EIA or PR-EIA kits provided by
Abbott Laboratories (Maidenhead, Berkshire, U.K.),
according to the manufacturer's instructions [20]. The
protein content of the cytosol was determined by the
method of Bradford [21] and receptor concentrations
were expressed as fmol/mg protein. We arbitrarily
consider tissue/cells containing less than 5 fmol/mg
protein as "receptor-negative".
Determination of pS2 by flow cytometry
Cells were plated at a density of 5-10 x 104/ml
(2 mi/well) into 6-well plates (Falcon) and subjected to
3 or 6 days exposure to medium with or without
10"'°M E,. pS2 was then detected by flow cytometry
as follows. Cells were trypsinized, fixed in 70% ethanol
at 4°C for 30 min and washed twice in PBS containing
5% FCS and 0.5% Tween 20 (wash buffer). Anti-pS2
antibody (100^1; Histo-CIS, Gif-sur-Yvette Cedex,
France) was diluted 1:2 in the above buffer on ice and
added to the cells for 30 min. Cells were then washed
in buffer. Sheep anti-mouse FITC conjugate (Sigma,
U.K.) diluted 1:20 in buffer was added for 30 min to
cells on ice. Cells were then washed once in buffer, then
twice in PBS, resuspended in PBS and analysed on a
FACScan flow cytometer (Becton Dickinson).
RESULTS
Effect of E, on growth
The 8 ovarian carcinoma cell lines were treated with
E, at concentrations ranging from 10"12 to 10"5 M for
6 days. The 3 lines with moderate-high levels of ER
(PE04, PE01 and PE06) were all growth stimulated by
E, at concentrations between 10"l2and 10"7M(Fig. 1).
Growth stimulation was maximal at concentrations of
10"'° and 10"'M E, and the former concentration was
selected for the protein modulation experiments below.
The growth of the other lines (PEA1, PEA2, PE014,
PE023 and PE016) with low to zero levels of ER were
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Fig. 1. Effect of 17 ^-estradiol (E,) on the growth of ER-posi-
tive ovarian carcinoma cell lines. Cells were treated for 6
days with E, (as described in Experimental) at the concen¬
trations shown. Each value is the mean value of quadrupli¬
cate observations. Error bars represent standard error. The
experiment shown is representative of at least 3 identical
experiments.
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Fig. 2. Estrogen receptor content of ovarian and breast cancer cell lines in the absence and presence of 17
/i-estradiol (E,). Each point is the mean value of 3 independent measurements and error bars represent
standard error. Solid bars represent values obtained on ceils grown in the absence of E, and hatched bars arc
for cells grown in the presence of 10"loM E. for 6 days (as described in Experimental).
not shown). Consistent with previous reports [22],
growth of the ER-positive breast cancer ZR-75-1 cell
line was stimulated by 10~'°M E, (120% increase in
ceil number relative to control) while growth of the
ER-negative MDA-MB-231 line was unaffected (data
not shown).
Effect of E2 on ER concentrations
Two of the 3 ovarian carcinoma cell lines (PE04 and
PE01) with high concentrations of ER demonstrated a
reduction (approx. 50%) in the level of ER after
exposure to 10~i0M E, compared to untreated ceils
(Fig. 2). This response was similar to that seen in the
ZR-75-1 cell line (Fig. 2). The PE06 (81 fmol ER/mg
protein) and the PEA1 (18 fmol ER/mg protein) lines
did not show a significant reduction in ER content after
exposure to E, compared to untreated cells. The other
ovarian carcinoma cell lines examined possessed levels
around the limit of detection (<10 fmol/mg protein) in
the absence or presence of 10~'°M E,.
Effect of E2 on PR concentrations
Two of the 3 ovarian carcinoma cell lines with high
levels ofER (PE04 and PE06) showed an increase in the
level of PR after exposure to 10"'° M E, compared to
untreated ceils (Fig. 3). The other ovarian lines demon¬
strated levels at the limit of detection of the assay. The
ZR-75-1 line contained a much higher concentration of
PR in the absence of E2 (212 fmoi/mg protein), than the
ovarian carcinoma cell lines; PR was increased 5-fold
after exposure to 10~,oM E2.
Effect of Ei on pS2 concentrations
The expression of pS2 in five of the ovarian carci¬
noma cell lines (PE04, PE01, PE06, PEA1 and PE014)
was investigated in the presence or absence of 10"'° .VI
E2. No expression was found in these ovarian lines after
either 3 or 6 days exposure to E,. In contrast, the
protein could be detected in the ZR-75-1 line and
was increased by 260% in the presence of E, (data
not shown). The ER-negative MDA-MB-231 breast
cancer line did not express this protein.
DISCUSSION
This study indicates that E, can stimulate the growth
of certain human ovarian carcinoma ceil lines and this
stimulation is associated with the presence of moder¬
ate-high levels of ER. These findings are similar to
those found for breast cancer cell lines [23] and, as for
breast cancer, suggest that the minimum requirement
for ovarian tumour cells to be sensitive to estrogen is
the presence of moderate numbers of ER. The ER
value widely used to indicate likely sensitivity of breast
cancer cells to anti-estrogen therapy (thus implying
estrogen sensitivity) is 20-30 fmol/mg protein. To the
best of our knowledge, no other ovarian cancer cell
lines than those described in this report have been
reported to have moderate-high levels of ER; therefore
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these are the first systems which could act as a model
for primary ovarian tumours with significant ER levels.
Previous studies investigating the hormonal sensitivity
of ovarian cancer have demonstrated that the BG-1 line
ovarian carcinoma line which possesses an ER value of
23 fmol/mg protein is growth stimulated by E, [5] while
the NIH:OVCAR-3 ovarian carcinoma line with an
ER content of 28 fmol/mg protein is not [4] indicating
that variable effects on growth are obtained around this
cut-off point. A report describing clonogenic assays of
human ovarian carcinoma ceils obtained directly from
clinical specimens indicated that 2 of 4 samples with an
ER content greater than 30 fmol/mg protein responded
to the anti-estrogen tamoxifen, while 0 of 14 samples
with an ER value less than 30 fmol/mg were unrespon¬
sive, suggesting again that this value is a reasonable
crude index of estrogen sensitivity [24]. Further exper¬
iments with clinical specimens of ovarian carcinoma are
required to define a more accurate cut-off value.
Consistent with the view that E, is operating via the
ER, levels of ER decreased in those ovarian carcinoma
lines with the highest levels of ER after exposure to E,
in a manner similar to that found for ER-positive breast
cancer lines [10, 11].
For breast cancer, additional markers of estrogen
response have been sought to help delineate more
precisely that group of ER-positive tumors that are
most likely to respond to anti-estrogen therapy. Among
these are the PR and pS2 proteins [10-13]. In rtvo of
the three ER-positive ovarian carcinoma lines which
were stimulated by E,, PR was induced to a concen¬
tration of 20-30 fmol/mg protein. In the ZR-75-1
breast carcinoma line, PR levels in the absence of E,
were 212 fmoi/mg protein and this was increased to
920 fmol/mg protein after exposure to 10"'°M E,.
While the magnitude of the PR contents are markedly
different between the ER-positive breast and ovarian
carcinoma lines, the factor by which PR increases in the
presence of E, is comparable in breast and ovarian cells.
We have previously investigated the effects of exogen¬
ous E, on PE04 xenografts growing in nude mice and,
in that system, the PR content increases from approx.
100 fmol to 800 fmol/mg protein after exposure to E,
[3]. This increase, however, is associated with growth
inhibition. The NIH:OVCAR-3 line also demon¬
strates an induction of PR after exposure to E,; how¬
ever, in this line there is no effect on growth [4],
Induction, therefore, of the PR in ER-positive ovarian
carcinoma cell lines may indicate that protein ex¬
pression is being modulated by estrogen, but does not
imply that growth stimulation is also occurring. High
levels of PR, therefore, in primary ER-positive ovarian
tumours, may be indicative of a tumor being exposed
to estrogen rather than a marker of estrogen sensitivity.
The expression of pS2 was investigated in several
ovarian cancer cell lines. While expression of pS2 was
detected in the ZR-75-1 breast line as previously
reported, and was increased after exposure to E,, no
expression of this protein was found in the ovarian
lines. Previous studies ofprimary ovarian tumours have
identified pS2 in a subset of tumours [25-27]. Wvsocki
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Fig. 3. Progesterone receptor content of ovarian and breast cancer cell lines in the absence and presence of
17 ^-estradiol (E,). Each point is the mean value of 3 independent measurements and error bars represent
standard error. Solid bars represent values obtained on cells grown in the absence of E; and hatched bars are
for cells grown in the presence of 10~l0M E2 for 6 days (as described in Experimental).
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which were of the mucinous subtype while Henry
et a/.[26] detected the protein (by immunohistochem-
istry) in 9 of 25 cases, of which 6 were also of the
mucinous subtype, suggesting a possible association
with this subtype. In contrast, Foekens et al.[27] using
a radiometric immunoassay, were unable to detect
levels above 11 ng/mg protein (the level they defined as
clinically relevant) in 26 ovarian cancers. None of our
cell lines was derived from a mucinous ovarian carci¬
noma but are derived from the serous subtype and thus
our findings may be more representative of the "normal
spectrum" of tumours. However, it is of interest, that
in the study ofWysocki et al.{25], although 59% of the
29 rumours were ER-positive, 5 of the 6 demonstrating
expression of pS2 had an ER concentration less than
20 fmol/mg protein suggesting that, in contrast to data
for breast cancer, these two parameters are not linked.
Indeed, the mucinous subtype, in contrast to the serous
and endometriod forms of ovarian cancer, is more
frequently ER-negative [1], again suggesting a prob¬
able lack of association of ER with pS2 in this disease.
In conclusion, we have demonstrated that the growth
of a proportion of ovarian carcinoma cell lines can be
stimulated by estrogen in culture. This stimulation
appears to be associated with the presence of moder¬
ate-high levels of ER and may also be associated with
the induction of PR. We are contributing to use these
models to study other molecular pathways under con¬
trol by estrogen to help identify indicators of hormonal
sensitivity in clinical tumors.
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ABSTRACT
The relationship of the heat shock protein HSP27 in
ovarian cancer to several biological and clinical parameters
was investigated in a series of primary tumors and ceil lines.
Analysis of 72 primary tumors (54 malignant. 5 borderline,
and 13 benign neoplasms) indicated that malignant tumors
expressed higher HSP27 concentrations than benign tumors
(median values. 0.56 versus 0.25 ng/frg cytosolic protein: P —
0.032). Tumors from patients with advanced stage (stages II.
III. or IV) disease contained significantly higher HSP27 con¬
centrations than tumors from stage I patients (P — 0.018), and
an HSP27 content >2.0 ng/pig cytosolic protein was associated
with reduced survival (P = 0.03). Tumors that had demon¬
strated progressive growth after chemotherapy had a signifi¬
cantly higher HSP27 content than tumors that were static or
responsive (P = 0.022). These data indicate that HSP27 is
associated with more aggressive malignant ovarian disease and
with inherent resistance to chemotherapy.
Concentrations of HSP27 were also correlated with
indicators of estrogen sensitivity. Therefore, the HSP27 con¬
centration correlated with the estrogen receptor (aH tumors.
P = 0.0014: malignant tumors only, P = 0.047) but not with
the progesterone receptor concentration. Analysis of ovarian
cancer cell lines in vitro and in vivo indicated that the HSP27
content was higher in cell lines that were estrogen receptor
rich and whose growth was modulated by estrogen as com¬
pared with those that were not. Additionally, two estrogen
receptor-rich ovarian carcinoma lines demonstrated a small
but significant decrease in HSP27 levels in response to 17(1-
estradioi in culture. These results suggest that HSP27 may
help identify tumors responsive to estrogens.
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INTRODUCTION
HSP27 is a Mt 27,000 member of the heat shock protein
family which has previously been studied as p29 (1. 2). srp27
(3), and p24 (4, 5). In addition to its putative role in thermotol-
erance. it has been proposed to have a role in the development
of drug resistance, to act as a molecular chaperone. and to be
involved in signal transduction pathways (reviewed in Ret". 6).
High concentrations of HSP27 have been associated with rapid
proliferation in hormonally sensitive tissues, such as breast and
endometrium, and relate to poor disease-free survival in breast
cancer patients (7). Consistent with this view of HSP27 as a
marker of proliferation, it is a negative prognostic factor in
gastric cancer (8).
In breast and endometrial cancer, concentrations of HSP27
are qualitatively and quantitatively linked to the ER3 (1.2. 9).
HSP27 was initially identified in the human breast tumor cell
line MCF-7 as an estrogen-responsive protein (10), and subse¬
quent studies in other ER-posittve breast cancer cell lines have
supported its potential as a biochemical marker of estrogen
regulation (II. 12). Furthermore, the protein has been shown to
be a predictor of clinical response to hormonal therapy in breast
cancer (2. 13) and a marker of estrogenic response in normal and
malignant endometrium (14-16). In cell line models of breast
cancer, a good correlation has been demonstrated between the
presence of ER and high amounts of HSP27 (9). The links
between HSP27 and ER and between HSP27 and rapid prolif¬
eration in breast cancer are somewhat anomalous since hor¬
monal sensitivity is generally associated with slow proliferation.
However, in endometrial cancer, elevated levels of both ER and
HSP27 are separately associated with good overall survival (17).
We are unaware of any previous reports of HSP27 in
ovarian cancer, and in this article we describe the incidence of
HSP27 in primary ovarian tumors and in ovarian cancer cells
grown in culture or as xenografts. Furthermore, because evi¬
dence is accumulating to suggest that a proportion of ovarian
adenocarcinomas are under endocrine control, we have investi¬
gated the relationship between HSP27. ERs. and estrogen-reg¬
ulated growth in all of the aforementioned systems of ovarian
cancer and have studied whether HSP27 is regulated by estrogen
in ovarian cancer cell models in vitro.
MATERIALS AND METHODS
Cell Lines and Xenografts. The characterization of the
ovarian cancer cell lines (PE04, PE06. PE0I. PEAl. PEA2.
PE016. PE014, and PE023) and xenografts (PE04-X and HOX
60) has been described previously (18-21). The PE01CDO1" line
is a cisplatin-resistant subline derived from the PE01 line. Cell
i The abbreviations used are: ER. estrogen receptor PR. progesterone
receptor, EIA, enzyme immunoassay; £.. 173-estradiol.
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lines were routinely cultured at 37°C. 90% humidity, and 5%
CCK in RPMI 1640 (GIBCO-BRL. Paisley, United Kingdom)
containing 10% heat-inacrivated FCS. streptomycin (100 p-g/mi),
and penicillin (100 IU/mi). The ZR-75-1 and MDA-MB-231
breast carcinoma cell lines were used as controls and were cultured
in DMEM (GIBCO-BRL) supplemented with the above additives
plus L-glutamine. The PE04-X and HOX 60 ovarian carcinoma
and ZR-75-1 and T1068 breast carcinoma xenografts were
maintained in the flanks of female nude (nu/nu) mice (obtained
from OLAC, Oxford, United Kingdom) kept in negative pres¬
sure isolators (La Calhene. Cambridge. United Kingdom).
Primary Tumors. Tissue samples from 72 patients were
collected at iniuai debulking surgery for suspected ovarian
cancer. These were snap frozen in liquid nitrogen and stored at
-180°C until use. Tumor histology was assessed on paraffin
sections and classified according to WHO criteria (22). Tumors
were classified as either malignant (54 tumors), borderline [low
malignant potential (5 tumors)], or benign (13 tumors). Of the
54 malignant tumors. 25 were serous. 16 were endometrioid. 2
were mucinous, 5 were clear cell. 3 were mixed malignant
mesodermal tumors. 1 was a steroid cell tumor, and 2 were
mixed pathologies. The borderline group consisted of three
mucinous and two serous subtypes. The benign group consisted
of four mucinous adenomas, one serous adenoma, one Brenner
tumor, two cystadenofibromas. one thecofibroma. three fibro-
mas. and one tubo-ovarian cyst. Information on clinical stage
was available for 52 of the 54 women with malignant tumors,
and the group consisted of 13 stage I. 4 stage II. 33 stage III. and
2 stage IV tumors. Data on the histological grade were available
for 51 of these tumors, and the group consisted of 2 well-
differentiated. 16 moderately differentiated, and 33 poorly dif¬
ferentiated tumors. Survival data were available for 51 of 54
patients with malignant disease: postoperative chemotherapy
was given to 37 of these 51 patients (5 received chlorambucil.
32 received cisplatin), while 14 patients with limited disease
received no further treatment after surgery. A clinical evaluation
of response to chemotherapy was available for 13 of the 37
treated patients. The criteria for response were as follows:
complete response required the disappearance of all assess¬
able disease on clinical and radiological examination and
second-look laparotomy, clinical progression (or surgical
progression at second-look laparotomy) constituted progres¬
sive disease, while static disease refers to no change at
6-month assessment.
Recombinant HSP27. Recombinant HSP27 was ob¬
tained from Sigma (Poole, United Kingdom). This was supplied
lyophilized with phosphate buffer salts and sodium chloride,
dissolved in distilled water, and then stored as aliquots at
-80°C until used.
Preparation of Materials for ELISA. To determine the
HSP27 concentrations in cell lines cultured in vitro, cell pellets
were prepared as follows. Cells were grown in 10% FCS to
late-log phase in 25-cm" flasks (Falcon. Cedex. France) and
harvested by scraping, pelleted by centrifugation. and then
stored at — 80°C until use. In experiments where the effects of
17 |3-estradiol were investigated, cells were grown to mid-log
phase in I75-cm~ flasks, washed with PBS. and media changed
to phenol red-free media containing 5% double charcoal-
stripped serum (23) plus penicillin, streptomycin, and glu-
tamine. Twenty-four h later, cells were refed with the same
media with or without 10" m 17 (3-estradiol. After an addi¬
tional 72 h. cells were collected by scraping and stored at
-80°C. The cell pellets were resuspended in 0.5 ml Tris-EDTA
buffer (10 mM Tris. 1 mM EDTA. and 2 dim DTT: pH 7.4 at4°C)
and homogenized by hand. Samples were then spun at 200.000
X g for 1 h at 4°C, supematants were collected for analysis, and
pellets were discarded.
Human tumor xenografts, grown s.c. in the flanks of nude
mice, were collected when mean diameters were 1 cm and
stored in liquid nitrogen until use. Tumor material was ho¬
mogenized in 5 volumes of Tris-EDTA buffer for 2 X 15 s in
a Silverson homogenizer. centrifuged at 200.000 X g for 60
min. and stored at —80°C. Protein levels in the cytosol fractions
were determined using a colorimetric assay adapted from Bradford
(24).
ELISA Method for Measurement of HSP27. HSP27
expression was delected in sample cytosols by ELISA as de¬
scribed previously (13). Cytosols were diluted in PBS. plated in
Immulon 4 flat-bottomed 96-well plates (Dvnatech) at 200
p-lAvell. and incubated at 37°C for 90 min. The following
protein concentrations were used: primary tumors. 2-10 p.g/
well: ovarian ceil lines. 10—10 pg/well: and recombinant
HSP27. 2-10 ng/well. Each concentrauon was examined in
duplicate, and final values obtained were the mean values for
three assays conducted on different occasions. Plates were
washed three times with PBS-0.05% Tween 20 and then treated
with or without the anti-HSP27 antibody D5 (0.15 p.g in 200 p.1
PBS-Tween 20/well: Ref. 25) for 2 h at 37°C. After washing
three times, wells were incubated with 200 pl/well peroxidase-
conjugated antimouse immunoglobulin (DAKO. High Wy¬
combe. United Kingdom) at 1:1000 in PBS-Tween 20 at 37°C
for I h. Following additional washing. 200 |xl of one of two
peroxidase substrates were added for 4 to 10 min in the dark at
37°C. Primary tumor samples were treated with 0.5 mg o-
phenyiene diamine hvdrochloride/ml substrate buffer (0.05 m
sodium phosphate-0.02 M citric acid. pH 5.0) plus 8 p.1 30%
hydrogen peroxide. For the cell lines and xenografts with lower
HSP27 levels, a more sensitive substrate was used: 100 p.1
tetramethvl benzidine (20 mg/ml DMSO)/20 ml substrate buffer
plus 14 p.1 30% hydrogen peroxide. The reactions were termi¬
nated with 50 |xl/well 0.5 m sulfuric acid, and plates were read
at either 492 nm (o-phenylene diamine hydrochloride substrate)
or 450 nm (tetrametnyl benzidine substrate) in a Bio-Rad piaie
reader. Background values (in the absence of D5) were sub¬
tracted. and comparison to a standard curve generated for re¬
combinant HSP27 in each set of reactions yielded final values.
Measurement of ER and PR. Tissue fragments (50-
200 mg) were weighed and homogenized in buffer (10 mM Tris.
0.25 m sucrose. 1 mM EDTA. pH 8.0, at 22°C, plus 1% mono-
thioglycerol. and 10% v/v glycerol). After centrifugauon at
105.000 x g, the supernatant cytosol was assayed by EIA using
ER-EIA or PR-EIA kits (Abbott Ltd., Basingstoke. United
Kingdom) according to the manufacturer's instructions. The
protein content of the cytosol was determined as described
above, and receptor concentrations were expressed as fmol/mg
protein.




























Fig. 2 Relationship betwen HSP27 expression and stage of ovarian
cancer. HSP27 concentration was measured using an ELISA as de¬
scribed in "Materials and Methods." Bars, median values. Comparison
of groups (Mann-Whitney U test): stage I versus stages II. III. and IV.
P = 0.018.
MAUSNANT BORDERLINE
Fig. / Expression of HSP27 in primary ovarian tumors. HSP27 con¬
centration was measured using an ELISA as described in "Materials and
Methods." Bars, median values. Comparison of groups (Mann-Whitney
U test): malignant versus benign. P — 0.032: malignant versus border¬
line: and borderline versus benign. nonstgntficanL
RESULTS
HSP27 Expression in Primary Ovarian Tumors. The
concentrations of HSP27 were measured using an ELISA in 72
primary ovarian tumors consisting of 54 malignant, 5 border¬
line. and 13 benign neoplasms. The measured values ranged
from 0 to 4.7 ng HSP27/p.g cytosolic protein (Fig. I). Although
there was overlap in the values between the malignant and other
groups, the median value (0.56 ng/p.g protein) for the malignant
group was significantly higher than that of the benign group
(0.25 ng/p.g protein: P — 0.032, Mann-Whitney U test), whereas
borderline tumors possessed a median value (0.13 ng/|xg pro¬
tein) comparable to that of the benign group.
HSP27 Expression and Clinicopathologicai Parameters
in Malignant Tumors. Analysis of the malignant group by
stage indicated that tumors of advanced stage (stages II-IV; i.e.,
extending beyond the ovaries) possessed a higher median value
(0.81 ng/p.g protein) than stage I tumors (median. 0.22 ng/p.g
protein: P = 0.018. Mann-Whitney U test: Fig. 2). There were
no significant associations between HSP27 content and either
histological type or grade of differentiation (data not shown).
Analysis of the survival of the group of patients with malignant







Fig. 3 Relationship between HSP27 expression and survival of pa¬
tients with ovarian cancer. HSP27 concentration was measured using an
ELISA as described in "Materials and Methods." Kaplan-Meter curves
were compared using the log rank test, P = 0.03. Ticks, censored values.
tumors indicated that those patients (n = 6) with tumors con¬
taining an HSP27 concentration >2 ng/p.g protein had a signif¬
icantly poorer survival than the majority of patients (n = 44)
who had a value <2 ng/p.g protein (P - 0.03, log rank test; Fig.
3). Although this cutoff point was arbitrarily selected, it was
noticeable that all padents with tumors above this value died
before 2 years.







Fin. 5 Relationship between HSP27 and ER in pnmary ovarian tu¬
mors. HSP27 concentration was measured using an ELISA and ER
using an EIA as described in "Materials and Methods." HSP27 and ER
were correlated using the Spearman rank correlation: tor ail (i.e.. ma¬
lignant. borderline, and benign) tumors. P = 0.0014: for malignant
tumors only. P = 0.047.
RESPONSIVE/STATIC PROGRESSIVE
n =• 7 n a S
Fin. J Relationship between HSP27 and response to chemotherapy in
ovarian cancer patients. HSP27 concentration was measured using an
ELISA as described in "Materials and Methods." Criteria of response
to chemotherapy are also described in "Materials and Methods." Bars.
median values. Comparison of groups (Mann-Whitney U test): respon¬
sive or staric tumors versus progressive tumors. P = 0.022.
HSP27 Expression and Response to Chemotherapy.
The relationship between HSP27 content and response to che¬
motherapy was investigated in a subset of the 37 patients who
had received treatment: evaluation of the response to chemo¬
therapy was possible in only 13. of whom 7 tumors were
"responsive" (2 complete responses and 5 static), while 6
progressed on chemotherapy. The HSP27 concentrations in
these two groups of tumors are shown in Fig. 4. and the median
value was significantly higher in the group of tumors that
progressed compared to those that responded or remained static
(1.09 versus 0.26 ng HSP27/p.g protein: P = 0.022. Mann-
Whitney U test).
HSP27 and ER and PR in Ovarian Tumors. The rela¬
tionship between HSP27 and ER or PR was examined in a
subset of 66 tumors in which data were available for ER and PR.
A significant correlation was found between ER and HSP27 (all
tumors, P - 0.0014; malignant tumors only, P = 0.047, Spear¬
man's rank test: Fig. 5) .but not between PR and HSP27 (P =
0.97; Spearman's rank test: data not shown).
HSP27 Expression in Ovarian Carcinoma Cell Lines in
Vitro and in Vivo. The concentration of HSP27 was measured
in nine ovarian carcinoma ceil lines grown in 10% FCS-RPMI
1640 (Fig. 6). The values for these ovarian lines range from 0 to
3.8 ng HSP27/p.g protein. The three ovarian lines (PE01. PE04,
and PE06) with the highest levels (£0.9 ng/p.g protein) of
HSP27 have previously been shown to be ER rich (>80
fmol/mg protein) and to be growth stimulated by E. (20). The
cell lines PEA I. PEA2. PE016. PE014. and PE023 have lower
levels (S0.8 ng/p.g protein) of HSP27; these lines have previ¬
ously been shown to be ER poor (< 20 fmol/mg protein I. and
their growth is unaffected by the addition of E-. The cell line
PE0lCDDP is a line derived from PE01. which has been made
resistant to cisplatin. Although ER positive, it is growth inhib¬
ited by concentrations of E;. which stimulate the growth of the
other ER-positive cell lines, and in conditions of 10% FCS. it
possesses a low HSP27 content.
The expression of HSP27 in two ovarian carcinoma xe¬
nografts was also investigated. The ER-positive PE04 xenograft,
whose growth is modulated by E-. possessed higher levels of
HSP27 compared to the ER-negative HOX 60 xenograft, whose
growth is unaffected by E- (Fig. 6). The HSP27 content of the
PE04 xenograft was approximately 50% that of the cultured cell
line (Fig. 6).
Regulation of HSP27 Expression by E-. To assess
whether HSP27 expression was under the regulation of estrogen
in ovarian cancer cells, a range of ceil lines were exposed to
10"10 .vt E, for 72 h. The ZR-75-1 breast cancer cell line was
used as a positive control, in which exposure to E. increased
expression of HSP27 (Fig. 7). In contrast, among the ovarian
cell lines, only the PE01 line showed an increase (which was
small and nonsignificant) alter exposure to E-, while the ER-
positive PE04 and PE01cddp lines demonstrated a significant
reduction in their HSP27 content. HSP27 expression in the
ER-negative PE0I4 ovarian and MDA-MB-231 breast lines was
unaffected by exposure to E-.
DISCUSSION
This is the first report on the expression of HSP27 in
ovarian cancer, and the results show that ovarian tumors possess
a range of values varying between 0 and 5 ng/|xg cytosolic
protein. In support of this protein having a role in the biology of
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Ft?. 6 HSP27 expression in ovarian cancer cell lines. HSP27 concentration was measured using an ELISA as described in "Materials and Methods."
Values shown for the cultured ceil lines are for cells grown in 10% FCS-90% RPM1 1640. Standard deviation shown.
this disease, a number of positive associations were observed
between HSP27 concentration and pathological and clinical
features in a series of primary ovarian tumors. Firsu malignant
tumors as a group express significantly greater levels of this
protein than benign tumors while borderline tumors have a level
comparable to that of the benign group. This increase in con¬
centration with malignancy is also consistent with the observa¬
tion that HSP27 is absent in the normal ovary (4). It is possible
that the increase in malignant tissues may be partially explained
by increased ceilulanty, and to assess this and to also define
which cell types are positive for HSP27, immunohistochemical
studies will be needed.
Second, advanced stage tumors (stages 1I-1V) have a
greater content of HSP27 than tumors limited to the ovary (I.e..
stage I tumors). Third, patients with tumors expressing higher
levels of HSP27 (>2 ng/p.g protein) had a significandy poorer
prognosis than those patients with low tumor content of HSP27.
This cutoff point was selected retrospectively and requires con¬
firmation in a prospective cohort of patients. However, together
these data indicate that increased expression of HSP27 is asso¬
ciated with aggressive disease. HSP27 has previously been
shown to be associated with short disease-free survival in breast
cancer (3, 7) and with poor survival in gastric cancer (8).
Although HSP27 has not been previously investigated in ovar¬
ian cancer, the related protein HSP60 has been and also has been
shown to be associated with a poor prognosis (26).
HSP27 has also been suggested to have a role in the drug
resistance of tumor cells. For example, transfection of Chinese
hamster ovary cells with HSP27 cDNA resulted in the develop¬
ment of resistance to a variety of antitumor agents (27). In the
present study, HSP27 concentrations were significantly higher
in tumors that progressed on therapy, as compared to those that
were either static or clearly responsive. This is therefore com¬
patible with the suggestion that high levels of HSP27 are asso¬
ciated with drug resistance.
In breast and endometrial cancer. HSP27 is also a predictor
of endocrine sensitivity (2. 7, 9. 14. 16). In these tumor types.
HSP27 correlates with ER but only weakly or not at all with PR
(13, 14). The link between ER and HSP27 is not universal, and
in. for example, squamous carcinomas of the uterine cervix or
endometrial adenocarcinomas with squamous carcinoma cells,
there is no association between HSP27 and ER (14). However,
in the present study, HSP27 correlated with ER but not PR. To
elucidate further whether there was a connection between
HSP27 and estrogen sensitivity in ovarian cancer cells, the
levels of HSP27 were measured in a range of cell line models
whose sensitivity to estrogen had been defined previously (18-
20). HSP27 concentrations were higher in the three lines that
contained the highest levels of ER and whose growth was
stimulated by E-.. It should be noted, however, that all three lines
were derived from the same patient at different stages of clinical
treatment and are therefore not truly independent (18). The five
lines with low or negligible levels of ER and whose growth was
unaffected by E, possessed lower levels of HSP27. The ceil line
PE01cddp possesses a level of ER comparable to its parent cell
line PE01. In contrasL however, its growth is inhibited by the
addition of E,.4 This cell line contained a low concentration of
HSP27 when grown in 10% unstripped serum conditions but
demonstrated a value comparable to the other ER-positive cell
lines when grown in 5% stripped serum conditions. In xenograft
models of ovarian cancer. HSP27 content was higher in an
ER-positive xenograft whose growth was modulated in vivo by
4 Unpublished data.
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Fig. 7 Modulation of HSP27 by E2 in ovarian cancer cell lines. HSP27 concentration was measured using an ELISA as described in "Materials and
Methods." The ER-positive ZR-75-1 and ER-negative MDA-MB-231 breast carcinoma cell lines were included as controls. Untreated (control) cells
were grown in 5% double charcoal-stripped serum in phenol red-free media (RPMI 1640 for the ovarian cancer lines and DMEM for the breast cancer
lines). Estrogen-treated cells were exposed to E2 (0.1 nM) for 72 h as described in "Materials and Methods. *. comparison of E^-ireaied and untreated
groups (/ test), P > 0.05. Standard deviation shown.
E2 compared to an ER-negative, unresponsive xenograft. These
data with cell lines, in vitro and in vivo, are similar to a previous
report for breast cancer cell lines in which the six ER-positive
breast cancer ceil lines studied contained a higher HSP27 con¬
tent than two ER-negative breast lines and nine ER-negative
nonbreast cancer cell lines (9). Additional evidence of a con¬
nection between ER and HSP27 was obtained by comparing the
HSP27 concentrations in cells treated with or without E^. Only
cell lines with moderate to high concentrations of ER demon¬
strated a response, although, interestingly, the HSP27 concen¬
tration increased in the ER-positive ZR-75-1 breast line but
decreased in two of the ER-positive ovarian cell lines. Previous
studies of estrogen-sensitive systems have demonstrated that E2
increases HSP27 levels in the ER-positive MCF-7 and ZR-75-1
cell lines (4, 11. 12) but not in the T47D line (.9).
This is the first report of the expression of HSP27 in
ovarian cancer, and these data indicate that HSP27 has both
biological and clinical significance in this disease. In addition to
being associated with poor prognosis and drug resistance,
HSP27 is linked to the ER status and may help define endocrine-
sensitive tumors.
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Abstract The role of the insulin-like growth factors (IGFs) in
3 cultured human ovarian cancer cell lines (PEOl, PE04,
PE014) was investigated. All three cell lines express mRNA
for 1GF-I and the PE014 cell line expresses mRNA for IGF-II.
Protein expression of IGF-II was demonstrated in the PEOI4
and PE04 ceil lines. All 3 cell lines expressed mRNA for the
IGF type I. IGF type II and insulin receptors; the presence of
type I IGF receptors was confirmed by immuno-cytochemistry.
IGF-I and insulin markedly stimulated the proliferation of
PEOl and PE04 but not PEOl4 cells while all 3 lines were
insensitive to the addition of exogenous IGF-II.
Introduction
There is an increasing awareness of the importance of
polypeptide growth factors in the control of proliferation in
cancers. In this respect, both the TGF-a/EGF and TGF-S
growth factor families have been shown to influence the
growth of ovarian cancer ceils in culture (1-5). To date,
limited information is available on the role of the insulin-like
growth factors (IGFs) in this important gynecological cancer
(6-9). Nevertheless, the IGFs have been widely implicated in
the paracrine control of normal ovarian function, acting both
as local growth regulators and modulating the actions of
pituitary gonadotropins on the various cell types found in
the normal ovary (10-12). IGFs have also been suggested to
have a role in the growth control of breast cancer (13-15).
The distribution of IGFs in breast tumor tissues implies that
their primary role in this tumor may be paracrine (16,17), but
reports that breast cancer cell lines express IGFs and their
receptors de novo suggests that autocrine regulation cannot
be wholly ruled out (16).
These observations, plus recent reports that indicate that
IGF-I and its receptor are widely expressed in ovarian cancer
models (6) and that type I IGF receptors may be present in
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ovarian tumors (18-22) have provided the impetus for the
current study. The aim was to establish whether members of the
IGF family play a role in regulating proliferation of ovarian
carcinoma ceil lines in vitro.
Materials and methods
Cell lines. The human ovarian carcinoma cell lines PEOl.
PE04 and PE014 were established and characterised as
described previously (231 They were maintained routinely at
37°C in a humidified atmosphere of 5% COz in air in RPMI
1640 (Gibco) containing 10% heat-inacuvated fetal calf serum
(FCS) supplemented with streptomycin (100 |dg/ml), penicillin
(100 IU/ml) and glutamine (2 mM).
Growth experiments. Exponentially growing cells were
harvested by trypsinisation and plated in 24-well plates
(Coming) at densities of 2.5x10* cells /well (for PEOl and PE04)
or 5x10* (for PE014) (4 wells per experimental condition) in
RPMI 1640 containing 10% heat inactivated fetal calf serum
(FCS). After 24 h. medium was removed, ceils were washed
with phosphate buffered saline (pH 7.4; PBS) and medium
replaced with RPMI 1640 (phenol red free) containing either
5% double charcoal stripped-FCS (DCS-FCS), 0.5% DCS-FCS,
HTS (hydrocortisone; 10 nm. transferrin 10 |4g/ml. sodium
selenite: 30 nm) or HTS containing 5 (J.g/ml insulin (HITS);
and incubated for a further 24 h. Medium was then removed
and replaced with RPMI with the corresponding additives (as
above) with or without human insulin, recombinant 1GF-I or
IGF-II (Boehringer) added at concentrations ranging from 107
to 10"'° M. This time point was designated day 0. Media was
replenished on day 3. On days 0, 3, and 6, cells were harvested
by trypsinisation and counted using a Coulter counter.
mRNA extraction. mRNA was extracted as previously described
(2), using the lithium chloride/urea method.
Synthesis of riboprobes. Labelled RNA was prepared from
linearised template DNA using a Gemini II system (Promega
Ltd, Southampton, UK) (see ref. 2) in the presence of an
RNAse inhibitor, cold ribonucleosides, dithiothreitol and 32P-
rCTP with the appropriate RNA polymerase. The DNA
template was then removed using RQ1 DNase. Labelled RNA
was precipitated in the presence of added tRNA and full
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length transcripts were isolated by polyacrylamide gel
electrophoresis and labelled RNA eluted from the gel,
precipitated under ethanol and resuspended in hybridisation
buffer prior to use in RNAse protection assays. The IGF-I and
IGF-II riboprobes were kindly supplied by Dr Jim Scott
(CRC, Middlesex, UK).
RNAse protection assay. Test RNA (20 ug) was precipitated
under ethanol, dried and resuspended in 30 p.1 hybridisation
buffer (80% formamide. 40 mM Pipes (pH 6.7), 400 mM
NaCl, 1 mM EDTA); tRNA was used as a negative control.
Test probes plus actin probe were added to each sample.
Samples were incubated at 85°C for 20 min and hybridized
overnight at 51°C. After hybridization, single stranded RNA
was removed using an RNAse A and T1 mix, followed by
incubation with proteinase K in SDS. Protein was extracted
by using phenol-chloroform-isoamyl alcohol. Protected RNA
was precipitated with carrier tRNA (5 |lg) and separated by
gel electrophoresis. Full length transcripts for test probes
were scored as positive, whilst transcripts for actin were used
as an internal control.
Reverse transcriptase-polymerase chain reaction. Reverse-
transcriptase polymerase chain reactions for type I and type II
IGF receptors were carried out using a Techne PHC-3 thermal
cycling block. Essentially, 20 jig aliquots of total cellular
RNA were reverse transcribed by incubation with Superscript
(Life Technologies. Paisley, UK) reverse transcriptase (200 units)
for 1 h at 42°C. Subsequently 0.2-1 Ltl of this reaction product
was utilized for PCR reactions. PCR reactions were performed
in a volume of 100 pi. 0.5 units of TAQ polymerase (Promega,
Southampton. UK) were combined with 1.25 itM dATP.
dTTP, dCTP and dGTP (Pharmacia, UK), 100 ng of each primer
in buffer containing KC1 50 mM, Tris-HQ 10 mM. Triton X-100
0.1% with added MgCL 2.5 mM. The amplification reaction
was earned out over 40 cycles with the following parameters:
step 1: 94"C for 38 seconds, step 2: 50°C for 53 seconds, step
3: 72°C for 68 seconds. For the final cycle tH| 72°C step was
extended to 7 min to ensure ail transcripts were full length.
The following primers were used in these reactions: Insulin
receptor: 407 bp fragment spanning bases 515-922 of the
insulin receptor mRNA (24); type I IGF receptor: 549 bp
fragment spanning bases 1856 to 2405 of the type I IGF
receptor mRNA (25) type IT IGF-receptor 394 bp fragment
spanning bases 787 to 1181 of the type II IGF receptor mRNA
(26).
Immunocytochemical detection of type I IGF receptor. The
presence of type I IGF receptors was detected using an
immunoperoxidase method employing avidin-biotinylated
horseradish peroxidase complex (27); cells were trypsinised,
washed with serum-free RPMI 1640, and placed onto multispot
slides (Hendley Ltd, Essex, UK) at approximately 2x10* ceils/spot.
These were then fixed in acetone:methanol (1:1) for 5 minutes
and stored at -20°C until use. Slides were thawed and incubated
for 10 minutes at room temperature with 3% hydrogen peroxide
in methanol. The slides were then washed in 0.05 M Tris
Buffer (TB), pH 7.6 and incubated with rabbit serum (Dako)
in TB (1:5) for 20 minutes followed by incubation with the
mouse monoclonal antibody (a-IR-3, 100 |ig IgG/ml diluted
1:5 with TB: Oncogene Science) for 30 minutes. A further
wash in TB was followed by incubation for 30 minutes with
biotinylated rabbit anti-mouse immunoglobulin (Dako) diluted
in TB (1:200). After washing, AB complex (Dako) was applied
to cells and left for 30 min. A final TB wash was given before
peroxidase was localised using a fresh 1 mg/ml mixture of
3,3'-diaminobenzidine tetrahydrochloride (DAB) and 0.01%
hydrogen peroxide in Tris imidazole buffer, pH 7.6 for 10 minutes.
After washing with water, cells were counterstained with
hematoxylin and scored for the presence and intensity of
positive staining. TB was included in each staining run as a
negative control and the monoclonal antibody CAM 5.2 which
reacts against cytokeratin as a positive control.
Statistics. Ceil growth and cell cycle responses in vitro were
analyzed using the Wilcoxon Rank test and significant differences
at the p<0.05 level defined.
IGF-II protein expression. Cells were grown to late-log phase
in 175 cm; flasks. Media (50 ml: either 5% DCS-FCS in
RPMI 1640 or RPMI 1640 alone) conditioned by 48 h exposure
to PE04 or PEOI4 cells was collected and concentrated 25-fold.
10 ug of each sample was separated by electrophoresis on a 15%
sodium dodecyl sulphate polyacrylamide gel electrophoresis
gel. Proteins were transferred to nitrocellulose overnight.
These filters were then immunoblotted using a monoclonal
antibody to IGF-II (Sera-Lab. Sussex. England). Detecfion was
by enhanced chemoiuminescence with exposure of the film
for 15 seconds.
Results
mRNA expression for IGFs and IGF-receptors in ovarian
carcinoma cell lines. All three cell lines tested (PEOI. PE04
and PE014) expressed high levels of mRNA for IGF-I (Fig. la).
Expression of mRNA for IGF-II could be detected in PEOI4
but not in either PEOI or PE04 cells (Fig. lb). All three cell
lines expressed mRNA for the insulin receptor and type 1 and II
IGF receptors as determined by RT-PCR (Fig. 2).
Protein expression of IGF-II. The presence of IGF-II was
investigated in conditioned media obtained from PE04 and
PE014 cells. In the presence of 5% DCS-FCS. both cell lines
express IGF-II. though PE014 cells express much greater
quantifies (Fig. 3). PE04 cells express primarily the mature 7 kDa
form of the peptide with small amounts of a 15 kDa pro IGF-II
form. PEOI4 cells express greater quantities of both these
forms of IGF-II than PE04, together with an additional band
at 24 kDa probably representing prepro IGF-II. Small amounts
of the 7 kDa form were found in the serum control but the
levels detected in the medium from PE04 cells were greater.
In conditioned media, collected in the absence of serum, a
much smaller quantity of IGFII (than found in serum-containing
conditions) could be detected in the PE014 samples but not
in the PE04 samples.
Immunocytochemistry of type I IGF receptor. Over 90% of cells
from all three cell lines stained positively for the type I IGF
receptor as determined using the a-IR-3 monoclonal antibody
(data not shown).








Figure I. IGF-I and IGF-II mRNA expression detected by RNAse protection
assay. 6% poiyacryiamide gels, showing bands representing mRNA from
IGF-I. IGF-II and human-c-actin. Panel A. IGF-I expression. Lane 13 contains
•,5S labelled molecular weight markers: Lanes 11 and 12 contain untreated
nboprobes for IGF-l and actin respectively; Lane 4-5 and 9 contain tRNA as
a negative control: Lanes 1-3 and 6-8 contain test samples. mRNA from all
three cell lines showed positive hybridization with IGF-I riboprobe. Panel B.
IGF-II expression. Lane 7 contains J5S labelled molecular weight markers:
Lanes 6 and 5 contain untreated riboprobes for actin and IGF-II
respectively; Lane 4 contains tRNA as a negative control: Lanes 1-3 contain
test samples. Only mRNA from the PE014 cell line showed positive
hybridization with IGF-II riboprobe.
Figure 2. Insulin-, type I- and type II IGF receptor mRNA expression
detected by RT-PCR. 6% poiyacryiamide gels, showing bands representing
mRNA from type I IGF receptor, type II IGF receptor and insulin receptor.Top
row. mRNA from PE014 (lane I). PE04 (lane 2) and PEOI (lane 3). All
cell lines show a band at approx 549 base pairs equivalent to the type I IGF
receptor. Middle row. mRNA from PE014 (lane 1). PE04 (lane 2) and PEOI
(lane 3). All cell lines show a band at approx 407 base pairs equivalent to
the insulin receptor. Bottom row. mRNA from PEOI4 (lane 1). PE04 (lane 2)
and PEOI (lane 3). All cell lines show a band at approx 394 base pairs
equivalent to the type II IGF receptor. The primers used to detect these
receptors are described in Materials and methods.
Growth responsiveness ofPEOI ovarian carcinoma cell line.
The addition of IGF-I to cultures of PEOI ceils growing in
serum-free conditions produced significant, dose related
(range 1OM0*10 M) stimulation of growth after both 3 (data not
shown) and 6 days in culture (Fig. 4a). Addition of insulin at
the concentration widely used in serum-free media, 7xl0*7 M
(5 p.g/ml), did not alter the effects produced by IGF-I but
growth stimulation was less marked in the presence of 0.5%
DCS-FCS and absent in the presence of 5% DCS-FCS (data
not shown). Addition of exogenous IGF-II over the dose
range 10*7-lO10 M to the PEOI ovarian cell line produced no
detectable effect on cell growth after 6 days culture in serum
free medium (Fig. 4b); again addition of insulin or DCS-FCS
did not alter this response (data not shown). Insulin alone
produced significant, dose related (range 10"MO10 M) stimulation
of growth of PEOI cells under serum-free conditions after both
3 (data not shown) and 6 days in culture (Fig. 4c). Growth
stimulation was also seen when cells were cultured in the presence
of 0.5 or 5% DCS-FCS (data not shown).
7 kDa—
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Figure 3. IGF-II peptide expression in conditioned media from the PE04
and PEOI4 ceil lines. Immunoblot with monoclonal antibody to IGF-II of
conditioned media (CM) followed by enhanced chemoluminescence for
15 seconds. Lane I: CM from M17 cell line transfected with IGF-II cDNA
contains 3 major forms of IGF-H at 22. 15 and 7 kDa: Lane 2: Molecular
weight markers: Lane 3: 20 ng mature IGF-II; Lane 4: CM from PE04 cells
grown in serum: Lane 5: CM from PEOI4 cells grown in serum; Lane 6:
Control medium containing serum in the absence of cells.













Figure 4. Growth responses of PEOl ovarian carcinoma cells. Ceil counts per
well of PEOl ovarian carcinoma cells in serum-ffee and insulin-free RPMI
containing HTS. Solid bars represent untreated cells. Each point represents
mean ± S.E. of quadruplicate points. Solid = untreated ceils: horizontal =
10'10 M. hatched = 10'9, stnpes = 10'8 M. open =10"7 M: ceils exposed to 10"
l0. 10T 10 ". It)"7 M growth factor respecuvely over 6 days. 'Statistically
significant difference with respect to time matched control fp<0.051. Panel
a: Cells exposed to exogenous IGF-I. Panel b: Cells exposed to exogenous
IGF-II. Panel c: Cells exposed to exogenous insulin fsee text for details).
Figure 5. Growth response of PE04 ovarian carcinoma ceils: Cell counts
per well of PE04 ovarian carcinoma cells in serum-free and insulin-free
RPMI containing HTS. Solid bars represent untreated cells. Each point
represents mean ± s.e. of quadruplicate points. Solid = untreated ceils:
horizontal = 10"'° M. hatched = 10"" M. stripes = 10"8 M. open =10"' M: ceils
exposed to 10"'°. 10'9. 10*8. 10"7 M growth factor respectively over 6 days.
'Statistically significant difference with respect to time matched control
(p<0.05). Panel a: Ceils exposed to exogenous IGF-I. Panel b: Cells exposed
to exogenous IGF-II. Panel c: Cells exposed to exogenous insulin (see text
for details).
Growth responsiveness ofPE04 ovarian carcinoma cell line.
IGF-I produced a significant, dose related (range IO7-1010 M)
stimulation of growth of PE04 cells under serum-free
conditions after both 3 (data not shown) and 6 days in culture
(Fig. 5a). Addition of insulin (7x10"' M) to serum free-media
did not alter the effects observed but growth stimulation was
not observed in the presence of either 0.5 or 5% DCS-FCS
(data not shown). Addition of exogenous IGF-II over the dose
range 10"7-K>'0 M to the PE04 ovarian cell line produced no
detectable effect on cell growth after 6 days culture in serum-
free medium (Fig. 5b); addition of insulin or DCS-FCS did
not alter this response. Insulin produced significant, dose
related (range 10"M0"'° M) stimulation of growth of PE04
cells under serum-free conditions after both 3 (data not shown)
and 6 days in culture (Fig. 5c). Growth stimulation was also
seen when cells were cultured in the presence of 0.5 or 5%
DCS-FCS (data not shown).
Growth responsiveness of PE014 ovarian carcinoma cell line.
No significant response was observed in PE014 cells exposed
to exogenous IGF-I, IGF-II or insulin in either the absence or
presence of insulin (IGF-I and -II only), 0.5 or 5% DCS-FCS
(data not shown).
Discussion
Using three established cell lines, the growth regulation of
ovarian carcinoma cells by IGFs has been investigated. High
levels of mRNA expression for IGF-I were found in all three
cell lines, along with mRNA for the type I IGF receptor.
Immunocytochemical analysis of these cell lines confirmed
that the type I IGF receptor was expressed in all three lines.
Following incubation with exogenously added IGF-I. significant
increases in the rates of cell proliferation were noted in both the
PEOl and PE04 cell lines, whilst proliferation in the PE014
cell line was not markedly affected. Taken together, these data
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suggest that IGF-I may act as a regulator of proliferation in
some ovarian carcinoma cell lines. Similar growth response
and receptor data were obtained for insulin.
Of the three cell lines tested, only the PEO14 cell Line showed
expression of mRNA for IGF-II using RNAse protection
methodology. The production of this peptide by this cell line
was confirmed by Western blotting which demonstrated the
presence of at least 3 forms of the peptide consistent with
prepro-, pro- and mature 1GF-II. The presence of the larger
forms may be indicative of saturation of processing. The increased
production of this peptide in serum-containing compared to
serum-free conditions suggests that serum factors are involved
in IGF-II production/secretion; alternatively, binding proteins
in serum might increase the half-life of the peptide or might
sequester the peptide from the type I receptor, thus preventing
internalisation. 1GF-II peptide was also produced by PE04
cells, although the mRNA was not detected.
This may be due to the long conditioning period used for
collection of the peptide allowing sufficient quantities to
accumulate for detection. This endogenous production of IGF-II
by the cell lines may provide maximal stimulation within the
cells and prevent a growth response to exogenous factor.
The variation in growth responsiveness between cell lines
may reflect either changes in levels of endogenous production
of IGFs or may be due to alterations in the post-receptor
transduction of the IGF mitogenic signal. It is also possible;
that the production of IGF binding proteins may alter the
response of cells to IGF (28-33) since at least five IGF binding
proteins are produced by PE04 cells (7).
The finding that the effect of IGF-I is progressively
diminished by addition of serum may be explained if it is
assumed that binding proteins present in serum are sequestering
IGF and preventing its action upon its receptor: alternatively,
IGF-t within serum may mask any growth effect. Studies in a
lung cancer cell line suggest that the presence of IGF binding
proteins of different types may affect the ability of the IGFs
to bind to receptors and to induce proliferative responses:
some binding proteins may preferentially block the action of
IGF-II allowing normal responses to 1GF-I to persist (Reeve
et al. Proc AACR 33: (Abst) 71, 1992). Such observations
might account for the differences in effects of IGF-I and IGF-II
observed here.
These data support a role for the IGF family in the growth
regulation of ovarian carcinoma and confirm and extend
previous studies which have demonstrated that IGF-I and its
receptor are not only present in ovarian cancer but are
responsive to modulation by the growth factor and anti-sense
oligodeoxynucieotide inhibition (6,8). As such these pathways
provide possible targets for therapy. The type-I. type-II and
insulin receptors all possess tyrosine kinase activity and a
great deal of attention is currently focussing on the therapeutic
potential of tyrosine kinase inhibitors as antitumor agents
(34). Interruption of these pathways may prove a beneficial
approach in this disease.
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